EPICORE Embase Updates: April 2022

Total documents retrieved: 123

Results Generated From:
Embase <1980 to 2022 Week 17>
Embase Weekly Updates (updates since 2022-04-22)

<1>
Accession Number
2012318527
Title
Near-infrared spectroscopy device selection affects intervention
management for cerebral desaturation during cardiopulmonary bypass
surgery.
Source
General Thoracic and Cardiovascular Surgery. 70(1) (pp 11-15), 2022. Date
of Publication: January 2022.
Author
Kobayashi K.; Kitamura T.; Kohira S.; Inoue N.; Fukunishi T.; Miyaji K.
Institution
(Kobayashi, Kitamura, Inoue, Fukunishi, Miyaji) Department of
Cardiovascular Surgery, Kitasato University School of Medicine, 1-15-1
Kitasato, Minami, Kanagawa, Sagamihara 252-0375, Japan
(Kohira) Department of Medical Engineering, Kitasato University Hospital,
Sagamihara, Japan
Publisher
Springer Japan
Abstract
Objective: Currently, several near-infrared spectroscopy oximetry devices
are used for detecting cerebral ischemia during cardiopulmonary bypass
(CPB) surgery. We investigated whether two different models of
near-infrared spectroscopy oximetry devices affect the assessment of
cerebral ischemia and its management during CPB. Method(s): From
January 2017 to August 2017, 70 adult cardiovascular surgery cases were
randomly assigned to 1 of 2 different near-infrared spectroscopy oximetry
devices. The devices were INVOS 5100C (Medtronic, Minneapolis, MN, USA)
(group I; n = 35) and FORE-SIGHT ELITE (CAS Medical Systems, Branford, CT,
USA) (group F; n = 35). Result(s): There were no significant
differences in patient characteristics. The rSO<inf>2</inf> values were
significantly higher for patients in group F than for patients in group I.
Scalp-Cortex distance showed negative correlations with the mean
rSO<inf>2</inf> values in group I (P = 0.01). Interventions for low
rSO<inf>2</inf> during CPB for groups I and F were increase perfusion flow
(13:5; P = 0.03), blood transfusion (7:1; P = 0.02), and both (6:1; P =
0.04), respectively. The Scalp-Cortex distance in group I was
significantly longer in patients who required intervention than in
patients who did not (17.1 +/- 2.5 vs 15.1 +/- 1.6 mm; P = 0.007).
 Conclusion(s): It is inappropriate to use the same intervention
criteria for different near-infrared spectroscopy oximetry devices.
Moreover, brain atrophy influence rSO<inf>2</inf> values depending on
device selection. It is important to note that inappropriate device
selection may misguide perfusionists into performing unnecessary or
excessive intervention during CPB. Copyright © 2021, The Japanese
Association for Thoracic Surgery.

<2>
Accession Number
2014806647
Title
Evaluation of Different Pain-Control Procedures for Post-cardiac Surgery:
A Systematic Review and Network Meta-Analysis.
Source
Surgical Innovation. 29(2) (pp 269-277), 2022. Date of Publication: April
2022.
Author
Hu M.; Wang Y.; Hao B.; Gong C.; Li Z.
Institution
(Hu, Gong, Li) Department of Hepatobiliary and Pancreatic Surgery,
Zhongnan Hospital of Wuhan University, Wuhan, China
(Wang) Department of Cardiovascular Surgery, TEDA International
Cardiovascular Hospital, Chinese Academy of Medical Sciences Peking Union
Medical College, Tianjin, China
(Hao) School of Nursing, Huanggang Polytechnic College, Huanggang, China
Publisher
SAGE Publications Inc.
Abstract
Objective: To identify superior pain-control procedures for postoperative
patients who undergo cardiac surgeries. Method(s): Literature
searches were conducted in globally recognized databases, including
MEDLINE, EMBASE and Cochrane Central, to identify randomized controlled
trials (RCTs) investigating pain-control procedures after cardiac
surgeries. The parameters evaluating analgesic efficacy and postoperative
recovery, namely, the pain score and ICU stay, were quantitatively pooled
and estimated using Bayesian methods. The values of the surface under the
cumulative ranking (SUCRA) probabilities regarding each parameter were
calculated to enable the ranking of various pain-control procedures.
Node-splitting analysis was performed to test the inconsistency of the
main results, and the publication bias was assessed by examining the
funnel-plot symmetry. Result(s): After a detailed review, 13 RCTs
containing 7 different procedures were included in the network
meta-analysis. After pooling the results together, an erector spinae plane
block (ESPB) and a local parasternal block (LPB) plus target-controlled
infusion (TCI) presented the best analgesic effects for reducing pain at
rest (SUCRA,.47) and during movement (SUCRA,.52), respectively, while the
former also achieved the shortest ICU stay (SUCRA,.48). Moreover, the
funnel-plot symmetries showed no inconsistencies or obvious publication
bias in the current study. Conclusion(s): The current evidence
indicates that ESPB is a potential superior analgesic strategy for
post-cardiac surgery patients. To verify this conclusion further, it is
imperative to obtain more high-quality evidence and conduct relevant
investigations in the future. Copyright © The Author(s) 2022.

<3>
Accession Number
636930953
Title
Incidence of postoperative delirium in patients with preoperative and
postoperative Obstructive Sleep Apnea Syndrome. A Systematic Review of the
literature.
Source
Saudi Journal of Anaesthesia. 16(1) (pp 94-103), 2022. Date of
Publication: January-March 2022.
Author
Dooijeweerd S.; Torensma B.; Faraj D.; Eldawlatly A.A.
Institution
(Torensma) Department of Anaesthesiology, Leiden University Medical
Center, Leiden, Netherlands
(Dooijeweerd, Torensma) Department of Surgery, Dutch Obesity Clinic West,
The Hague, Netherlands
(Faraj) Department of Surgery, Groene Hart Hospital, Gouda, Netherlands
(Eldawlatly) King Saudi University Hospital, Riyadh, Saudi Arabia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Clinical research has suggested that there might be a
correlation between postoperative delirium (POD) and obstructive sleep
apnea (OSA) syndrome. We aimed to assess the association between POD and
OSA syndrome. Method(s): The electronic database PubMed was searched
using combinations of terms for 'Delirium,"'Obstructive Sleep Apnea,"and
'postoperative delirium."Excluded were studies without comparison as well
as cross-sectional studies, case series, and case reports. The search was
conducted with restriction toward English or not to the date of
publication. Result(s): We included four studies in this review. In
two of those studies, an association was found between POD and OSA
syndrome. Pooled analysis showed a significant correlation between the
two. Conclusion(s): High-quality studies regarding the subject are
rare and heterogeneous. However, despite the lack of high-quality studies
regarding the subject, the ones that are performed well conclude that
there is a correlation between POD and OSA syndrome. Future studies
addressing the matter should be well set up controlled clinical trials to
draw conclusions and be able to investigate modifiable factors that can be
used in a standardized protocol. Copyright © 2022 Saudi Journal
of Anesthesia.

<4>
Accession Number
636930805
Title
Prophylactic use of donut-shaped cushion to reduce sacral pressure
injuries during open heart surgery.
Source
Saudi Journal of Anaesthesia. 16(1) (pp 17-23), 2022. Date of Publication:
January-March 2022.
Author
Heo M.H.; Kim J.Y.; Park B.I.; Lee S.I.; Kim K.-T.; Park J.S.; Choe W.J.;
Kim J.H.
Institution
(Heo, Kim, Park, Lee, Kim, Park, Choe, Kim) Department of Anesthesiology
and Pain Medicine, Inje University Ilsan Paik Hospital, Gyeonggi-do,
Goyang, South Korea
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Pressure injuries are likely to develop in the operating room
due to the high temperature and humidity underneath the patients. This
study was designed to reduce sacral pressure injuries using donut-shaped
cushions on patients undergoing open heart surgery in a supine position
for more than three hours. Material(s) and Method(s): Patients
undergoing open heart surgery for more than three hours were randomly
allocated. Depending on the allocation, either the donut-shaped cushion
(donut group) or hydrophilic foam dressing (control group) was applied
before draping. Patients were evaluated for the development of pressure
injuries, National Pressure Ulcer Advisory Panel (NPUAP) stage, and injury
size immediately after surgery, 48 hours, and seven days after surgery.
 Result(s): Forty-five patients were enrolled in this study.
Twenty-two were assigned to the donut group and 23 were assigned to the
control group. Three patients developed pressure injuries of NPUAP stage I
or higher. All injuries occurred in the control group, but there was no
statistically significant difference (P = 0.083). Conclusion(s):
Patients who underwent cardiac surgery for more than three hours and used
a donut-shaped cushion did not develop pressure injuries, although no
statistical difference was noted. Specific preventative measures in the
operating room may play a crucial role in preventing pressure injuries,
and further research should be pursued. Copyright © 2022 Saudi
Journal of Anesthesia.

<5>
Accession Number
2015418216
Title
Effects of Preserving the Pulmonary Vagus Nerve Branches on Cough After
Pneumonectomy During Video-Assisted Thoracic Surgery.
Source
Frontiers in Oncology. 12 (no pagination), 2022. Article Number: 837413.
Date of Publication: 09 Mar 2022.
Author
Gu S.; Wang W.; Wang X.; Wu K.; Zhang X.; Xie S.; Zhou Y.
Institution
(Gu, Wang, Wang, Wu, Zhang, Xie, Zhou) Department of Thoracic Surgery,
Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai,
China
Publisher
Frontiers Media S.A.
Abstract
Background: Cough is one of the most common complications of early-stage
non-small cell lung cancer (NSCLC) after video-assisted thoracoscopic
surgery (VATS). The vagus nerve plays an important role in pulmonary
inflammation and the cough reflex. In this study, we attempted to reduce
the incidence of postoperative chronic cough and other complications by
preserving the pulmonary vagus nerve branches. Patients and Methods:
This study was a randomized controlled double-blinded trial of subjects
and observers. A total of 158 NSCLC patients were enrolled. We randomly
assigned 79 patients to Group A (pulmonary branch of vagus nerve
preservation group) and 79 cases to Group B (conventional surgical
treatment group). In the final analysis, 72 patients from Group A and 69
patients from Group B were included. The main outcome measure of the study
was the occurrence of CAP or other postoperative complications within five
weeks. This trial was registered with ClinicalTrials.gov (number
NCT03921828). Result(s): There was no significant difference in
preoperative general clinical data between the two groups. No death during
the perioperative period occurred in either of the two groups. There was
no significant difference between the two groups in operation time,
intraoperative bleeding, number of lymph nodes sent for examination,
number of cases transferred to ICU after operation, postoperative
catheterization time, or postoperative hospital stay (P>0.05). There was
no significant difference in other pulmonary and cardiovascular
complications between the two groups, including pulmonary infection (2.78%
vs. 8.70%, P = 0.129), atelectasis (1.39% vs. 0%, P = 0.326), pleural
effusion (2.78% vs. 1.45%, P = 0.585), persistent pulmonary leakage (2.78%
vs. 2.90%, P = 0.965), arrhythmia (2.78% vs. 1.45%, P = 0.585), and heart
failure (0% vs. 1.45%, P = 0.305). The incidence of CAP in Group A was
significantly lower than that in Group B (13.89% vs. 30.43%, P = 0.018).
The LCQ-MC scores in Group A were significantly higher than those in Group
B at two and five weeks after operation (P<0.05). Univariate and
multivariate analysis showed that the risk factors for postoperative CAP
were surgical side (right lung), surgical lung lobe (upper lobe),
preservation of pulmonary branch of the vagus nerve during operation, and
duration of anesthesia. Conclusion(s): Preserving the pulmonary vagus
nerve branches during VATS in patients with stage IA1-2 NSCLC can reduce
the incidence of postoperative CAP. Copyright © 2022 Gu, Wang,
Wang, Wu, Zhang, Xie and Zhou.

<6>
Accession Number
2016400950
Title
Clinical Presentation and Management of Methicillin-Resistant
Staphylococcus Aureus Pericarditis-Systematic Review.
Source
Journal of Cardiovascular Development and Disease. 9(4) (no pagination),
2022. Article Number: 103. Date of Publication: April 2022.
Author
Radovanovic M.; Petrovic M.; Hanna R.D.; Nordstrom C.W.; Calvin A.D.;
Barsoum M.K.; Milosavljevic N.; Jevtic D.; Sokanovic M.; Dumic I.
Institution
(Radovanovic, Hanna, Nordstrom, Calvin, Barsoum, Milosavljevic, Dumic)
Mayo Clinic Alix School of Medicine, Rochester, MN 55905, United States
(Radovanovic, Nordstrom, Dumic) Department of Hospital Medicine, Mayo
Clinic Health System, Eau Claire, WI 54703, United States
(Petrovic, Jevtic) Icahn School of Medicine at Mount Sinai, New York, NY
10029, United States
(Hanna, Calvin, Barsoum) Department of Cardiology, Mayo Clinic Health
System, Eau Claire, WI 54703, United States
(Milosavljevic) Department of Pediatric and Adolescent Medicine, Mayo
Clinic Health System, Eau Claire, WI 54703, United States
(Jevtic) Department of Internal Medicine, Elmhurst Hospital Center,
Elmhurst, NY 11373, United States
(Sokanovic) Department of Infectious Disease, Jackson Hospital,
Montgomery, AL 36106, United States
Publisher
MDPI
Abstract
In the expanding era of antibiotic resistance, new strains of
Staphylococcus aureus have emerged which possess resistance to
traditionally used antibiotics (MRSA). Our review aimed to systematically
synthesize information on previously described MRSA pericarditis cases.
The only criterion for inclusion was the isolation of MRSA from the
pericardial space. Our review included 30 adult and 9 pediatric patients
(aged: 7 months to 78 years). Comorbid conditions were seen in most adult
patients, whereas no comorbidities were noted amongst the pediatric
patients. Pericardial effusion was found in 94.9% of cases, with evidence
of tamponade in 83.8%. All cases isolated MRSA from pericardial fluid and
25 cases (64.1%) had positive blood cultures for MRSA. Pericardiocentesis
and antibiotics were used in all patients. The mortality rate amongst
adults was 20.5%, with a mean survival of 21.8 days, and attributed to
multi-organ failure associated with septic shock. No mortality was
observed in the pediatric population. In adult patients, there was no
statistical difference in symptom duration, antibiotic duration, presence
of tamponade, age, and sex in relation to survival. Conclusion(s):
MRSA pericarditis often presents with sepsis and is associated with
significant mortality. As such, a high clinical suspicion is needed to
proceed with proper tests such as echocardiography and pericardiocentesis.
In more than one third of the cases, MRSA pericarditis occurs even in the
absence of documented bacteremia. Copyright © 2022 by the
authors. Licensee MDPI, Basel, Switzerland.

<7>
Accession Number
635563754
Title
Multiple versus single arterial grafting in the elderly: a meta-analysis
of randomized controlled trials and propensity score studies.
Source
The Journal of cardiovascular surgery. 63(2) (pp 169-178), 2022. Date of
Publication: 01 Apr 2022.
Author
Saraiva F.A.; Moreira R.; Cerqueira R.J.; Mancio J.; Barros A.S.; Lourenco
A.P.; Leite-Moreira A.F.
Institution
(Saraiva, Moreira, Cerqueira, Mancio, Barros, Lourenco) Department of
Surgery and Physiology, Cardiovascular Research and Development Center,
Faculty of Medicine, University of Porto, Porto, Portugal
(Cerqueira, Leite-Moreira) Department of Cardiothoracic Surgery, Sao Joao
University Hospital, Porto, Portugal
(Mancio) Bart's Health NHS Trust, St. Bartholomew's Hospital, London,
United Kingdom
(Lourenco) Department of Anesthesiology, Sao Joao University Hospital,
Porto, Portugal
(Leite-Moreira) Department of Surgery and Physiology, Cardiovascular
Research and Development Center, Faculty of Medicine, University of Porto,
Porto, Portugal
Publisher
NLM (Medline)
Abstract
INTRODUCTION: The benefit of adding a second arterial conduit is still
controversial, mainly in specific subgroups. We conducted a meta-analysis
of randomized controlled trials (RCTs) and propensity score (PS) studies
comparing survival and early results in elderly patients who underwent
coronary artery bypass grafting (CABG) with multiple (MAG) versus single
arterial grafting (SAG). EVIDENCE ACQUISITION: MEDLINE, Web of Science and
Cochrane Library were used to find relevant literature (1960-April 2020).
Survival at a >=1-year follow-up and early outcomes were evaluated.
Outcomes were collected from matched samples or PS adjusted analysis:
hazard ratio (HR) along with their variance, frequencies or odds ratios.
Random effect models were used to compute combined statistical measures
and 95% confidence intervals (CI) through generic inverse variance method
(time-to-event) or Mantel-Haenszel method (binary events). EVIDENCE
SYNTHESIS: Eleven PS cohorts and 1 RCT comprising >18,800 patients older
than 70 (>6200 MAG and >12,500 SAG) were included in this meta-analysis.
MAG was associated with lower long-term mortality (pooled HR: 0.81, 95%
CI: 0.72-0.91, P<0.01, I2=64%) in the absence of higher risk of early
mortality (pooled OR: 0.74, 95% CI: 0.44 to 1.25, P=0.27, I2=0%). In a
meta-regression, MAG survival advantage was more pronounced in studies
with a higher MAG usage rate (beta=-0.0052, P=0.021). CONCLUSION(S):
Current evidence suggests that advanced age should not limit MAG's use
considering its benefits in long-term survival. Of note, an individualized
patient selection for this approach is warranted.

<8>
Accession Number
2013387147
Title
The role of viscoelastic testing in assessing peri-interventional platelet
function and coagulation.
Source
Platelets. 33(4) (pp 520-530), 2022. Date of Publication: 2022.
Author
Tantry U.S.; Hartmann J.; Neal M.D.; Schoechl H.; Bliden K.P.; Agarwal S.;
Mason D.; Dias J.D.; Mahla E.; Gurbel P.A.
Institution
(Tantry, Bliden, Gurbel) Sinai Center for Thrombosis Research and Drug
Development, Sinai Hospital of Baltimore, Baltimore, MD, United States
(Hartmann, Mason, Dias) Medical Affairs and Clinical Development,
Haemonetics Corporation, Boston, MA, United States
(Neal) Department of General Surgery, The University of Pittsburgh Medical
Center, Pittsburgh, PA, United States
(Schoechl) Department of Anesthesiology and Intensive Care Medicine, AUVA
Trauma Centre Salzburg, Academic Teaching Hospital, Paracelsus Medical
University, Salzburg, Austria
(Schoechl) AUVA Trauma Research Centre, Ludwig Boltzmann Institute for
Experimental and Clinical Traumatology, Vienna, Austria
(Agarwal) Department of Anaesthesia, Manchester University Foundation
Trust, Manchester, United Kingdom
(Mahla) Department of Anaesthesiology and Intensive Care Medicine, Medical
University of Graz, Graz, Austria
Publisher
Taylor and Francis Ltd.
Abstract
We carried out a literature search in MEDLINE (PubMed) and EMBASE
literature databases to provide a concise review of the role of
viscoelastic testing in assessing peri-interventional platelet function
and coagulation. The search identified 130 articles that were relevant for
the review, covering the basic science of VHA and VHA in clinical settings
including cardiac surgery, cardiology, neurology, trauma, non-cardiac
surgery, obstetrics, liver disease, and COVID-19. Evidence from these
articles is used to describe the important role of VHAs and platelet
function testing in various peri-interventional setups. VHAs can help us
to comprehensively assess the contribution of platelets and coagulation
dynamics to clotting at the site-of-care much faster than standard
laboratory measures. In addition to standard coagulation tests, VHAs are
beneficial in reducing allogeneic transfusion requirements and bleeding,
in predicting ischemic events, and improving outcomes in several
peri-interventional care settings. Further focused studies are needed to
confirm their utility in the peri-interventional case. Copyright
© 2021 The Author(s). Published with license by Taylor & Francis
Group, LLC.

<9>
Accession Number
2015881163
Title
The impact of the COVID-19 pandemic on care delivery and quality of life
in lung cancer surgery.
Source
Journal of Surgical Oncology. (no pagination), 2022. Date of Publication:
2022.
Author
Teteh D.K.; Barajas J.; Ferrell B.; Zhou Z.; Erhunmwunsee L.; Raz D.J.;
Kim J.Y.; Sun V.
Institution
(Teteh) Department of Health Sciences, Crean College of Health and
Behavioral Sciences, Chapman University, Orange, CA, United States
(Barajas, Ferrell, Zhou, Sun) Division of Nursing Research and Education,
Department of Population Sciences, City of Hope Comprehensive Cancer
Center, Duarte, CA, United States
(Erhunmwunsee, Raz, Kim, Sun) Department of Surgery, City of Hope
Comprehensive Cancer Center, Duarte, CA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (COVID-19) pandemic and associated restrictions have altered
the delivery of surgical care. The purpose of this study was to explore
the impact of COVID-19 on care delivery and quality of life (QOL) from the
perspectives of lung cancer surgery patients, family caregivers (FCGs),
and thoracic surgery teams. Method(s): Patients/FCGs enrolled in a
randomized trial of a self-management intervention for lung cancer surgery
preparation/recovery were invited to participate in this qualitative
study. Patients/FCGs data were collected separately 1-month postdischarge.
Interviews were also conducted with thoracic surgery team members. Content
analysis approaches were used to develop themes. Result(s): Forty-one
respondents including 19 patients, 18 FCGs, three thoracic surgeons, and
one nurse practitioner participated in the study. Patient themes included
isolation, psychological distress, delayed/impacted care, and financial
impact. FCGs themes included caregiving challenges, worry about COVID-19,
financial hardship, isolation, and physical activity limitations. Surgical
team themes included witnessing patient/FCG's distress, challenges with
telehealth, communication/educational challenges, and delays in treatment.
 Conclusion(s): COVID-19 had a varied impact on care delivery and QOL
for lung cancer surgery dyads. Some dyads reported minimal impact, while
others experienced added psychological distress, isolation, and caregiving
challenges. Surgical teams also experienced challenges in the approach
used to provide care. Copyright © 2022 The Authors. Journal of
Surgical Oncology published by Wiley Periodicals LLC.

<10>
Accession Number
2015804538
Title
Surgical versus medical treatment for infective endocarditis in patients
on dialysis: a systematic review and meta-analysis.
Source
Renal Failure. 44(1) (pp 706-713), 2022. Date of Publication: 2022.
Author
Ting S.-W.; Chen J.-J.; Lee T.-H.; Kuo G.
Institution
(Ting) Department of Dermatology, New Taipei City Municipal Tucheng
Hospital, New Taipei City, Taiwan (Republic of China)
(Chen, Lee, Kuo) Department of Nephrology, Kidney Research Center, Linkou
Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China)
(Lee) Department of Nephrology, New Taipei City Municipal Tucheng
Hospital, New Taipei City, Taiwan (Republic of China)
Publisher
Taylor and Francis Ltd.
Abstract
Infective endocarditis (IE) is a serious infection and causes significant
morbidity and mortality. However, the benefit of surgery for endocarditis
besides antibiotic treatment in dialysis patients remains controversial.
We performed a systematic review of studies published between 1960 and
February 2022. Meta-analysis was conducted with a random-effects model to
explore the in-hospital, 30, 60, 90, 180-d, and 1-year mortality rates in
adult dialysis patients with IE. Sensitivity analysis, subgroup analysis,
and meta-regression were performed to explore potential sources of
heterogeneity. Confidence of evidence was evaluated by the GRADE system.
Thirteen studies were included. The pooled odds ratio of in-hospital
mortality was 0.62 (95% confidence interval [CI]: 0.30-1.28, p =.17), with
moderate heterogeneity (I 2 = 62%, p <.01). Three studies
reported 30-d mortality, and the pooled odds ratio for surgery compared
with medical treatment was even lower (0.36; 95% CI: 0.22-0.61, p <.01),
with low heterogeneity (I 2 = 0%, p =.86). With studies on
fewer than 30 patients excluded, the sensitivity analysis revealed a low
odds ratio of in-hospital mortality for surgery versus medical treatment
(0.52; 95% CI: 0.27-0.99, p =.047), with moderate heterogeneity (I
2 = 63%, p <.01). Subgroup analysis revealed no significant
differences between any two comparator subgroups. Based on a very low
strength of evidence, compared with medical treatment, surgical treatment
for IE in patients on dialysis is not associated with lower in-hospital
mortality. When studies on fewer than 30 patients were excluded, surgical
treatment was associated with better survival. Copyright © 2022
The Author(s). Published by Informa UK Limited, trading as Taylor &
Francis Group.

<11>
Accession Number
2014217421
Title
Radial versus femoral secondary access for transcatheter aortic valve
replacement: A systematic review and meta-analysis.
Source
Catheterization and Cardiovascular Interventions. 99(4) (pp 1225-1233),
2022. Date of Publication: March 1, 2022.
Author
Das T.M.; Shin J.; Czarny M.J.; Nanavati J.; Resar J.R.; Hasan R.K.
Institution
(Das, Shin) Department of Medicine, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
(Czarny, Resar, Hasan) Department of Medicine, Division of Cardiology,
Johns Hopkins University School of Medicine, Baltimore, MD, United States
(Nanavati) Welch Medical Library, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
Publisher
John Wiley and Sons Inc
Abstract
Objectives: We aimed to evaluate the risk of procedural complications
after TAVR using secondary radial access (RA) versus femoral access (FA)
through a systematic review and meta-analysis of the published literature.
 Background(s): Transcatheter aortic valve replacement (TAVR) entails
both large-bore arterial access for device delivery and secondary arterial
access for hemodynamic and imaging assessments. It is unknown whether RA
versus FA for this secondary access reduces the risk of procedural
complications. Method(s): We searched PubMed, Embase, the Cochrane
Library, and Web of Science for observational studies comparing TAVR
procedural complications in RA versus FA. Event rates were compared via
weighted summary odds ratios using the Mantel-Haenszel method.
 Result(s): Six manuscripts encompassing 6132 patients were included.
Meta-analysis showed that RA reduced the risk of major vascular
complications (OR 0.58, 95% CI 0.43-0.77, p < 0.001, I2 0%) and
major/life-threatening bleeding (OR 0.46, 95% CI 0.36-0.59, p < 0.001,
I2 0%) as compared to FA for secondary TAVR access. We also
observed a reduction 30-day mortality (OR 0.55, 95% CI 0.38-0.79, p =
0.001, I2 0%), acute kidney injury (OR 0.45, 95% CI 0.34-0.60,
p < 0.001, I2 0%), and stroke and transient ischemic attack (OR
0.43, 95% CI 0.27-0.67, p < 0.001, I2 0%). Conclusion(s):
RA reduced the risk of major vascular and bleeding complications when
compared to FA for secondary access in TAVR. RA is associated with reduced
risk of other adverse outcomes including mortality, but these associations
may be related to selection bias and confounding given the observational
study designs. Copyright © 2021 Wiley Periodicals LLC.

<12>
Accession Number
2015929267
Title
Acute Kidney Injury and 3-Year Mortality in Elderly Patients After
Non-cardiac Surgery.
Source
Frontiers in Medicine. 9 (no pagination), 2022. Article Number: 779754.
Date of Publication: 12 Apr 2022.
Author
Wu Q.-F.; Xing M.-W.; Hu W.-J.; Su X.; Zhang D.-F.; Mu D.-L.; Wang D.-X.
Institution
(Wu, Xing, Su, Mu, Wang) Department of Anesthesiology and Critical Care
Medicine, Peking University First Hospital, Beijing, China
(Hu) Department of Anesthesiology, The 305th Hospital of the Chinese
People's Liberation Army, Beijing, China
(Zhang) Department of Anesthesiology, Fujian Medical University Union
Hospital, Beijing, China
Publisher
Frontiers Media S.A.
Abstract
Objective: The present study aimed to investigate whether acute kidney
injury (AKI) was associated with 3-year mortality in elderly patients
after non-cardiac surgery. Method(s): The present study was a 3-year
follow-up study of two randomized controlled trials. A total of 1,319
elderly patients who received non-cardiac surgery under general anesthesia
were screened. AKI was diagnosed by the elevation of serum creatinine
within a 7-day postoperative period according to Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines. A long-term telephonic follow-up was
undertaken by investigators who were not involved in the previous two
trials and had no access to the study group assignment. The date of death
was taken from the official medical death certificate. The primary outcome
was to investigate the association between AKI and postoperative 3-year
mortality using the multivariable Cox regression risk model.
 Result(s): Of the 1,297 elderly patients (mean age 71.8 +/- 7.2 years
old) who were included in the study, the incidence of AKI was 15.5%
(201/1297). Of the patients with AKI, 85% (170/201) were at stage 1, 10%
(20/201) at stage 2, and 5% (11/201) at stage 3. The 3-year all-cause
mortality was 28.9% (58/201) in patients with AKI and 24.0% (263/1,096) in
patients without AKI (hazard ratio 1.247, 95% confidence interval
0.939-1.657, P = 0.128). The multivariable Cox regression showed that AKI
was not associated with 3-year mortality after adjustment of confounding
factors (adjusted hazard ratio 1.045, 95% confidence interval 0.780-1.401,
P = 0.766). Conclusion(s): AKI was a common postoperative
complication, but it was not associated with 3-year mortality in elderly
patients who underwent non-cardiac surgery. The low incidence of severe
AKI might underestimate its underlying association with long-term
mortality. Copyright © 2022 Wu, Xing, Hu, Su, Zhang, Mu and Wang.

<13>
Accession Number
2017780743
Title
Bone Marrow Cells Improve Coronary Flow Reserve in Ischemic
Nonrevascularized Myocardium: A MiHeart/IHD Quantitative Perfusion CMR
Substudy.
Source
JACC: Cardiovascular Imaging. 15(5) (pp 812-824), 2022. Date of
Publication: May 2022.
Author
Assuncao-Jr A.N.; Rochitte C.E.; Kwong R.Y.; Wolff Gowdak L.H.; Krieger
J.E.; Jerosch-Herold M.
Institution
(Assuncao-Jr, Rochitte, Wolff Gowdak, Krieger) Heart Institute (InCor),
University of Sao Paulo Medical School, Brazil, Sao Paulo, Brazil
(Kwong, Jerosch-Herold) Division of Cardiovascular Medicine and Radiology,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United
States
Publisher
Elsevier Inc.
Abstract
Objectives: This study investigated whether intramyocardial bone
marrow-derived hematopoietic progenitor cells (BMCs) increase coronary
flow reserve (CFR) in ischemic myocardial regions where direct
revascularization was unsuitable. Background(s): Patients with
diffuse coronary artery disease frequently undergo incomplete myocardial
revascularization, which increases their risk for future adverse
cardiovascular outcomes. The residual regional ischemia related to both
untreated epicardial lesions and small vessel disease usually contributes
to the disease burden. Method(s): The MiHeart/IHD study randomized
patients with diffuse coronary artery disease undergoing incomplete
coronary artery bypass grafting to receive BMCs or placebo in ischemic
myocardial regions. After the procedure, 78 patients underwent
cardiovascular magnetic resonance (CMR) at 1, 6, and 12 months and were
included in this cardiac magnetic resonance substudy with perfusion
quantification. Segments were classified as target (injected), adjacent
(surrounding the injection site), and remote from injection site.
 Result(s): Of 1,248 segments, 269 were target (22%), 397 (32%)
adjacent, and 582 (46%) remote. The target had significantly lower CFR at
baseline (1.40 +/- 0.79 vs 1.64 +/- 0.89 in adjacent and 1.79 +/- 0.79 in
remote; both P < 0.05). BMCs significantly increased CFR in target and
adjacent segments at 6 and 12 months compared with placebo. In target
regions, there was a progressive treatment effect (27.1% at 6 months, P =
0.037, 42.2% at 12 months, P = 0.001). In the adjacent segments, CFR
increased by 21.8% (P = 0.023) at 6 months, which persisted until 12
months (22.6%; P = 0.022). Remote segments in both the BMC and placebo
groups experienced similar improvements in CFR (not significant at 12
months compared with baseline). Conclusion(s): BMCs, injected in
severely ischemic regions unsuitable for direct revascularization, led to
the largest CFR improvements, which progressed up to 12 months, compared
with smaller but persistent CFR changes in adjacent and no improvement in
remote segments. Copyright © 2022 The Authors

<14>
Accession Number
637841567
Title
Bleeding risk differences after TAVR according to the ARC-HBR criteria:
insights from SCOPE 2.
Source
EuroIntervention : journal of EuroPCR in collaboration with the Working
Group on Interventional Cardiology of the European Society of Cardiology.
(no pagination), 2022. Date of Publication: 22 Apr 2022.
Author
Garot P.; Neylon A.; Morice M.-C.; Tamburino C.; Bleiziffer S.; Thiele H.;
Scholtz S.; Schramm R.; Cockburn J.; Cunnington M.; Wolf A.; Barbanti M.;
Tchetche D.; Pagnotta P.; Gilard M.; Bedogni F.; Van Belle E.;
Vasa-Nicotera M.; Chieffo A.; Bogaerts K.; Hengstenberg C.; Capodanno D.
Institution
(Garot, Neylon, Morice) Institut Cardiovasculaire Paris-Sud, Hopital Prive
Jacques Cartier, Massy, France
(Tamburino, Capodanno) Division of Cardiology Azienda Ospedaliero
Universitaria "Policlinico-Vittorio Emanuele" University of Catania,
Catania, Italy
(Bleiziffer, Schramm) Department of Thoracic and Cardiovascular Surgery,
Heart and Diabetes Center Northrhein-Westfalia, University Hospital,
Ruhr-University Bochum, Bad Oeynhausen, Germany
(Thiele) Department of Cardiology, Leipzig Heart Center, University of
Leipzig, Leipzig, Germany
(Scholtz) Department of Interventional Cardiology, Heart and Diabetes
Center North Rhine Westfalia, Bad Oeynhausen, Germany
(Cockburn) Department of Cardiology, Brighton & Sussex University
Hospitals NHS Trust, Brighton, United Kingdom
(Cunnington) Department of Cardiology, Leeds General Infirmary, Leeds
Teaching Hospitals NHS Trust, Leeds, United Kingdom
(Wolf) Department of Interventional Cardiology, Elisabeth Hospital Essen,
Essen, Germany
(Barbanti) Department of Cardio-Thoracic-Vascular diseases and
transplantation, Catania, Italy
(Tchetche) Groupe CardioVasculaire Interventionnel, Clinique Pasteur,
Toulouse, France
(Pagnotta) Department of Cardiovascular Medicine, Humanitas Clinical and
Research Center, Milano, Italy
(Gilard) Department of Cardiology, Brest University Hospital, Brest,
France
(Bedogni) Cardiology Department, IRCCS Policlinico San Donato, Milano,
Italy
(Van Belle) Department of Cardiology, Lille University Hospital, Lille,
France
(Vasa-Nicotera) Department of Cardiology, Goethe University Hospital
Frankfurt, Frankfurt am Main, Germany
(Chieffo) Interventional Cardiology Unit, IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Bogaerts) KU Leuven, Faculty of Medicine, I-BioStat, Leuven, Belgium and
UHasselt, I-BioStat, Hasselt, Belgium
(Hengstenberg) Department of Internal Medicine II, Medical University of
Vienna, Vienna, Austria
Publisher
NLM (Medline)
Abstract
BACKGROUND: The Academic Research Consortium - High Bleeding Risk
(ARC-HBR) initiative defined conditions associated with percutaneous
coronary intervention (PCI)-related bleeding. AIMS: We sought to further
explore these HBR conditions in the setting of transcatheter aortic valve
replacement (TAVR). METHOD(S): Patients from the SCOPE 2 trial were
stratified by their bleeding risk status based on the ARC-HBR definitions.
Baseline and procedural characteristics, as well as key clinical outcomes
including Bleeding Academic Research Consortium (BARC) 3-5 bleeding, were
compared in ARC-HBR positive (HBR+) and ARC-HBR negative (HBR-) patients.
 RESULT(S): Of 787 patients randomised in SCOPE 2 and included in this
study, 633 were HBR+ (80.4%). Compared with HBR- patients, those HBR+ were
older and more frequently presented with diabetes, a history of coronary
artery disease, atrial fibrillation, prior cerebrovascular accident, and a
Society of Thoracic Surgeons predicted risk of 30-day mortality (STS-PROM)
(4.9+/-2.9% vs 3.3%+/-2.1%; p<0.0001). In addition, HBR+ patients were
more frequently on oral anticoagulation therapy. At 1 year, HBR+ patients
had higher rates of all-cause death (12.4% vs 4.3%, respectively, risk
difference 8.09%; 95% confidence interval [CI]: 3.76-12.41; p=0.0002); the
rates of BARC 3-5 type bleeding were relatively high but not statistically
different compared with HBR- patients (7.7% vs 6.1%, risk difference
1.67%; 95% CI: -2.72-6.06; p=0.46). Subgroup analyses for bleeding events
showed no significant interaction in terms of STS-PROM score, age, or
medications. CONCLUSION(S): The ARC-HBR criteria failed to isolate a
subgroup of patients at higher bleeding risk in TAVR patients from a
randomised trial. These findings have potential implications, especially
for the selection of post-TAVR antithrombotic regimens based on individual
bleeding-risk profiles. Specific HBR criteria should be defined for TAVR
patients.

<15>
Accession Number
637841011
Title
Characterization of Near-Infrared Imaging and Indocyanine-Green Use
Amongst General Surgeons: A Survey of 263 General Surgeons.
Source
Surgical innovation. (pp 15533506221094962), 2022. Date of Publication:
22 Apr 2022.
Author
Verhoeff K.; Mocanu V.; Fang B.; Dang J.; Sun W.; Switzer N.J.; Birch
D.W.; Karmali S.
Institution
(Verhoeff, Mocanu, Fang, Dang, Sun, Switzer) Department of Surgery,
3158University of Alberta, AB, Edmonton, Canada
(Birch, Karmali) Centre for Advancement of Surgical Education and
Simulation (CASES), Royal Alexandra Hospital, AB, Edmonton, Canada
Publisher
NLM (Medline)
Abstract
BACKGROUND: Near-infrared fluorescence imaging (NIRFI) is an increasingly
utilized imaging modality, however its use amongst general surgeons and
its barriers to adoption have not yet been characterized. METHOD(S):
This survey was sent to Canadian Association of General Surgeons and the
Society of American Gastrointestinal and Endoscopic Surgeons members.
Survey development occurred through consensus of NIRFI experienced
surgeons. RESULT(S): Survey completion rate for those opening the
email was 16.0% (n = 263). Most respondents had used NIRFI (n = 161,
61.2%). Training, higher volumes, and bariatric, thoracic, or foregut
subspecialty were associated with use (P < .001).Common reasons for NIRFI
included anastomotic assessment (n = 117, 72.7%), cholangiography (n =
106, 65.8%), macroscopic angiography (n = 66, 41.0%), and bowel viability
assessment (n = 101, 62.7%). Technical knowledge, training and poor
evidence were cited as common barriers to NIRFI adoption.
 CONCLUSION(S): NIRFI use is common with high case volume, bariatric,
foregut, and thoracic surgery practices associated with adoption. Barriers
to use appear to be lack of awareness, low confidence in current evidence,
and inadequate training. High quality randomized studies evaluating NIRFI
are needed to improve confidence in current evidence; if deemed
beneficial, training will be imperative for NIRFI adoption.

<16>
Accession Number
637840912
Title
Preoperative Oral Magnesium loading to prevent postoperative Atrial
Fibrillation following Coronary Surgery (POMAF-CS): A prospective
randomized controlled trial.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2022.
Date of Publication: 22 Apr 2022.
Author
Tohme J.; Sleilaty G.; Jabbour K.; Gergess A.; Hayek G.; Jebara V.;
Madi-Jebara S.
Institution
(Tohme, Jabbour, Gergess, Hayek, Madi-Jebara) Department of anesthesia and
critical care, Hotel-Dieu de France hospital, Universite Saint-Joseph,
Beirut, Lebanon
(Sleilaty, Jebara) Department of cardiovascular and thoracic surgery,
Hotel-Dieu de France hospital, Universite Saint-Joseph, Beirut, Lebanon
(Sleilaty) Clinical Research Center, Faculty of Medicine, Universite
Saint-Joseph, Beirut, Lebanon
Publisher
NLM (Medline)
Abstract
OBJECTIVES: Postoperative atrial fibrillation is common following coronary
artery bypass grafting surgery. Hypomagnesemia is frequent after coronary
artery bypass grafting surgery. No previous trials have assessed the
effect of preoperative magnesium loading on postoperative atrial
fibrillation incidence. METHOD(S): Design: This was a single-center,
double-blind, placebo-controlled, parallel-group trial, with balanced
randomization [1:1]. Participant(s): were recruited from November
2018 until May 2019. Patients received either 3.2g of magnesium daily (4
tablets of 0.4g each twice daily) for 72hours preoperatively and 1.6g of
magnesium (4 tablets) on the day of surgery, or placebo tablets.
 RESULT(S): The primary outcome was the incidence of postoperative
atrial fibrillation. Secondary outcomes included time to extubation,
transfusion rate, critical care unit and hospital length of stay. Of the
210 randomized participants, 200 (100 in each group) completed the study.
10 (10%) and 22(22%) subjects developed postoperative atrial fibrillation
in the magnesium and placebo groups, respectively (RR=0.45, 95% CI: 0.23 -
0.91). Hospital and critical care unit length of stay were comparable
between the 2 groups. No side effect related to magnesium administration
were documented. CONCLUSION(S): In this randomized controlled trial,
preoperative loading with oral administration of magnesium for 3days in
patients admitted for coronary artery bypass grafting surgery decreases
the incidence of postoperative atrial fibrillation compared to placebo
(NCT03703349). CLINICAL TRIAL REGISTRY NUMBER: NCT03703349. Copyright
© The Author(s) 2022. Published by Oxford University Press on behalf
of the European Association for Cardio-Thoracic Surgery. All rights
reserved.

<17>
Accession Number
2014101907
Title
Should asymptomatic cervical stenosis be treated in the setting of
progressive thoracic myelopathy? A systematic review of the literature.
Source
European Spine Journal. 31(2) (pp 275-287), 2022. Date of Publication:
February 2022.
Author
Dowlati E.; Mualem W.; Black J.; Nunez J.; Girish A.; Fayed I.; McGrail
K.M.; Voyadzis J.-M.
Institution
(Dowlati, Fayed, McGrail, Voyadzis) Department of Neurosurgery, MedStar
Georgetown University Hospital, 3800 Reservoir Rd. NW, PHC 7, Washington,
DC 20007, United States
(Mualem, Black, Nunez, Girish) Georgetown University School of Medicine,
3900 Reservoir Rd. NW, Washington, DC, United States
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Purpose: Unlike tandem stenosis of the cervical and lumbar spine, tandem
cervical and thoracic stenosis (TCTS) of the spine is less common, and the
approach and order of intervention are controversial. We aim to review the
literature to evaluate the incidence and interventions for patients with
cervical and thoracic stenosis. We provide illustrative cases to
demonstrate that thoracic myelopathy in the setting of asymptomatic
cervical stenosis can be treated safely. Method(s): A systematic
review of the literature through electronic databases of PubMed, EMBASE,
Web of Science, and Cochrane Library was performed to present the current
literature that evaluates TCTS as it relates to incidence and surgical
interventions. We also present two cases of patients undergoing operative
intervention for thoracic myelopathy in the setting of concurrent cervical
stenosis. Result(s): A total of 26 English original studies and case
reports were identified. Nine studies evaluated the incidence of TCTS. 20
studies with a total of 168 patients with TCTS presented information on
surgical intervention options. There is an overall aggregate incidence of
11.6% (530/4751) based on incidence studies. 165 patients underwent
thoracic intervention. Of these patients, 63 patients underwent cervical
intervention first, 29 underwent thoracic intervention first, and 73
underwent simultaneous, single-stage intervention. Conclusion(s): In
patients presenting with myelopathy, both cervical and thoracic spine
should be evaluated for TCTS. Order of operative intervention is tailored
to clinical and radiographic information. In cases of thoracic myelopathy
with asymptomatic cervical stenosis, thoracic intervention can be pursued
with precautions to prevent further cervical cord injury. Copyright
© 2021, The Author(s), under exclusive licence to Springer-Verlag
GmbH Germany, part of Springer Nature.

<18>
Accession Number
2017608955
Title
Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian
middle-aged and older adults: a joint analysis of three cohorts.
Source
European Journal of Preventive Cardiology. 29(3) (pp E128-E137), 2022.
Date of Publication: 01 Feb 2022.
Author
Hilvo M.; Dhar I.; Laaperi M.; Lysne V.; Sulo G.; Tell G.S.; Jousilahti
P.; Nygard O.K.; Brenner H.; Schottker B.; Laaksonen R.
Institution
(Hilvo, Laaperi, Laaksonen) Zora Biosciences Oy, Tietotie 2C, Espoo 02150,
Finland
(Dhar, Lysne) Department of Clinical Science, Centre for Nutrition,
University of Bergen, Klinisk Institutt 1, Postboks 7804, Bergen 5020,
Norway
(Lysne, Nygard) Department of Heart Disease, Haukeland University
Hospital, Jonas Lies vei 65, Bergen 5021, Norway
(Sulo) Centre for Disease Burden, Division of Mental and Physical Health,
Norwegian Institute of Public Health, Zander Kaaesgate 7, Bergen 5015,
Norway
(Tell) Department of Global Public Health and Primary Care, University of
Bergen, Arstadveien 17, Bergen 5020, Norway
(Tell) Division of Mental and Physical Health, Norwegian Institute of
Public Health, Zander Kaaes gate 7, Bergen 5808, Norway
(Jousilahti) Department of Public Health and Welfare, Finnish Institute
for Health and Welfare, Mannerheimintie 166, Helsinki 00271, Finland
(Brenner, Schottker) Division of Clinical Epidemiology and Ageing
Research, German Cancer Research Center, Im Neuenheimer Feld 581,
Heidelberg 69120, Germany
(Schottker) Network Aging Research, University of Heidelberg, Bergheimer
Strasse 20, Heidelberg 69115, Germany
(Laaksonen) Finnish Cardiovascular Research Center, University of Tampere,
Tampere University Hospital, Arvo Ylpon Katu 34, Tampere 33520, Finland
Publisher
Oxford University Press
Abstract
Aims: Low-density lipoprotein cholesterol (LDL-C) is an established causal
driver of atherosclerotic cardiovascular disease (ASCVD), but its
performance and age-dependency as a biomarker for incident events and
mortality arising from ASCVD is less clear. The aim was to determine the
value of LDL-C as a susceptibility/risk biomarker for incident coronary
heart disease (CHD), ASCVD, and stroke events and deaths, for the age
groups <50 and >=50 years. Methods and Results: The performance of
LDL-C was evaluated in three cohorts, FINRISK 2002 (n = 7709), HUSK (n =
5431), and ESTHER (n = 4559), by Cox proportional hazards models,
C-statistics, and net reclassification index calculations. Additionally,
the hazard ratios (HRs) for the three cohorts were pooled by
meta-analysis. The most consistent association was observed for CHD [95%
confidence interval (CI) for HRs per standard deviation ranging from 0.99
to 1.37], whereas the results were more modest for ASCVD (0.96-1.18) due
to lack of association with stroke (0.77-1.24). The association and
discriminatory value of LDL-C with all endpoints in FINRISK 2002 and HUSK
were attenuated in subjects 50 years and older [HRs (95% CI) obtained from
meta-analysis 1.11 (1.04-1.18) for CHD, 1.15 (1.02-1.29) for CHD death,
1.02 (0.98-1.06) for ASCVD, 1.12 (1.02-1.23) for ASCVD death, and 0.97
(0.89-1.05) for stroke]. Conclusion(s): In middle-aged and older
adults, associations between LDL-C and all the studied cardiovascular
endpoints were relatively weak, while LDL-C showed stronger association
with rare events of pre-mature CHD or ASCVD death among middle-aged
adults. The predictive performance of LDL-C also depends on the studied
cardiovascular endpoint. Copyright © 2021 The Author(s).

<19>
Accession Number
2017608935
Title
Participation in exercise-based cardiac rehabilitation is related to
reduced total mortality in both men and women: Results from the SWEDEHEART
registry.
Source
European Journal of Preventive Cardiology. 29(3) (pp 485-492), 2022. Date
of Publication: 01 Feb 2022.
Author
Ekblom O.; Cider A.; Hambraeus K.; Back M.; Leosdottir M.; Lonn A.;
Borjesson M.
Institution
(Ekblom, Lonn) Astrand Laboratory of Work Physiology, Swedish School of
Sport and Health Sciences, Lidingovagen 1, P. O. Box 5626, Stockholm 114
86, Sweden
(Cider, Back, Borjesson) Department of Occupational Therapy and
Physiotherapy, Sahlgrenska University Hospital Gothenburg, Gothenburg,
Sweden
(Cider) Department of Health and Rehabilitation/Physiotherapy, Institute
of Neuroscience and Physiology, University of Gothenburg, Gothenburg,
Sweden
(Hambraeus) Department of Cardiology, Falun Hospital, Falun, Sweden
(Back) Department of Molecular and Clinical Medicine, Institute of
Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg,
Sweden
(Leosdottir) Department of Cardiology, Skane University Hospital, Malmo,
Sweden
(Leosdottir) Department of Clinical Sciences, Lund University, Malmo,
Sweden
(Lonn) Functional Area Occupational Therapy and Physiotherapy, Allied
Health Professionals Function, Karolinska University Hospital, Karolinska,
Sweden
(Borjesson) Department of Food Nutrition and Sport Science, Center for
Health and Performance, University of Gothenburg, Gothenburg, Sweden
Publisher
Oxford University Press
Abstract
Aims: Participation in exercise-based cardiac rehabilitation (exCR)
increases aerobic capacity and improves outcomes in patients following
myocardial infarction (MI) and is therefore universally recommended. While
meta-Analyses consistently report that participation in exCR reduces
cardiovascular mortality, there are conflicting results regarding effects
on total mortality. Presently, many eligible patients do not receive exCR
in clinical practice. We aimed to investigate the relation between
participation in exCR post-MI and total mortality in men and women in a
nationwide real-world cohort from the SWEDEHEART registry. Design(s):
Longitudinal, observational cohort study. Methods and Results: In
total, 20 895 patients from the SWEDEHEART registry were included.
Mortality data were obtained from the Swedish National Population
Registry. During a mean of 4.55 (+/-2.33) years of follow-up, 1000
patients died. Using Cox regression for proportional odds and taking a
wide range of potential confounders into consideration, participation in
exCR was related to significantly lower total mortality [hazard ratio (HR)
0.72, 95% confidence interval 0.62-0.83]. Excluding patients with shorter
follow-up than 2 years did not alter the results. Exercise-based CR
participation was related to lowered total mortality in most of the
investigated subgroups. The risk reduction was more pronounced in women
than in men (HR 0.54 vs. 0.81, respectively). Conclusion(s):
Participation in exCR was associated with reduced total mortality, and
more pronounced in women, compared with men. Our results further support
the recommendations to participate in exCR, and hence we argue that exCR
should be a mandatory part of comprehensive CR programmes, offered to all
patients post-MI. Copyright © 2021 The Author(s) 2021. Published
by Oxford University Press on behalf of the European Society of
Cardiology.

<20>
Accession Number
637460966
Title
Does left atrial epicardial conduction time reflect atrial fibrosis and
the risk of atrial fibrillation recurrence after thoracoscopic ablation?
Post hoc analysis of the AFACT trial.
Source
BMJ Open. 12(3) (no pagination), 2022. Article Number: e056829. Date of
Publication: 09 Mar 2022.
Author
Wesselink R.; Neefs J.; Van Den Berg N.W.E.; Meulendijks E.R.; Terpstra
M.M.; Kawasaki M.; Nariswari F.A.; Piersma F.R.; Van Boven W.J.P.;
Driessen A.H.G.; De Groot J.R.
Institution
(Wesselink, Neefs, Van Den Berg, Meulendijks, Terpstra, Kawasaki,
Nariswari, Piersma, Van Boven, Driessen, De Groot) Heart Center,
Department of Clinical and Experimental Cardiology and Cardiothoracic
Surgery, Amsterdam Cardiovascular Sciences, Amsterdam UMC Location AMC,
Noord-Holland, Amsterdam, Netherlands
Publisher
BMJ Publishing Group
Abstract
Objectives To determine the association between left atrial epicardial
conduction time (LAECT), fibrosis and atrial fibrillation (AF) recurrence
after thoracoscopic surgical ablation of persistent AF. Setting Single
tertiary care centre in the Netherlands. Participants Patients with
persistent AF from the randomised Atrial Fibrillation Ablation and
Autonomic Modulation via Thoracoscopic Surgery (AFACT)-trial were
included. Patients eligible for thoracoscopic AF ablation were included,
full inclusion and exclusion criteria were previously published. All
patients underwent thoracoscopic ablation, encompassing pulmonary vein
isolation with an additional roof and trigone lesion. In patients with
conduction block across the roof and trigone lesion, LAECT was measured.
LAECT was defined as the time to local activation at one side of the
roofline on pacing from the opposite side. Collagen fibre density was
quantified from left atrial appendage histology. Outcome measures Primary
outcome: AF recurrence during 2 years of follow-up. Results 121 patients
were included, of whom 35(29%) were women, age was 60.4+/-7.8 and 51% (62)
had at least one AF recurrence during 2 years of follow-up. LAECT was
longer in patients with versus without AF recurrence (182+/-43 ms vs
147+/-29 ms, p<0.001). LAECT was longer in older patients, in patients
with a higher body mass index (BMI) and in patients using class IC
antiarrhythmic drugs. LAECT was shorter in patients with higher collagen
fibre density. A previously failed catheter ablation, LAECT and BMI were
independently associated with AF recurrence. Conclusion LAECT is
correlated with collagen fibre density and BMI and is independently
associated with AF recurrence in patients with persistent AF. In these
patients, LAECT appears to reflect substrate characteristics beyond
clinical AF type and left atrial volume. Trial registration number
NCT01091389. Copyright © Author(s) (or their employer(s)) 2022.
Re-use permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ.

<21>
Accession Number
2016506473
Title
Colchicine for Secondary Prevention of Coronary Artery Disease: A
Meta-Analysis of Randomised Controlled Trials.
Source
Heart Lung and Circulation. 31(5) (pp 685-695), 2022. Date of Publication:
May 2022.
Author
Xu H.; Mao L.; Liu H.; Lin Z.; Zhang Y.; Yang J.
Institution
(Xu, Liu, Lin, Yang) Department of Cardiology, The Affiliated Huaian No. 1
People's Hospital of Nanjing Medical University, Jiangsu, Huai'an, China
(Mao) Department of Thyroid and Breast Surgery, The Affiliated Huai'an
Hospital of Xuzhou Medical University and The Second People's Hospital of
Huai'an, Jiangsu, Huai'an, China
(Zhang) Department of Medical Laboratory, The Affiliated Huaian No. 1
People's Hospital of Nanjing Medical University, Jiangsu, Huai'an, China
Publisher
Elsevier Ltd
Abstract
Background: Colchicine has become prominent as an anti-inflammatory
therapy for secondary cardiovascular prevention in patients with coronary
artery disease (CAD). This meta-analysis was performed to evaluate the
efficacy and safety of colchicine in patients with CAD. Method(s):
Randomised controlled trials (RCTs) that compare major adverse
cardiovascular events (MACEs) between patients with CAD randomised to
colchicine versus placebo (or no colchicine) were included. Random effect
risk ratios (RRs) were calculated for clinical outcomes. Result(s): A
total of 12,071 patients in seven RCTs were included in the meta-analysis.
Compared with placebo or no colchicine, colchicine was associated with a
significantly lower incidence of MACEs (RR 0.64, 95% CI 0.51-0.80,
p<0.01). The reduction in MACEs in the colchicine group was driven by
statistically significant reductions in the incidence of myocardial
ischaemia (RR 0.74, 95% CI 0.58-0.95, p=0.02), coronary revascularisation
(RR 0.61, 95% CI 0.42-0.89, p=0.01), and stroke (RR 0.48, 95% CI
0.28-0.83, p=0.01). However, there was no statistically significant
difference for cardiovascular death (RR 0.82, 95% CI 0.55-1.22, p=0.33).
All-cause and non-cardiovascular mortality, gastrointestinal events,
infection, and cancer were not significantly different between the
colchicine and control groups. Conclusion(s): Colchicine is a
reasonably efficacious and safe drug that could be successfully utilised
for the secondary prevention of CAD. Copyright © 2021 Australian
and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the
Cardiac Society of Australia and New Zealand (CSANZ)

<22>
Accession Number
2016426333
Title
The effect of anesthetic agents on intraocular pressure during
laparoscopic gynecological surgery performed in the Trendelenburg
position: A randomized clinical trial.
Source
Ulusal Travma ve Acil Cerrahi Dergisi. 28(4) (pp 498-507), 2022. Date of
Publication: April 2022.
Author
Balkan B.; Tontu F.; Moralar D.G.; Demirayak B.; Emir N.S.; Yektas A.
Institution
(Balkan, Tontu, Moralar, Emir) Department of Anesthesiology and
Reanimation, Health Science University, Bakirkoy Dr. Sadi Konuk Training
and Research Hospital, Istanbul, Turkey
(Demirayak) Department of Ophthalmology, Health Science University,
Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
(Yektas) Department of Anesthesiology and Reanimation, Health Science
University, Diyarbakir Gazi Yasargil Training and Research Hospital,
Diyarbakir, Turkey
Publisher
Turkish Association of Trauma and Emergency Surgery
Abstract
BACKGROUND: Intraocular pressure (IOP) increases due to pneumoperitoneum
and the Trendelenburg position during laparoscopic surgery. Apart from
ketamine and suxamethonium, anesthetic agents generally reduce IOP by
various extents. The present study investigated the effects of
combinations of four anesthetic agents on IOP during laparoscopic
gynecological surgery. METHOD(S): Patients (n=100) were assigned to
one of the four groups: Group 1 (n=25; pentothal induction +
desflurane/remifen-tanil maintenance), Group 2 (n=25; propofol induction +
sevoflurane/remifentanil maintenance), Group 3 (n=25; propofol induction +
desflurane/remifentanil maintenance), and Group 4 (n=25; pentothal
induction + sevoflurane/remifentanil maintenance). The IOPs recorded
before anesthesia induction, after intubation, after carbon dioxide
insufflation, in the Trendelenburg position, and after ex-tubation were
compared among the groups. Hemodynamic parameters were also evaluated.
 RESULT(S): Induction in Group 2 and Group 3 used propofol. When the
IOP in the Trendelenburg position was compared with the IOP before
induction, there was no statistically significant difference in Groups 2
and 3 (p>0.05). In Groups 1 and 4, pentothal was used for induction. The
IOP in Groups 1 and 4 was statistically significantly higher in the
Trendelenburg position than it was before induction (0.027-0.001).
 CONCLUSION(S): To minimize the variation in IOP in the Trendelenburg
position during laparoscopic gynecological surgeries, we recommend the use
of propofol for induction, independent of desflurane or sevoflurane
use. Copyright ©2022 Turkish Association of Trauma and Emergency
Surgery.

<23>
Accession Number
2016347738
Title
Diagnosis and Management of Genetic Causes of Middle Aortic Syndrome in
Children: A Comprehensive Literature Review.
Source
Therapeutics and Clinical Risk Management. 18 (pp 233-248), 2022. Date of
Publication: 2022.
Author
Lazea C.; Al-Khzouz C.; Sufana C.; Miclea D.; Asavoaie C.; Filimon I.;
Fufezan O.
Institution
(Lazea, Al-Khzouz) Department Mother and Child, University of Medicine and
Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania
(Lazea, Sufana) Department of Pediatrics I, Emergency Pediatric Hospital,
Cluj-Napoca, Romania
(Al-Khzouz, Miclea) Department of Medical Genetics, Emergency Pediatric
Hospital, Cluj-Napoca, Romania
(Miclea) Department of Molecular Sciences, University of Medicine and
Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania
(Asavoaie, Filimon, Fufezan) Department of Radiology and Medical Imaging,
Emergency Pediatric Hospital, Cluj-Napoca, Romania
Publisher
Dove Medical Press Ltd
Abstract
Middle aortic syndrome (MAS) is a rare vascular disease representing an
important cause of severe hypertension in children. MAS is characterized
by segmental or diffuse narrowing of the abdominal and/or distal
descending aorta with involvement of the renal and visceral branches. Most
cases of MAS are idiopathic, but MAS may occur in genetic and acquired
disorders. The most common genetic causes of MAS are neurofibromatosis
type I, Williams syndrome, Alagille syndrome, tuberous sclerosis and
mucopolysaccharidosis. This review article discusses the
pathophysiological aspects, distinctive associated features, and
management of genetic forms of MAS in children. Copyright © 2022
Lazea et al.

<24>
Accession Number
2016165010
Title
Comparison of invasive blood pressure monitoring versus normal
non-invasive blood pressure monitoring in ST-elevation myocardial
infarction patients with percutaneous coronary intervention.
Source
Injury. 53(3) (pp 1108-1113), 2022. Date of Publication: March 2022.
Author
Jiang Y.; Liu J.; Peng W.; Wang A.; Guo L.; Xu Z.
Institution
(Jiang, Liu, Peng, Wang, Guo, Xu) Department 2 of Cardiology, Cangzhou
Central Hospital, No. 16 Xinhua Road, Hebei, Cangzhou 061000, China
Publisher
Elsevier Ltd
Abstract
Background: Hypotension post percutaneous coronary intervention (PCI)
causes stent thrombosis and reduced coronary perfusion, which aggravate
myocardial ischemia and lead to patient death. Therefore, the accuracy and
timeliness of blood pressure monitoring (BPM) are crucial for the nursing
of patients post PCI. However, it is still controversial whether invasive
blood pressure monitoring (IBPM) or non-invasive blood pressure monitoring
(NIBPM) should be used for patients post PCI, and the magnitude of their
assistance for patients' recovery remains unclear. Method(s): A
randomized controlled trial was performed in this study. 126 ST-segment
elevation myocardial infarction (STEMI) patients post PCI were recruited
and randomly divided into two groups (NIBPM group n = 63; IBPM group n =
63). Result(s): Clinical characteristics and physiological outcomes
of participants received different BPM methods were collected and analyzed
to compare the effects of these two methods on the nursing of PCI
patients. Compared to NIBPM group, IBPM assisted to shorten the time of
myocardial ischemia, promote coronary reperfusion, reduce the occurrence
of cardiovascular disease and other complications, and ultimately reduce
the mortality of patients post PCI. Conclusion(s): The application of
IBPM contributed to reduce the occurrence of complications, shorten the
time of vascular reperfusion, and guide treatment of clinicians in
time. Copyright © 2021 Elsevier Ltd

<25>
Accession Number
2015121358
Title
Targeting Higher Intraoperative Blood Pressures Does Not Reduce Adverse
Cardiovascular Events Following Noncardiac Surgery.
Source
Journal of the American College of Cardiology. 78(18) (pp 1753-1764),
2021. Date of Publication: 02 Nov 2021.
Author
Wanner P.M.; Wulff D.U.; Djurdjevic M.; Korte W.; Schnider T.W.; Filipovic
M.
Institution
(Wanner, Djurdjevic, Schnider, Filipovic) Division of Anaesthesiology,
Intensive Care, Rescue and Pain Medicine, Cantonal Hospital St. Gallen,
St. Gallen, Switzerland
(Wulff) University of Basel, Basel, Switzerland and Max Planck Institute
for Human Development, Berlin, Germany
(Korte) Center for Laboratory Medicine, St. Gallen, Switzerland
Publisher
Elsevier Inc.
Abstract
Background: Intraoperative arterial hypotension is strongly associated
with postoperative major adverse cardiovascular events (MACE); however,
whether targeting higher intraoperative mean arterial blood pressures
(MAPs) may prevent adverse events remains unclear. Objective(s): This
study sought to determine whether targeting higher intraoperative MAP
lowers the incidence of postoperative MACE. Method(s): This
single-center randomized controlled trial assigned adult patients at
cardiovascular risk undergoing major noncardiac surgery to an
intraoperative MAP target of >=60 mm Hg (control) or >=75 mm Hg (MAP
>=<inf>75</inf>). The primary outcome was acute myocardial injury on
postoperative days 0-3 and/or 30-day MACE/acute kidney injury (AKI) (acute
coronary syndrome, congestive heart failure, coronary revascularization,
stroke, AKI, and all-cause mortality). The secondary outcome was 1-year
MACE. Result(s): In total, 458 patients were randomized
(intention-to-treat population: 451). The cumulative intraoperative
duration with MAP <65 mm Hg was significantly shorter in the MAP
>=<inf>75</inf> group (median 9 minutes [interquartile range: 3 to 24
minutes] vs 23 minutes [interquartile range: 8-49 minutes]; P < 0.001).
The primary outcome incidence was 48% for MAP >=<inf>75</inf> and 52% for
control (risk difference -4.2%; 95% CI: -13% to +5%), the primary
contributor being AKI (incidence 44%). Acute myocardial injury occurred in
15% (MAP >=<inf>75</inf>) and 19% (control) of patients. The secondary
outcome incidence was 17% for MAP >=<inf>75</inf> and 15% for control
(risk difference +2.7; 95% CI: -4% to +9.5%). Conclusion(s): These
findings do not support universally targeting higher intraoperative blood
pressures to reduce postoperative complications. Despite a 60% reduction
in hypotensive time with MAP <65 mm Hg, no significant reductions in acute
myocardial injury or 30-day MACE/AKI could be found. (Biomarkers, Blood
Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk
in Major Noncardiac Surgery [BBB]; NCT02533128) Copyright © 2021
The Authors

<26>
Accession Number
2012840003
Title
Everolimus eluting bioresorbable vascular scaffolds in patients with acute
coronary syndromes: Two-year results from the German-Austrian ABSORB
registry.
Source
Catheterization and Cardiovascular Interventions. 98(4) (pp E564-E570),
2021. Date of Publication: October 2021.
Author
Trobs M.; Achenbach S.; Nef H.M.; Gori T.; Naber C.; Neumann T.; Richardt
G.; Schmermund A.; Wohrle J.; Zahn R.; Hamm C.W.
Institution
(Trobs, Achenbach) Friedrich-Alexander Universitat Erlangen-Nurnberg,
Department of Cardiology, Erlangen, Germany
(Nef, Hamm) Medizinische Klinik I, Department of Cardiology, University of
Giessen, Giessen, Germany
(Gori) Department of Medicine II, University Medical Center, Johannes
Gutenberg University Mainz, Mainz, Germany
(Naber) Medizinische Klinik 1, Klinikum Wilhelmshaven, Wilhelmshaven,
Germany
(Neumann) Department of Cardiology, University of Essen, Essen, Germany
(Richardt) Herzzentrum, Segeberger Kliniken GmbH, Bad Segeberg, Germany
(Schmermund) CCB Cardioangiologisches Centrum, Bethanien Hospital,
Frankfurt, Germany
(Wohrle) Department of Cardiology, Medical Campus Lake Constance,
Friedrichshafen, Germany
(Zahn) Abteilung fur Kardiologie, Herzzentrum Ludwigshafen, Ludwigshafen,
Germany
(Hamm) Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad
Nauheim, Germany
Publisher
John Wiley and Sons Inc
Abstract
Objectives: To identify potential differences in 2-year outcome between
patients who underwent coronary revascularization using bioresorbable
vascular scafffolds (BVS) in stable coronary artery disease (CAD) and
acute coronary syndromes (ACS). Background(s): Data from randomized
trials suggest a significantly higher event rate following coronary
revascularization using everolimus-eluting BVS as compared to new
generation drug eluting stents. Whether particular patient subgroups are
at increased risk for scaffold thrombosis and target lesion failure (TLF)
has not clearly been demonstrated. Method(s): German-Austrian ABSORB
RegIstRy is a prospective all-comer multi-center observational study of
consecutive patients who were considered for coronary revascularization
with BVS. We compared 1499 patients with stable CAD to 1594 patients with
ACS. Endpoints were major adverse cardiac events (MACE), TLF, and scaffold
thrombosis. Result(s): While single vessel disease was more prevalent
in ACS (46% vs. 37%, p < 0.0001), lesion complexity (B2/C stenosis 37% vs.
36%, bifurcation 2.4% vs. 3.4%, p < 0.05), number of implanted
scaffolds/patient (1.34 vs. 1.43), scaffold length (18 vs. 18 mm) or the
rate of high pressure postdilatation (68% vs. 70%) did not differ between
ACS and stable CAD. Two-year MACE rates were 11.6% in ACS and 11.4% in
stable CAD, TLF occurred in 7.0% versus 7.4% and target vessel
revascularization in 8.8 versus 10.2% (n.s. for all). Definite scaffold
thrombosis rates were not significantly different (ACS 1.9% vs. stable CAD
2.1%). Conclusion(s): Real-world 2-year event rates after coronary
revascularization with BVS are not significantly different between
individuals with ACS as compared to stable CAD. Copyright © 2021
The Authors. Catheterization and Cardiovascular Interventions published by
Wiley Periodicals LLC.

<27>
Accession Number
2013871234
Title
Long-term outcome of mechanical and biological prostheses in patients with
left-side infective endocarditis: A systematic review and meta-analysis.
Source
Journal of Clinical Medicine. 10(19) (no pagination), 2021. Article
Number: 4356. Date of Publication: 01 Oct 2021.
Author
Formica F.; Maestri F.; Gripshi F.; Gallingani A.; Grossi S.; Nicolini F.
Institution
(Formica, Nicolini) Department of Medicine and Surgery, University of
Parma, Parma 43126, Italy
(Formica, Maestri, Gripshi, Gallingani, Nicolini) Cardiac Surgery Unit,
University Hospital of Parma, Parma 43126, Italy
(Grossi) Department of Anesthesia and Intensive Care, Parma University
Hospital, Parma 43126, Italy
Publisher
MDPI
Abstract
Background. Long-term outcomes of patients with infective endocarditis
(IE) who received either a mechanical (MP) or biological prosthesis (BP)
are conflicting. A meta-analysis of observational studies comparing the
long-term outcomes of left-side IE with the use of MP versus BP was
performed. Methods. Electronic databases from January 2000 to June 2021
were screened. Studies reporting long-term mortality were analyzed. The
primary endpoint was long-term overall mortality. Secondary endpoints were
in-hospital/.30-day mortality and freedom from both prosthesis reinfection
and reintervention. The pooled hazard ratio (HR) with 95% confidence
interval (CI) was calculated for survival according to the random effect
model. Results. Thirteen retrospective observational studies reporting on
8645 patients (MP: 4688; BP: 4137) were included for comparison. Twelve
studies reported data of long-term survival for a total of 8285 patients
(MP: 4517; BP: 3768). The pooled analysis revealed that the use of MP was
statistically associated with longer benefits compared to BP (HR 0.74; 95%
CI 0.63-0.86; p < 0.0001). The median follow-up time ranged from 1 to 15.3
years. The pooled analysis of five studies reporting data on prosthesis
reinfection in 4491 patients (MP: 2433; BP: 2058) did not reveal
significant differences (HR 0.60; 95% CI 0.30-1.21; p = 0.15). Five
studies reported data on prosthesis reintervention in 4401 patients (MP:
2307; BP: 2094). The meta-analysis revealed a significant difference in
favor of MP (HR 0.40; 95% CI 0.29-0.55; p < 0.0001). Meta-regression
reported no effect of male gender (p = 0.09) and age (p = 0.77) on
long-term survival. Conclusions. In a meta-analysis of retrospective
observational studies comparing the long-term outcome of patients who
underwent surgery for left-sided IE, the use of MP compared to BP is
associated with a significant longer-term survival and with a reduced
incidence of late reoperation. The incidence of late reinfection is
comparable between the two prostheses. Copyright © 2021 by the
authors. Licensee MDPI, Basel, Switzerland.

<28>
Accession Number
636881517
Title
Impact of Chronic Kidney Disease on the Prognosis of Transcatheter Aortic
Valve Replacement in Patients with Aortic Stenosis: A Meta-Analysis of
133624 Patients.
Source
Annals of thoracic and cardiovascular surgery : official journal of the
Association of Thoracic and Cardiovascular Surgeons of Asia. 28(2) (pp
83-95), 2022. Date of Publication: 20 Apr 2022.
Author
Wang J.; Liu S.; Han X.; Chen Y.; Chen H.; Dong S.; Song B.
Institution
(Wang, Han, Chen, Chen) First Clinical Medical College of Lanzhou
University, Lanzhou University, Lanzhou, China
(Liu, Dong, Song) Department of Cardiovascular Surgery, First Hospital of
Lanzhou University, Lanzhou, China
Publisher
NLM (Medline)
Abstract
PURPOSE: The impact of chronic kidney disease (CKD) on the prognosis of
transcatheter aortic valve replacement (TAVR) remains unclear. The purpose
of this meta-analysis was to assess the impact of CKD and different stages
of CKD on prognosis in patients undergoing TAVR. METHOD(S): As of
June 2020, we performed a comprehensive literature search on relevant
studies using PubMed, Embase, Cochrane Library, and Web of Science.
Subsequently, we pooled the risk ratio (RR) of individual studies via
random effects to analyze heterogeneity, quality assessment, and
publication bias. RESULT(S): A total of 20 studies, involving 133624
patients, were eligible for analysis. Patients with CKD had higher
all-cause mortality at 30 days (RR: 1.39, 95% confidence interval [CI]:
1.31-1.47, P <0.001), 1 year (RR: 1.36, 95% CI: 1.24-1.49, P <0.001), and
2 years (RR: 1.2, 95% CI: 1.05-1.38, P = 0.009) of follow-up. Moreover,
they also had higher acute kidney injury (AKI) (RR: 1.38, 95% CI:
1.16-1.63, P <0.001) and bleeding (RR: 1.33, 95% CI: 1.18-1.50, P <0.001)
at 30 days. CKD3 alone also increased all-cause mortality at follow-ups.
Risk of all-cause mortality increased with severity of CKD for stages 3,
4, and 5 at follow-up. CONCLUSION(S): Patients with CKD are at an
increased risk of all-cause mortality, AKI, and bleeding events after
TAVR. Moreover, the mortality risk rises with increasing severity of CKD.

<29>
Accession Number
636691280
Title
N-Acetylcysteine's Renoprotective Effect in Cardiac Surgery: A Systematic
Review and Meta-Analysis.
Source
Annals of thoracic and cardiovascular surgery : official journal of the
Association of Thoracic and Cardiovascular Surgeons of Asia. 28(2) (pp
138-145), 2022. Date of Publication: 20 Apr 2022.
Author
Tan Y.K.; Luo H.; Kang G.S.; Teoh K.L.; Kofidis T.
Institution
(Tan) Department of Cardiac Surgery, Yong Loo Lin School of Medicine,
Singapore
(Luo, Kang, Teoh, Kofidis) Department of Cardiac Thoracic & Vascular
Surgery, National University Heart Centre, Singapore
Publisher
NLM (Medline)
Abstract
OBJECTIVE: To examine N-acetylcysteine's (NAC's) renoprotective effect in
adult cardiac surgeryMethods: PubMed, Ovid Medline, and Embase were
searched for randomized controlled trials published between January 1990
and May 2021 that investigated the effect of NAC in preventing acute
kidney injury (AKI) in patients undergoing cardiac surgery. The inclusion
criterion was studies that assessed the effect of NAC in comparison to
placebo by measuring the incidence of AKI. RESULT(S): Overall
meta-analytic estimates of all 10 included trials showed that NAC did not
have a significant effect (odds ratio [OR]: 0.84, 95% confidence interval
[CI]: 0.64-1.10) on AKI. Further subgroup analysis did not show a
significant benefit of NAC in preventing AKI. CONCLUSION(S): This
meta-analysis suggests that NAC does not have a significant effect in
reducing the incidence of AKI. However, there is notable heterogeneity
among the included studies that could possibly account for the
non-significant effect observed. It is worth noting that only one trial
administered NAC high dosages perioperatively, and it is the only included
trial to show a significant benefit in reducing the incidence of AKI (OR:
0.30, 95% CI: 0.11-0.81). Further studies on this dosage and duration of
administration should be conducted to best elucidate the effect of
administering NAC.

<30>
Accession Number
2015843007
Title
Quality of Life of Mothers of Infants Subjected to Neonatal Cardiac
Surgery: The Importance of Psychosocial Factors.
Source
World Journal for Pediatric and Congenital Heart Surgery. 13(3) (pp
324-331), 2022. Date of Publication: May 2022.
Author
Lisanti A.J.; Golfenshtein N.; Marino B.S.; Huang L.; Hanlon A.L.; Lozano
A.J.; Curley M.A.Q.; Medoff-Cooper B.
Institution
(Lisanti, Curley, Medoff-Cooper) Research Institute, Children's Hospital
of Philadelphia, Philadelphia, PA, United States
(Lisanti, Golfenshtein, Huang, Medoff-Cooper) Department of Family and
Community Health, School of Nursing, University of Pennsylvania,
Philadelphia, PA, United States
(Golfenshtein) Haifa University, Haifa, Israel
(Marino) Department of Pediatric Cardiology, Cleveland Clinic Children's,
Cleveland, OH, United States
(Hanlon, Lozano) Center for Biostatistics and Health Data Science,
Department of Statistics, Virginia Tech, Blacksburg, VA, United States
(Curley) Nursing and Clinical Care Services, Children's Hospital of
Philadelphia, Philadelphia, PA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: The World Health Organization acknowledges quality of life
(QOL) as subjectively perceived overall well-being by the individual and
recognizes it as an essential construct for overall health and wellness.
The purpose of this study was to examine the association of infant,
environmental, and parental factors with the QOL of mothers of infants at
four months post-hospital discharge from cardiac surgery. Method(s):
Secondary analysis of prospectively collected data from the REACH
randomized clinical trial of telehealth home monitoring. The sample
included mothers (n = 148) of infants with congenital heart disease who
provided data at four months post-discharge. Ten imputations were
generated using fully conditional specification methods to address missing
data and were combined. All analyses were performed on the imputed data.
Mothers' QOL was the main outcome of the analysis, as measured by the Ulm
Quality of Life Inventory for Parents. Predictors on QOL were identified
based on the World Health Organization QOL framework which recognizes the
multidimensional domains influencing QOL that include personal factors,
environmental factors, and physical factors related to disease and
functioning. Result(s): The treatment and control groups did not
differ on any study variable, thus data were collapsed and analyzed
together. Final multivariable model found that the combination of dyadic
adjustment, social support, parenting stress, and post-traumatic stress
symptoms explained approximately three-quarters of the variance in QOL
scores. Conclusion(s): QOL for mothers of infants with congenital
heart disease is largely influenced by psychosocial factors. Future
research targeted toward improving maternal QOL should include
psychosocial interventions that address social networks and
stress. Copyright © The Author(s) 2022.

<31>
Accession Number
2005051033
Title
Outcomes of percutaneous temporary biventricular mechanical support: a
systematic review.
Source
Heart Failure Reviews. 27(3) (pp 879-890), 2022. Date of Publication: May
2022.
Author
Weber M.P.; O'Malley T.J.; Choi J.H.; Maynes E.J.; Prochno K.W.; Austin
M.A.; Wood C.T.; Patel S.; Morris R.J.; Massey H.T.; Tchantchaleishvili V.
Institution
(Weber, O'Malley, Choi, Maynes, Prochno, Austin, Wood, Patel, Morris,
Massey, Tchantchaleishvili) Division of Cardiac Surgery, Sidney Kimmel
Medical College, Thomas Jefferson University, 1025 Walnut St, Suite 607,
Philadelphia, PA 19107, United States
Publisher
Springer
Abstract
Percutaneous biventricular assist devices (BiVAD) are a recently developed
treatment option for severe cardiogenic shock. This systematic review
sought to identify indications and outcomes of patients placed on
percutaneous BiVAD support. An electronic search was performed to identify
all appropriate studies utilizing a percutaneous BiVAD configuration.
Fifteen studies comprising of 20 patients were identified. Individual
patient survival and outcomes data were combined for statistical analysis.
All 20 patients were supported with a microaxial LVAD, 12/20 (60%) of
those patients were supported with a microaxial (RMA) right ventricular
assist device (RVAD), and the remaining 8/20 (40%) patients were supported
with a centrifugal extracorporeal RVAD (RCF). All patients presented with
cardiogenic shock, and of these, 12/20 (60%) presented with a non-ischemic
etiology vs 8/20 (40%) with ischemic disease. For the RMA group, RVAD
support was significantly longer [RMA 5 (IQR 4-7) days vs RCF 1 (IQR 1-2)
days, p = 0.03]. Intravascular hemolysis post-BiVAD occurred in three
patients (27.3%) [RMA 3 (33.3%) vs RCF 0 (0%), p = 0.94]. Five patients
received a durable left ventricular assist device, one patient received a
total artificial heart, and one patient underwent a heart transplantation.
Estimated 30-day mortality was 15.0%, and 78.6% were discharged alive.
Both strategies for percutaneous BiVAD support appear to be viable options
for severe cardiogenic shock. Copyright © 2020, Springer
Science+Business Media, LLC, part of Springer Nature.

<32>
Accession Number
637825665
Title
Utility of plasma NGAL for the diagnosis of AKI following cardiac surgery
requiring cardiopulmonary bypass: a systematic review and meta-analysis.
Source
Scientific reports. 12(1) (pp 6436), 2022. Date of Publication: 19 Apr
2022.
Author
Sharrod-Cole H.; Fenn J.; Gama R.; Ford C.; Giri R.; Luckraz H.
Institution
(Sharrod-Cole, Fenn, Gama, Ford) Clinical Biochemistry, Black Country
Pathology Services, West Midlands, Wolverhampton, United Kingdom
(Sharrod-Cole) Department of Clinical Biochemistry, New Cross Hospital,
Wolverhampton WV10 0QP, United Kingdom
(Gama) School of Medicine and Clinical Practice, Wolverhampton University,
West Midlands, Wolverhampton, United Kingdom
(Giri) Cardiac Anaesthesia, Royal Wolverhampton NHS Trust, West Midlands,
Wolverhampton, United Kingdom
(Luckraz) Cardiac Surgery, Royal Wolverhampton NHS Trust, West Midlands,
Wolverhampton, United Kingdom
Publisher
NLM (Medline)
Abstract
The objective of this study was to assess the diagnostic value of plasma
neutrophil gelatinase-associated lipocalin (pNGAL) for the early diagnosis
of acute kidney injury (AKI) in adult patients following cardiac surgery
requiring cardiopulmonary bypass (CPB). Electronic databases and other
resources were systematically searched for relevant studies. Risk of bias
was assessed using the Quality Assessment for Diagnostic Accuracy Studies
2 (QUADAS-2) tool. Studies were assigned to a sub-group based on the
timing of the pNGAL sample in relation to the cessation of CPB. These
were<4 h, 4-8 h, 12 h or 24 h post-cessation of CPB. Summary values for
sensitivity and specificity were estimated using the hierarchical summary
receiver operator characteristic (ROC) curve model. A random-effects
meta-analysis of each pair of sensitivity and specificity estimates from
each included study was performed. In total, 3131 patients from 16 studies
were included. When taken at 4-8 h following CPB, pNGAL had superior
performance for the diagnosis of AKI in the defined population when
compared to earlier and later time points. Prediction regions and
confidence intervals, however, demonstrated significant variability in
pooled estimates of sensitivity and specificity. This is likely due to
population and study design heterogeneity, lack of standardisation of
assays and thresholds, and inability to distinguish the different
molecular forms of NGAL. In conclusion, the diagnostic utility of pNGAL in
this clinical setting is inconclusive and large individual studies of
representative populations of cardiac surgery patients using assays that
specifically detect NGAL in its monomeric form are required. Copyright
© 2022. The Author(s).

<33>
Accession Number
637751508
Title
Nomogram for Postoperative Headache in Adult Patients Undergoing Elective
Cardiac Surgery.
Source
Journal of the American Heart Association. 11(8) (pp e023837), 2022. Date
of Publication: 19 Apr 2022.
Author
Wang D.; Le S.; Wu J.; Xie F.; Li X.; Wang H.; Zhang A.; Du X.; Huang X.
Institution
(Wang, Le, Wang, Du, Huang) Department of Cardiovascular Surgery Union
Hospital Tongji Medical CollegeHuazhong University of Science and
Technology Wuhan China, China
(Wang, Xie) Department of Cardiovascular Surgery The First Affiliated
Hospital of Zhengzhou University Zhengzhou China, China
(Le) Department of Thoracic Surgery Zhongnan Hospital of Wuhan
UniversityWuhan University Wuhan China, China
(Wu) Key Laboratory for Molecular Diagnosis of Hubei Province The Central
Hospital of WuhanTongji Medical CollegeHuazhong University of Science and
Technology Wuhan China, China
(Li) Department of Nursing Huaihe Hospital of Henan University Kaifeng
Henan China, China
(Zhang) Department of Cardiology The Central Hospital of WuhanTongji
Medical CollegeHuazhong University of Science and Technology Wuhan China,
China
Publisher
NLM (Medline)
Abstract
Background Postoperative headache (POH) is frequent after cardiac surgery;
however, few studies on risk factors for POH exist. The aims of the
current study were to explore risk factors related to POH after elective
cardiac surgery and to establish a predictive system. Methods and Results
Adult patients undergoing elective open-heart surgery under
cardiopulmonary bypass from 2016 to 2020 in 4 cardiac centers were
retrospectively included. Two thirds of the patients were randomly
allocated to a training set and one third to a validation set. Predictors
for POH were selected by univariate and multivariate analysis. POH
developed in 3154 of the 13 440 included patients (23.5%) and the overall
mortality rate was 2.3%. Eight independent risk factors for POH after
elective cardiac surgery were identified, including female sex, younger
age, smoking history, chronic headache history, hypertension, lower left
ventricular ejection fraction, longer cardiopulmonary bypass time, and
more intraoperative transfusion of red blood cells. A nomogram based on
the multivariate model was constructed, with reasonable calibration and
discrimination, and was well validated. Decision curve analysis revealed
good clinical utility. Finally, 3 risk intervals were divided to better
facilitate clinical application. Conclusions A nomogram model for POH
after elective cardiac surgery was developed and validated using 8
predictors, which may have potential application value in clinical risk
assessment, decision-making, and individualized treatment associated with
POH.

<34>
Accession Number
2017706582
Title
Access-site hematoma in distal and conventional transradial access: a
randomized trial.
Source
Minerva Cardiology and Angiology. 70(2) (pp 129-137), 2022. Date of
Publication: April 2022.
Author
Lucreziotti S.; Persampieri S.; Gentile D.; Barbieri L.; Salerno-Uriart
D.; Valli F.; Sabatelli L.; Panzacchi G.; Centola M.; Carugo S.
Institution
(Lucreziotti, Persampieri, Gentile, Barbieri, Salerno-Uriart, Valli,
Sabatelli, Panzacchi, Centola, Carugo) Division of Cardiology, Department
of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan,
Italy
Publisher
Edizioni Minerva Medica
Abstract
BACKGROUND: Distal transradial access (dTRA) has been recently proposed as
an innovative access for coronary procedures and a valuable alternative to
conventional transradial access (cTRA). The aim of this study was to
assess the safety of dTRA versus cTRA in patients undergoing percutaneous
coronary angiography and intervention. METHOD(S): In this
single-center randomized trial, consecutive patients admitted for stable
cardiac condition or acute coronary syndrome (ACS) were assigned to dTRA
or cTRA. The primary endpoint was an early discharge after transra- dial
stenting of coronary arteries (EASY) grade =II access-site hematoma (ASH).
Vascular access failure, radial artery occlusion (RAO) at hospital
discharge, 30-day rates of death, myocardial infarction, stroke and
bleeding not related to coronary artery bypass grafting were considered as
secondary endpoints. RESULT(S): A total of 204 patients were included
and randomized to dTRA (N.=100) or cTRA (N.=104). The two populations were
similar, except for a higher percentage of ACS in the dTRA than in the
cTRA group (38% versus 24%, P=0.022). The rate of EASY grade >=II ASH was
lower in dTRA than in cTRA patients, but the difference was not
statistically significant (4% versus 8.4%, respectively, P=0.25). Vascular
access failure was more frequent in dTRA patients than in cTRA patients
(34% versus 8.7%, P<0.0001). We detected no case of RAO at hospital
discharge and similar rates of 30-day adverse events in both groups.
 CONCLUSION(S): DTRA is safe and feasible. When compared to cTRA, dTRA
is technically more demanding and limited by more frequent crossover to an
alternative vascular access. Copyright © 2021 EDIZIONI MINERVA
MEDICA.

<35>
Accession Number
2017684293
Title
Remifentanil versus Dexmedetomidine in Cardiac Surgery Patients with
Noninvasive Ventilation Intolerance: Protocol for the REDNIVI Trial.
Source
Reviews in Cardiovascular Medicine. 23(3) (no pagination), 2022. Article
Number: rcm2303084. Date of Publication: March 2022.
Author
Luo M.-H.; Hao G.-W.; Liu K.; Yin K.; Yu S.-J.; Wang H.; Su Y.; Luo J.-C.;
Wei Y.-Q.; Wang Y.-H.; Pan W.-Q.; Tu G.-W.; Luo Z.
Institution
(Luo, Wei, Wang, Pan) Shanghai Medical College, Fudan University, Shanghai
200032, China
(Hao, Liu, Yu, Wang, Su, Luo, Tu, Luo) Department of Critical Care
Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
(Yin) Department of Surgery, Massachusetts General Hospital, Harvard
Medical School, Boston, MA 02114, United States
(Luo) Department of Critical Care Medicine, Xiamen Branch, Zhongshan
Hospital, Fudan University, Fujian, Xiamen 361015, China
Publisher
IMR Press Limited
Abstract
Background: Respiratory failure is one of the most common complications
following cardiac surgery. Although noninvasive ventilation (NIV) has been
an effective treatment, it has a high rate of intolerance. Both
remifentanil and dexmedetomidine are used as sedatives in cardiac surgery
(CS) patients with NIV intolerance. However, no randomized controlled
trials have compared the effects of these drugs in relieving the
intolerance. Method(s): REDNIVI will be a multicenter, prospective,
single-blind, randomized controlled trial carried out in six clinical
sites in China. Subjects with NIV intolerance will be randomized to
receive remifentanil or dexmedetomidine in a ratio of 1:1. Primary
outcomes of intolerance remission rate at different timings (15 minutes,
1, 3, 6, 12, 24, 36, 48, 60, 72 hours after initiation of treatment) and
72 h average remission rate will be determined. In addition, secondary
outcomes such as mortality, duration of intensive care unit (ICU) stay,
duration of mechanical ventilation (MV), the need for endotracheal
intubation, hemodynamic changes, and delirium incidence will also be
determined. Conclusion(s): This trial will provide evidence to
determine the effects of remifentanil and dexmedetomidine in patients with
NIV intolerance after cardiac surgery. Copyright © 2022 The
Author(s).

<36>
Accession Number
2017684290
Title
The role of surgery for secondary mitral regurgitation and heart failure
in the era of transcatheter mitral valve therapies.
Source
Reviews in Cardiovascular Medicine. 23(3) (no pagination), 2022. Article
Number: rcm2303087. Date of Publication: March 2022.
Author
Noly P.-E.; Pagani F.D.; Obadia J.-F.; Bouchard D.; Bolling S.F.; Ailawadi
G.; Tang P.C.
Institution
(Noly, Bouchard) Department of Cardiac Surgery, University of Montreal,
Montreal, QC H1T 1C8, Canada
(Noly, Pagani, Bolling, Ailawadi, Tang) Department of Cardiac Surgery,
University of Michigan, Ann Arbor, MI 48109-5864, United States
(Obadia) Department of Cardiac Surgery, "Louis Pradel" Cardiologic
Hospital, Lyon 69001, France
Publisher
IMR Press Limited
Abstract
The approach to the management of mitral valve (MV) disease and heart
failure (HF) has dramatically changed over the last decades. It is well
recognized that severe mitral regurgitation secondary to ischemic or
non-ischemic cardiomyopathy is associated with an excess risk of
mortality. Understanding the impact of the surgical treatment modality on
mortality outcomes has been difficult due to the broad spectrum of
secondary mitral regurgitation (SMR) phenotypes and lack of randomized
surgical clinical trials. Over the last 30 years, surgeons have failed to
provide compelling evidence to convince the medical community of the need
to treat SMR in patients with severe HF. Therefore, the surgical treatment
of SMR has never gained uniform acceptance as a significant option among
patients suffering from SMR. Recent evidence from randomized trials in a
non-surgical eligible patients treated with transcatheter therapies, has
provided a new perspective on SMR treatment. Recently published European
and American guidelines confirm the key role of percutaneous treatment of
SMR and in parallel, these guidelines reinforce the role of mitral valve
surgery in patients who require surgical revascularization. Complex mitral
valve repair combining subvalvular apparatus repair along with
annuloplasty seems to be a promising approach in selected patients in
selected centers. Meanwhile, mitral valve replacement has become the
preferred surgical strategy in most patients with advanced heart failure
and severe LV remodeling or high risk of recurrent mitral regurgitation.
In this comprehensive review, we aimed to discuss the role of mitral
surgery for SMR in patients with heart failure in the contemporary era and
to provide a practical approach for its surgical management. Copyright
© 2022 The Author(s).

<37>
Accession Number
2017684289
Title
Learning from Controversy and Revisiting the Randomized Trials of
Secondary Mitral Regurgitation.
Source
Reviews in Cardiovascular Medicine. 23(3) (no pagination), 2022. Article
Number: 088. Date of Publication: March 2022.
Author
Fiore A.; Singh S.S.A.; Nappi F.
Institution
(Fiore) Department of Cardiac Surgery, University Hospitals Henri Mondor,
Assistance Publique-Hopitaux de Paris, Creteil 94000, France
(Fiore) Sapienza University of Rome, Rome 00185, Italy
(Singh) Department of Cardiothoracic Surgery, Golden Jubilee National
Hospital, Glasgow, Clydebank G81 4DY, United Kingdom
(Nappi) Department of Cardiac Surgery, Centre Cardiologique du Nord,
Saint-Denis 93200, France
Publisher
IMR Press Limited
Abstract
Until recently, conventional mitral valve surgery has been the treatment
of choice even in secondary mitral regurgitation. Recent evidence,
however, advocates the use of transcatheter edge-to-edge mitral valve
repair (TEER) of the mitral valve. This has been reflected by the change
in guidelines of the American College of Cardiology/American Heart
Association. We reviewed the literature to shed light on the risks and
benefits of all interventions, surgical, transcatheter and
guideline-directed medical therapy. Secondary mitral regurgitation occurs
due to an imbalance between closing forces and tethering forces. Given the
pathology extends beyond the valve alone, treatment should be directed at
restoring the geometrical shape of the left ventricle alongside the valve.
Myocardial revascularization plays a pivotal role in preventing
recurrence. The role of papillary muscle approximation in addition to
restrictive mitral annuloplasty should be considered in a select group of
patients. We also reviewed the current literature on TEERs from the COAPT
and Mitra-FR trials while highlighting the concept of
proportionate/disproportionate MR which may help identify which patients
benefit from mitral valve restoration. Treatment of this condition will
require robust randomized trials alongside the use of state-of-the-art
imaging technologies available with the full complement of the
multidisciplinary team to ensure the best outcomes for each
patient. Copyright: © 2022 The Author(s).

<38>
Accession Number
2017684276
Title
Concomitant surgical ablation for treatment of atrial fibrillation in
patients undergoing cardiac surgery.
Source
Reviews in Cardiovascular Medicine. 23(3) (no pagination), 2022. Article
Number: rcm2303101. Date of Publication: March 2022.
Author
Dominici C.; Chello M.
Institution
(Dominici, Chello) Cardiovascular Surgery, Universita Campus Bio-Medico di
Roma, Rome 00128, Italy
Publisher
IMR Press Limited
Abstract
Surgical ablation is a well-established therapy for patients with atrial
fibrillation (AF) undergoing cardiac surgery. However, it is not clear if
this translates to an improvement in patient important outcomes such as
mortality, stroke, and quality of life (QoL). Electronic searches were
performed of Ovid Medline and PubMed from their inception to October 2021.
Eligible literature included comparative studies with patient undergoing
surgical ablative treatment for AF concomitant to any cardiac surgery
procedure and patients without specific AF treatment. For this paper, the
studies listed are presented descriptively without statistical processing
or collection of a metaanalysis. Freedom from AF at 1 year was
consistently shown to be improved by surgical ablation. No differences in
30-day mortality or in safety outcomes were observed between the group who
received ablation and the control group. A significant increase in
pacemaker implantation in the ablation group was generally detected among
studies, especially if the lesions were biatrial. Amongst the studies that
reported on health-related quality of life (HRQoL) a statistically
significant improvement was seen in the ablation group over the control,
especially in the physical domains. Surgical ablation is the most
effective procedure to treat AF during cardiac surgery, and it is a unique
opportunity to return to sinus rhythm with no added mortality risk and a
potential improvement in quality of life. There is however an increased
risk of pacemaker implantation and complications such as renal failure
which must be weighed with tailored treatment and patient selection. It is
also not clear how long-term outcomes are affected due to underpowered
randomized controlled trials. This review summarized short term outcomes
of concomitant AF treatment during cardiac surgery and highlight the
importance of reporting long-term outcomes to confirm the
benefits. Copyright © 2022 The Author(s).

<39>
Accession Number
2017778389
Title
In low-risk patients aged >70-75 with severe aortic stenosis, is
transcatheter superior to surgical aortic valve replacement in terms of
reported cardiovascular composite outcomes and survival?.
Source
Interactive Cardiovascular and Thoracic Surgery. 34(1) (pp 40-44), 2022.
Date of Publication: 01 Jan 2022.
Author
Magro P.L.; Sousa-Uva M.
Institution
(Magro, Sousa-Uva) Department of Cardiothoracic Surgery, Hospital de Santa
Cruz, Carnaxide, Portugal
Publisher
Oxford University Press
Abstract
A best evidence topic in cardiac surgery was written according to a
structured protocol. The question addressed was: In low-risk patients aged
>70-75 with severe aortic stenosis, is transcatheter superior to surgical
aortic valve replacement in terms of reported composite outcomes and
survival? More than 73 papers were found using the reported search, of
which 8 represented the best evidence to answer the clinical question. The
authors, journal, date and country of publication, patient group studied,
study type, relevant outcomes and results of these papers were tabulated.
The only low-risk randomized control trial to date [Nordic Aortic Valve
Intervention (NOTION)] regarding an elderly population did not show a
statistically significant difference between the 2 approaches regarding
the composite endpoint of death, stroke or myocardial infarction. A
subgroup analysis of elderly patients in the 2 main low-risk randomized
control trials did not yield statistically different results from those of
the overall population; the results indicated the superiority of
transcatheter aortic valve implantation regarding the composite of death,
stroke or rehospitalization at 1 year [The Safety and Effectiveness of the
SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic
Stenosis (PARTNER 3)] and non-inferiority regarding a composite of death
or stroke at 2 years [Medtronic Evolut Transcatheter Aortic Valve
Replacement in Low-Risk Patients (Evolut LR)]. The results from lower
evidence studies are largely consistent with these findings. Overall,
there is no compelling evidence indicating that older age should be an
isolated criterion for the choice between transcatheter aortic valve
replacement and surgical aortic valve replacement in otherwise low-risk
patients. The superiority of either technique regarding the aforementioned
composite short-term outcomes in this particular subgroup of patients is
unclear. Copyright © 2021 The Author(s) 2021. Published by
Oxford University Press on behalf of the European Association for
Cardio-Thoracic Surgery. All rights reserved.

<40>
Accession Number
2017767068
Title
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in
Patients With Prior Myocardial Infarction.
Source
Journal of the American College of Cardiology. 79(17) (pp 1660-1671),
2022. Date of Publication: 03 May 2022.
Author
Gaba P.; Bhatt D.L.; Steg P.G.; Miller M.; Brinton E.A.; Jacobson T.A.;
Ketchum S.B.; Juliano R.A.; Jiao L.; Doyle R.T.; Granowitz C.; Tardif
J.-C.; Giugliano R.P.; Martens F.M.A.C.; Gibson C.M.; Ballantyne C.M.
Institution
(Gaba, Bhatt, Giugliano) Division of Cardiovascular Medicine, Brigham and
Women's Hospital, Harvard Medical School, Boston, MA, United States
(Steg) Universite de Paris, FACT (French Alliance for Cardiovascular
Trials), Assistance Publique-Hopitaux de Paris, Hopital Bichat, INSERM
Unite 1148, Paris, France
(Miller) Department of Medicine, University of Maryland School of
Medicine, Baltimore, MD, United States
(Brinton) Utah Lipid Center, Salt Lake City, UT, United States
(Jacobson) Office of Health Promotion and Disease Prevention, Department
of Medicine, Emory University School of Medicine, Atlanta, GA, United
States
(Ketchum, Juliano, Jiao, Doyle, Granowitz) Amarin Pharma, Inc (Amarin),
Bridgewater, NJ, United States
(Tardif) Montreal Heart Institute, Universite de Montreal, Montreal, QC,
Canada
(Martens) Werkgroep Cardiologische centra Nederland (WCN: Dutch Network
for Cardiovascular Research) and the Department of Cardiology, Deventer
Hospital, Deventer, Netherlands
(Gibson) Department of Cardiovascular Diseases, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, MA, United States
(Ballantyne) Department of Medicine, Baylor College of Medicine, Houston,
TX, United States
(Ballantyne) Center for Cardiovascular Disease Prevention, Methodist
DeBakey Heart and Vascular Center, Houston, TX, United States
Publisher
Elsevier Inc.
Abstract
Background: REDUCE-IT was a double-blind trial that randomized 8,179
statin-treated patients with controlled low-density lipoprotein
cholesterol and moderately elevated triglycerides to icosapent ethyl (IPE)
or placebo. There was a significant reduction in the primary endpoint,
including death from cardiovascular (CV) causes. The specific impact of
IPE among patients with prior myocardial infarction (MI) was unknown.
 Objective(s): Our goal was to examine the benefit of IPE on ischemic
events among patients with prior MI in REDUCE-IT. Method(s): We
performed post hoc analyses of patients with prior MI. The primary
endpoint was CV death, MI, stroke, coronary revascularization, or
hospitalization for unstable angina. The key secondary endpoint was CV
death, MI, or stroke. Result(s): A total of 3,693 patients had a
history of prior MI. The primary endpoint was reduced from 26.1% to 20.2%
with IPE vs placebo; HR: 0.74 (95% CI: 0.65-0.85; P = 0.00001). The key
secondary endpoint was reduced from 18.0% to 13.3%; HR: 0.71 (95% CI:
0.61-0.84; P = 0.00006). There was also a significant 35% relative risk
reduction in total ischemic events (P = 0.0000001), a 34% reduction in MI
(P = 0.00009), a 30% reduction in CV death (P = 0.01), and a 20% lower
rate of all-cause mortality (P = 0.054), although there was a slight
increase in atrial fibrillation. Sudden cardiac death and cardiac arrest
were also significantly reduced by 40% and 56%, respectively.
 Conclusion(s): Patients with a history of prior MI in REDUCE-IT
treated with IPE demonstrated large and significant relative and absolute
risk reductions in ischemic events, including CV death. (A Study of AMR101
to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk
Patients With Hypertriglyceridemia and on Statin. The Primary Objective is
to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of
a First Major Cardiovascular Event. [REDUCE-IT];
NCT01492361) Copyright © 2022 The Authors

<41>
Accession Number
2015586194
Title
Effect of listening to music on anxiety, pain, and cardiorespiratory
parameters in cardiac surgery: study protocol for a randomized clinical
trial.
Source
Trials. 23(1) (no pagination), 2022. Article Number: 278. Date of
Publication: December 2022.
Author
de Andrade E.V.; Haas V.J.; de Faria M.F.; dos Santos Felix M.M.; Ferreira
M.B.G.; Barichello E.; da Silva Pires P.; Barbosa M.H.
Institution
(de Andrade, Haas, de Faria, dos Santos Felix, Ferreira) Stricto sensu
Graduate Program in Health Care, Federal University of Triangulo Mineiro,
Av. Getulio Guarita, 107, Minas Gerais, Uberaba CEP: 38025-440, Brazil
(Barichello, Barbosa) Didactic-Scientific Department of Nursing in
Hospital Care, Institute of Health Sciences, Federal University of
Triangulo Mineiro, Av. Getulio Guarita, 107, Minas Gerais, Uberaba CEP:
38025-440, Brazil
(da Silva Pires) Multidisciplinary Health Institute, Federal University of
Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Bahia, Vitoria da
Conquista CEP: 45.029-094, Brazil
Publisher
BioMed Central Ltd
Abstract
Background: Preoperative anxiety and postoperative pain are frequent in
cardiac surgeries and constitute important stressors for patients, which
can cause several complications. One strategy that aims to alleviate these
phenomena is listening to music as a non-pharmacological intervention. The
aim of this study is to evaluate the effect of listening to music on
preoperative state-anxiety, postoperative pain, at rest and when
instructed to cough, and cardiorespiratory parameters in patients
undergoing cardiac surgery. Method(s): A randomized, parallel, simple
masking clinical trial will be conducted with patients 18 years of age or
older who have undergone elective cardiac surgery by sternotomy, who agree
to participate in the research and sign a free and informed consent form.
Study participants will be randomly divided, in a 1:1 ratio, to one of the
two groups: experimental (subjected to listening to music for 20 min in
the pre- and postoperative period) or control (standard care in the pre-
and postoperative period), using a randomization scheme generated by the
Randomization.com website. The sample size calculation was obtained after
conducting a pilot study. Discussion(s): The results of the study may
contribute to the implementation of non-pharmacological interventions in
health services, highlighting the protocols for listening to music, to
minimize anxiety and pain in cardiac surgery. Trial registration: ReBEC
RBR-8mdyhd. Posted on December 10, 2019 Copyright © 2022, The
Author(s).

<42>
Accession Number
2016497375
Title
Natriuretic Peptides and Troponins to Predict Cardiovascular Events in
Patients Undergoing Major Non-Cardiac Surgery.
Source
International Journal of Environmental Research and Public Health. 19(9)
(no pagination), 2022. Article Number: 5182. Date of Publication: May-1
2022.
Author
Perrone M.A.; Aimo A.; Bernardini S.; Clerico A.
Institution
(Perrone) Department of Cardiology, University of Rome Tor Vergata, Rome
00133, Italy
(Perrone, Bernardini) Department of Experimental Medicine and CardioLab,
University of Rome Tor Vergata, Rome 00133, Italy
(Aimo, Clerico) Fondazione CNR Regione Toscana G. Monasterio, Pisa 56124,
Italy
(Aimo, Clerico) Scuola Superiore Sant'Anna, Pisa 56124, Italy
Publisher
MDPI
Abstract
Patients undergoing major surgery have a substantial risk of
cardiovascular events during the perioperative period. Despite the
introduction of several risk scores based on medical history, classical
risk factors and non-invasive cardiac tests, the possibility of predicting
cardiovascular events in patients undergoing non-cardiac surgery remains
limited. The cardiac-specific biomarkers, natriuretic peptides (NPs) and
cardiac troponins (cTn) have been proposed as additional tools for risk
prediction in the perioperative period. This review paper aims to discuss
the value of preoperative levels and perioperative changes in
cardiac-specific biomarkers to predict adverse outcomes in patients
undergoing major non-cardiac surgery. Based on several prospective
observational studies and six meta-analyses, some guidelines recommended
the measurement of NPs to refine perioperative cardiac risk estimation in
patients undergoing non-cardiac surgery. More recently, several studies
reported a higher mortality in surgical patients presenting an elevation
in high-sensitivity cardiac troponin T and I, especially in elderly
patients or those with comorbidities. This evidence should be considered
in future international guidelines on the evaluation of perioperative risk
in patients undergoing major non-cardiac surgery. Copyright ©
2022 by the authors. Licensee MDPI, Basel, Switzerland.

<43>
Accession Number
2016477515
Title
Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic
Review of Non-Invasive Ways of Risk Stratification, Especially in Patients
Undergoing Transcatheter Aortic Valve Replacement.
Source
Journal of Personalized Medicine. 12(4) (no pagination), 2022. Article
Number: 603. Date of Publication: April 2022.
Author
Boxhammer E.; Berezin A.E.; Paar V.; Bacher N.; Topf A.; Pavlov S.; Hoppe
U.C.; Lichtenauer M.
Institution
(Boxhammer, Paar, Bacher, Topf, Hoppe, Lichtenauer) Department of Internal
Medicine II, Division of Cardiology, Paracelsus Medical University of
Salzburg, Salzburg 5020, Austria
(Berezin) Internal Medicine Department, State Medical University of
Zaporozhye, Zaporozhye 69035, Ukraine
(Pavlov) Department of Clinical Laboratory Diagnostics, State Medical
University of Zaporozhye, Zaporozhye 69035, Ukraine
Publisher
MDPI
Abstract
Patients with severe aortic valve stenosis and concomitant pulmonary
hypertension show a significantly reduced survival prognosis. Right heart
catheterization as a preoperative diagnostic tool to determine pulmonary
hypertension has been largely abandoned in recent years in favor of
echocardiographic criteria. Clinically, determination of
echocardiographically estimated systolic pulmonary artery pressure falls
far short of invasive right heart catheterization data in terms of
accuracy. The aim of the present systematic review was to highlight
noninvasive possibilities for the detection of pulmonary hypertension in
patients with severe aortic valve stenosis, with a special focus on
cardiovascular biomarkers. A total of 525 publications regarding
echocardiography, cardiovascular imaging and biomarkers related to severe
aortic valve stenosis and pulmonary hypertension were analyzed in a
systematic database analysis using PubMed Central. Finally, 39
publications were included in the following review. It was shown that the
current scientific data situation, especially regarding cardiovascular
biomarkers as non-invasive diagnostic tools for the determination of
pulmonary hypertension in severe aortic valve stenosis patients, is poor.
Thus, there is a great scientific potential to combine different
biomarkers (biomarker scores) in a non-invasive way to determine the
presence or absence of PH. Copyright © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.

<44>
Accession Number
2017766572
Title
Hybrid coronary revascularization versus coronary artery bypass grafting
for multivessel coronary artery disease: A systematic review and
meta-analysis.
Source
International Journal of Cardiology. (no pagination), 2022. Date of
Publication: 2022.
Author
Dixon L.K.; Akberali U.; Di Tommaso E.; George S.J.; Johnson T.W.; Bruno
V.D.
Institution
(Dixon) Bristol Medical School, Public Health Science, University of
Bristol, UK, Bristol, United Kingdom
(Akberali, Di Tommaso, George, Johnson, Bruno) Bristol Medical School,
Translational Health Science, University of Bristol, UK, Bristol, United
Kingdom
(Johnson, Bruno) Bristol Heart Institute, University Hospitals of Bristol
and Weston NHS Foundation Trust, UK, Bristol, United Kingdom
Publisher
Elsevier Ireland Ltd
Abstract
Background: Hybrid coronary revascularization (HCR) combines the benefits
of a left internal mammary artery to left anterior descending artery
anastomosis, via a mini thoracotomy, with percutaneous coronary
intervention (PCI) for other diseased coronaries. Aim(s): The aim of
this meta-analysis is to compare the short- and long-term outcomes of HCR
with those of coronary artery bypass grafting (CABG) for multi-vessel
coronary artery disease (MCAD). Method(s): We performed a
meta-analysis with a primary outcome of short-term mortality and secondary
outcomes of mid-term survival, length of hospital stay, stroke, renal
failure and mid-term MACE rate. Result(s): 3399 patients (HCR = 1164,
CABG = 2235) were included, with no significant difference in short-term
mortality between groups (OR = 1.50, 95% CI = [0.90,2.49], p = 0.11),
although a higher mortality rate was seen in the HCR group (0.73% vs
0.64%). The average length of stay in intensive care unit was
significantly shorter following HCR than CABG (mean difference = -15.52 h,
CI = [-22.47,-8.59], p<0.001) and overall hospital stay was also shorter
in this group, although not statistically significant (mean difference =
-3.15 days, 95% CI = [-6.55, 0.25], p = 0.07). HCR was associated with a
reduced odds of blood transfusion (OR = 0.34, 95% CI = [0.22,0.54], p <
0.001). There was not a significant difference in mid-term survival (OR =
0.86, 95% CI = [0.62,1.21], p = 0.39) or MACE rate (OR = 0.82, 95% CI =
[0.55,1.23], p = 0.34). No differences were found between HCR and CABG for
post-operative stroke (OR = 1.36, 95% CI = [0.87, 2.13], p = 0.16) or
renal failure (OR = 0.71, 95% CI = [0.43,1.16], p = 0.14).
 Conclusion(s): HCR has a higher incidence of short-term mortality
compared to CABG in patients with MCAD, although this difference is not
statistically significant. Similar rates of mid-term survival and other
short term post-operative complications were found between the two groups.
HCR has a shorter ICU stays and reduced requirement for blood
transfusion. Copyright © 2022 Elsevier B.V.

<45>
Accession Number
2015929575
Title
Cardiac surgery in the morbidly obese.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Djouani A.; Smith A.; Choi J.; Lall K.; Ambekar S.
Institution
(Djouani, Smith, Choi, Lall, Ambekar) The Department of Cardiac Surgery,
St Bartholomew's Hospital, London, United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: Obesity rates globally continue to rise and in turn the body
mass index (BMI) of patients undergoing cardiac surgery is set to mirror
this. Patients who are Class III obese (BMI >= 40) pose significant
challenges to the surgical teams responsible for their care and are also
at high risk of complications from surgery and even death. To improve
outcomes in this population, interventions carried out in the
preoperative, operative, and postoperative periods have shown promise.
Despite this, there are no defined best practice national guidelines for
perioperative management of obese patients undergoing cardiac surgery.
 Aim(s): This review is aimed at clinicians and researchers in the
field of cardiac surgery and aims to form a basis for the future
development of clinical guidelines for the management of obese cardiac
surgery patients. Method(s): The PubMed database was utilized to
identify relevant literature and strategies employed at various stages of
the surgical journey were analyzed. Conclusion(s): Data presented
identified the benefits of preoperative respiratory muscle training,
off-pump coronary artery bypass grafting where possible, and early
extubation. Further randomized controlled trials are required to identify
optimal operative and perioperative management strategies before the
introduction of such guidance into clinical practice. Copyright ©
2022 Wiley Periodicals LLC.

<46>
Accession Number
637838791
Title
Design and methods for the training in exercise activities and motion for
growth (TEAM 4 growth) trial: A randomized controlled trial.
Source
International journal of cardiology. (no pagination), 2022. Date of
Publication: 18 Apr 2022.
Author
Lambert L.M.; Pemberton V.L.; Trachtenberg F.L.; Uzark K.; Woodard F.;
Teng J.E.; Bainton J.; Clarke S.; Justice L.; Meador M.R.; Riggins J.;
Suhre M.; Sylvester D.; Butler S.; Miller T.A.
Institution
(Lambert) Division of Pediatric Cardiothoracic Surgery, University of
Utah, UT, Salt Lake City, United States
(Pemberton) Division of Cardiovascular Sciences, National Heart, Lung,
Blood Institute, NIH, MD, Bethesda, United States
(Trachtenberg, Teng) HealthCore Inc., MA, Watertown, United States
(Uzark) Division of Cardiology, C.S. Mott Children's Hospital, MI, Ann
Arbor, United States
(Woodard) Division of Pediatric Cardiology, Medical University of South
Carolina, SC, Charleston, United States
(Bainton) Division of Cardiology, Hospital for Sick Children, University
of Toronto, Toronto, ON, Canada
(Clarke) Division of Cardiology, Emory University School of Medicine,
Children's Healthcare of Atlanta, Atlanta, United States
(Justice, Suhre) Division of Cardiology, Cincinnati Children's Hospital
Medical Center, Cincinnati, OH, United States of America
(Meador) Division of Cardiology Pediatric Anesthesiology, Texas Children's
Hospital, Baylor College of Medicine, TX, Houston, United States
(Riggins) Division of Cardiovascular Surgery, Riley Hospital for Children
at IU Health, IN, Indianapolis, United States
(Sylvester) Division of Cardiology, Children's Hospital of Philadelphia,
Perelman School of Medicine, PA, Philadelphia, United States
(Butler) Department of Psychiatry, Children's Hospital Boston, MA, Boston,
United States
(Miller) Division of Cardiology, Maine Medical Center, ME, Portland,
United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: Growth is often impaired in infants with congenital heart
disease. Poor growth has been associated with worse neurodevelopment,
abnormal behavioral state, and longer time to hospital discharge.
Nutritional interventions, drug therapy, and surgical palliation have
varying degrees of success enhancing growth. Passive range of motion
(PROM) improves somatic growth in preterm infants and is safe and feasible
in infants with hypoplastic left heart syndrome (HLHS), after their first
palliative surgery (Norwood procedure). METHOD(S): This multicenter,
Phase III randomized control trial of a 21-day PROM exercise or standard
of care evaluates growth in infants with HLHS after the Norwood procedure.
Growth (weight-, height- and head circumference-for-age z-scores) will be
compared at 4months of age or at the pre-superior cavopulmonary connection
evaluation visit, whichever comes first. Secondary outcomes include
neonatal neurobehavioral patterns, neurodevelopmental assessment, and bone
mineral density. Eligibility include diagnosis of HLHS or other single
right ventricle anomaly, birth at >=37weeks gestation and Norwood
procedure at <30days of age, and family consent. Infants with known
chromosomal or recognizable phenotypic syndromes associated with growth
failure, listed for transplant, or expected to be discharged within 14days
of screening are excluded. CONCLUSION(S): The TEAM 4 Growth trial
will make an important contribution to understanding the role of PROM on
growth, neurobehavior, neurodevelopment, and BMD in infants with complex
cardiac anomalies, who are at high risk for growth failure and
developmental concerns. Copyright © 2022 Elsevier Ireland Ltd.
All rights reserved.

<47>
Accession Number
637834405
Title
Mechanical versus Bioprosthetic Valve for Aortic Valve Replacement:
Systematic Review and Meta-Analysis of Reconstructed Individual
Participant Data.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2022.
Date of Publication: 21 Apr 2022.
Author
Tasoudis P.T.; Varvoglis D.N.; Vitkos E.; Mylonas K.S.; Sa M.P.;
Ikonomidis J.S.; Caranasos T.G.; Athanasiou T.
Institution
(Tasoudis, Varvoglis, Vitkos) Department of Cardiothoracic Surgery,
Faculty of Medicine, School of Health Sciences, University of Thessaly,
Biopolis, Larissa, Greece; Surgery Working Group, Society of Junior
Doctors, Athens, Greece
(Mylonas) Department of Cardiac surgery, Onassis Cardiac Surgery Center,
Athens, Greece
(Sa) Department of Cardiothoracic Surgery Research, Lankenau Institute for
Medical Research, Wynnewood, PA, United States
(Ikonomidis) Professor of Surgery, Division of Cardiothoracic Surgery,
Department of Surgery, School of Medicine, University of North Carolina,
at Chapel Hill Chapel Hill
(Caranasos) Division of Cardiothoracic Surgery, Department of Surgery,
School of Medicine, University of North Carolina at Chapel Hill, Chapel
Hill
(Athanasiou) Department of Surgery and Cancer, Imperial College London, St
Mary's Hospital, London, W2 1NY, UK, Department of Cardiothoracic Surgery,
University Hospital of Larissa, Biopolis, Larissa, Greece, 41110
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To compare biological versus mechanical aortic valve
replacement. METHOD(S): We searched MEDLINE, Scopus, and Cochrane
Library databases for randomized clinical trials and propensity-score
matched studies published by October 14th, 2021 according to PRISMA
statement. Individual patient data on overall survival were extracted.
One- and two-stage survival analyses, and random-effects meta-analyses
were conducted. RESULT(S): 25 studies were identified, incorporating
8,721 bioprosthetic and 8,962 mechanical valves:. In the one-stage
meta-analysis, mechanical valves cumulatively demonstrated decreased
hazard for mortality (Hazard Ratio [HR] : 0.79, 95% Confidence interval
[CI] : 0.74-0.84, p<0.0001). Overall survival was similar between the
compared arms for patients <50years old (HR: 0.88, 95% CI : 0.71-1.1,
p=0.216), increased in the mechanical valve arm for patients 50-70years
old (HR : 0.76, 95% CI : 0.70-0.83, p<0.0001), and increased in the
bioprosthetic arm for patients >70years old (HR : 1.35, 95% CI :
1.17-1.57, p<0.0001). Meta-regression analysis revealed that the survival
in the 50-70years old group was not influenced by the publication year of
the individual studies. No statistically significant difference was
observed regarding in-hospital mortality, post-operative strokes and
post-operative reoperation. All-cause mortality was found decreased in the
mechanical group, cardiac mortality was comparable between the two groups,
major bleeding rates were increased in the mechanical valve group, and
reoperation rates were increased in the bioprosthetic valve group.
 CONCLUSION(S): Survival rates seem to not be influenced by the type
of prosthesis in patients <50years old. A survival advantage in favour of
mechanical valves is observed in patients 50-70years old, while in
patients >70years old bioprosthetic valves offer better survival
outcomes. Copyright © The Author(s) 2022. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<48>
Accession Number
637832532
Title
Sex Related Differences in Transcatheter Mitral Valve Repair: A Systematic
Review and Meta-analysis.
Source
Cardiology. (no pagination), 2022. Date of Publication: 20 Apr 2022.
Author
El-Andari R.; Bozso S.J.; Kang J.J.H.; Adams C.; Nagendran J.
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Inequalities in postoperative outcomes between males and
females are well described with females often experiencing inferior
outcomes after heart valve surgery. Recent literature has demonstrated
equivalent or improved outcomes for females after transcatheter aortic
valve replacement. Transcatheter mitral valve repair (TMVr) and
replacement (TMVR) is a relatively newer field with significantly less
literature comparing sex differences. This systematic review and
meta-analysis looks to provide a comprehensive summary of the published
literature comparing outcomes between males and females undergoing
transcatheter MV interventions. METHOD(S): PubMed, Medline, and
Scopus were systematically searched for all studies comparing outcomes
between males and females undergoing TMVr and TMVR. 2,178 English
manuscript titles and abstracts were reviewed. Articles were excluded if
data was not provided regarding sex differences, transcatheter MV
intervention, full-length text was not accessible, or if insufficient data
was provided. 2,170 articles were excluded and 8 articles were included in
this study. RESULT(S): Pooled estimates of outcomes demonstrated
rates of acute kidney injury [OR 1.28 (95% CI, 1.14-1.44; p<0.0001)]
favored females while rates of major bleeding favored males [OR 0.85 (95%
CI 0.76-0.96; p=0.01)]. Rates of mortality, postoperative MI, and stroke
did not differ significantly. CONCLUSION(S): A trend has emerged in
heart valve interventions with males tending to have improved outcomes
after surgical intervention and females experiencing equivalent or
improved outcomes after transcatheter interventions. This meta-analysis
identified increased rates of acute kidney injury for males, increased
rates of major bleeding for females, and otherwise comparable morbidity
and mortality in males and females undergoing TMVr. Copyright S.
Karger AG, Basel.

<49>
Accession Number
637832397
Title
Combined Programmed Intermittent Bolus Infusion with Continuous Infusion
For The Thoracic Paravertebral Block in Patients Undergoing Thoracoscopic
Surgery: A Prospective, Randomized, and Double-blinded Study.
Source
The Clinical journal of pain. (no pagination), 2022. Date of Publication:
20 Apr 2022.
Author
Huang X.; Cui Y.; Xiao Y.; Zhao X.; Xu J.; Yang L.
Institution
(Huang, Cui, Xiao, Zhao, Xu, Yang) Department of Anesthesiology, Second
Xiangya Hospital, Central South University, Hunan Province, Changsha,
China
(Huang, Cui, Xiao, Xu, Yang) Hunan Province Center for Clinical Anesthesia
and Anesthesiology, Research Institute of Central South UniversityHunan
Province, Changsha, China
(Zhao) Department of Anesthesiology, First Affiliated Hospital, Sun
Yat-sen University, Guangdong Province, Guangzhou, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Continuous thoracic paravertebral block (TPVB) connected with
a patient-controlled analgesia (PCA) pump is an effective modality to
reduce postoperative pain following thoracic surgery. For the PCA
settings, the programmed intermittent bolus infusion (PIBI) and continuous
infusion (CI) are commonly practiced. However, the comparative
effectiveness between the two approaches has been inconsistent. Thus, the
aim of this study was to explore the optimal PCA settings to treat
post-thoracotomy pain by combing PIBI and CI together. METHOD(S): All
enrolled patients undergoing thoracoscopic surgery accepted ultrasound
guided TPVB catheterization before the surgery, and then were randomly
allocated in to three groups depending on different settings of the PCA
pump connecting to the TPVB catheter: the PIBI+CI, PIBI, and CI groups.
the Numeric Rating Scales (NRS) were evaluated for each patient at T1 (one
hour after extubation), T2 (12h after the surgery), T3 (24h after the
surgery), T4 (36h after the surgery), and T5 (48h after the surgery).
Besides, the consumptions of patient-controlled analgesia (PCA)
ropivacaine, the number of blocked dermatomes at T3, and the requirement
for extra dezocine for pain relief among the three groups were also
compared. RESULT(S): Firstly, the NRS scores in the PIBI + CI group
were lower than the CI group at T2 and T3 (P<0.05) when patients were at
rest, and were also lower than the CI group at T2, T3, and T4 (P<0.01) and
the PIBI group at T3 when patients were coughing (P<0.01). Secondly, the
two-day cumulative dosage of PCA in the PIBI + CI group was lower than
both the CI and PIBI groups (P<0.01). Thirdly, the number of blocked
dermatomes in the PIBI and PIBI + CI groups were comparable, and were both
wider than the CI group at T3 (P<0.01). Finally, a smaller proportion (not
statistically significant) of patients in the PIBI + CI group (5.26%,
2/38) had required dezocine for pain relief when compared with the PIBI
group (19.44%, 7/36) and the CI group (15.79%, 6/38). CONCLUSION(S):
The combination of PIBI and CI provides superior analgesic modality to
either PIBI or CI alone in patients undergoing thoracoscopic surgery.
Therefore, it should be advocated to improve the management of
postoperative pain, clinical outcomes, and ultimately patient
satisfaction. Copyright © 2022 The Author(s). Published by
Wolters Kluwer Health, Inc.

<50>
Accession Number
637826343
Title
Systematic review of electrophysiology procedures in patients with
obstruction of the inferior vena cava.
Source
Journal of cardiovascular electrophysiology. (no pagination), 2022. Date
of Publication: 20 Apr 2022.
Author
Al-Sinan A.; Dip Cardiac G.; Chan K.H.; Young G.D.; Martin A.; Sepahpour
A.; Sy R.W.
Institution
(Dip Cardiac, Chan, Sy) Department of Cardiology, Royal Prince Alfred
Hospital, Sydney, Australia
(Dip Cardiac) Department of Cardiology, Waikato Hospital, Hamilton, New
Zealand
(Chan, Sy) Faculty of Medicine and Health, University of Sydney, Australia
(Young) Department of Cardiology, Royal Adelaide Hospital, Adelaide,
Australia
(Martin) Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
(Sepahpour) Department of Cardiology, St. George Hospital, Sydney,
Australia
Publisher
NLM (Medline)
Abstract
AIMS: The objective of the study was to conduct a systematic review to
describe and compare the different approaches for performing cardiac
electrophysiology (EP) procedures in patients with interrupted inferior
vena cava (IVC) or equivalent entities causing IVC obstruction.
 METHOD(S): We conducted a structured search to identify manuscripts
reporting electrophysiology (EP) procedures with interrupted IVC or IVC
obstruction of any aetiology published up until August 2020. No
restrictions were applied in the search strategy. We also included 7 local
cases that met inclusion criteria. RESULT(S): The analysis included
142 patients (mean age 48.9y; 48% female) undergoing 143 procedures.
Obstruction of the IVC was not known before the index procedure in 54% of
patients. Congenital interruption of IVC was the most frequent cause
(80%); and, associated congenital heart disease (CHD) was observed in 43%
of patients in this setting. The superior approach for ablation was the
most frequently used strategy (52%), followed by inferior approach via the
azygos or hemiazygos vein (24%), transhepatic approach (14%), and
retroaortic approach (10%). Electroanatomical mapping (58%), use of long
sheaths (41%), intracardiac echocardiography (19%), transesophageal
echocardiography (15%) and remote controlled magnetic navigation (13%)
were used as adjuncts to aid performance. Ablation was successful in 135
of 140 procedures in which outcomes were reported. Major complications
were only reported in patients undergoing AF ablation, including two
patients with pericardial effusion, one of whom required surgical repair,
and another patient who died after inadvertent entry into an undiagnosed
atrioesophageal fistula from a previous procedure. CONCLUSION(S): The
superior approach is most frequent approach for performing EP procedures
in the setting of obstructed IVC. Transhepatic approach is a feasible
alternative, and may provide a 'familiar approach' for transseptal access
when it is required. Adjunctive use of long sheaths, intravascular
echocardiography, electro-anatomical mapping and remote magnetic
navigation may be helpful, especially if there is associated complex CHD.
With careful planning, EP procedures can usually be successfully performed
with a low risk of complications. This article is protected by copyright.
All rights reserved.

<51>
Accession Number
637824925
Title
Standardized Aortic Valve Neocuspidization for Treatment of Aortic Valve
Diseases.
Source
The Annals of thoracic surgery. (no pagination), 2022. Date of
Publication: 16 Apr 2022.
Author
Amabile A.; Krane M.; Dufendach K.; Baird C.W.; Ganjoo N.; Eckstein F.S.;
Albertini A.; Gruber P.J.; Mumtaz M.A.; Bacha E.A.; Benedetto U.; Chikwe
J.; Geirsson A.; Holfeld J.; Iida Y.; Lange R.; Morell V.O.; Chu D.
Institution
(Amabile, Krane, Gruber, Geirsson) Division of Cardiac Surgery, Department
of Surgery, Yale University School of Medicine, CT, New Haven, United
States
(Dufendach, Ganjoo) Division of Cardiac Surgery, Department of
Cardiothoracic Surgery, University of Pittsburgh School of Medicine, PA,
Pittsburgh, United States
(Baird) Department of Cardiac Surgery, Boston Children's Hospital, Harvard
Medical School, MA, Boston, United States
(Eckstein) Department of Cardiac Surgery, University Hospital Basel,
University of Basel, Switzerland
(Albertini) Cardiovascular Surgery Department, Maria Cecilia Hospital GVM
Care & Research, Cotignola (RA), Italy
(Mumtaz) University of Pittsburgh Medical Center Heart & Vascular
Institute, PA, Pittsburgh, United States
(Bacha) Division of Cardiac, Thoracic and Vascular Surgery, Section of
Pediatric and Congenital Heart Surgery, Columbia University Medical
Center/New York-Presbyterian Hospital, NY, NY, United States
(Benedetto) Department of Cardiac Surgery, University Chieti Pescara,
Italy
(Chikwe) Department of Cardiac Surgery, Cedars-Sinai Medical Center, Smidt
Heart Institute, Los Angeles, CA, U.S.A
(Holfeld) Department of Cardiac Surgery, Innsbruck Medical University,
Innsbruck, Austria
(Iida) Department of Cardiovascular Surgery, Saiseikai Yokohamashi Tobu
Hospital, Yokohama, Japan
(Lange) Department of Cardiovascular Surgery, German Heart Center, Munich,
Germany
(Morell, Chu) Division of Cardiac Surgery, Department of Cardiothoracic
Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA,
U.S.A; University of Pittsburgh Medical Center Heart & Vascular Institute,
Pittsburgh, PA, U.S.A
Publisher
NLM (Medline)
Abstract
BACKGROUND: Aortic valve replacement is the traditional surgical treatment
for aortic valve diseases, yet standardized aortic valve neocuspidization
(AVNeo) is a promising alternative that is gaining popularity. The purpose
of this article is to review the available published literature of AVNeo
using glutaraldehyde-treated autologous pericardium, also known as the
Ozaki procedure, including indications, outcomes, potential benefits, and
modes of failure for the reconstructed valve. METHOD(S): A
comprehensive literature search was performed using keywords related to
aortic valve repair, AVNeo, or the Ozaki procedure. All articles
describing performance of AVNeo were reviewed. RESULT(S): Reported
early mortality following AVNeo varies from 0-5.88%. The largest cohort of
patients in the literature includes 850 patients with an in-hospital
mortality rate of 1.88%. Cumulative incidence of aortic valve reoperation
was 4.2% in the largest series. Reoperation was uncommon and mainly due to
infective endocarditis or degeneration of the reconstructed valve (most
commonly due to aortic valve regurgitation, rather than stenosis).
 CONCLUSION(S): AVNeo is a versatile and standardized alternative to
aortic valve replacement with a biological prosthesis. Early to midterm
outcomes from multiple centers are excellent and demonstrate the safety
and durability of the procedure. Long-term outcomes and clinical trial
data are necessary to determine which patients benefit the most from this
procedure. Copyright © 2022 The Society of Thoracic Surgeons.
Published by Elsevier Inc. All rights reserved.

<52>
Accession Number
2007164350
Title
Treatment options for ischemic mitral regurgitation: A meta-analysis.
Source
Journal of Thoracic and Cardiovascular Surgery. 163(2) (pp 607-622.e14),
2022. Date of Publication: February 2022.
Author
Nappi F.; Antoniou G.A.; Nenna A.; Michler R.; Benedetto U.; Avtaar Singh
S.S.; Gambardella I.C.; Chello M.
Institution
(Nappi) Department of Cardiac Surgery, Centre Cardiologique du Nord de
Saint-Denis, Paris, France
(Antoniou) Department of Vascular and Endovascular Surgery, The Royal
Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, United
Kingdom
(Antoniou) Division of Cardiovascular Sciences, School of Medical
Sciences, University of Manchester, Manchester, United Kingdom
(Nenna, Chello) Department of Cardiovascular Surgery, University Campus
Bio-Medico of Rome, Rome, Italy
(Michler) Department of Surgery and Cardiothoracic and Vascular Surgery,
Montefiore Medical Center, Albert Einstein College of Medicine, New York,
NY, United States
(Benedetto) Department of Cardiothoracic Surgery, Bristol Heart Institute,
University of Bristol, Bristol, United Kingdom
(Avtaar Singh) Department of Cardiac Surgery, Golden Jubilee National
Hospital, Glasgow, United Kingdom
(Gambardella) Department of Cardiothoracic Surgery, Weill Cornell
Medicine, New York, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Treatment of ischemic mitral regurgitation (IMR) is in
evolution, as percutaneous procedures and complex surgical repair have
been recently investigated in randomized clinical trials and matched
studies. This study aims to review and compare the current treatment
options for IMR. Method(s): A comprehensive literature search was
conducted using electronic databases. The primary outcome was all-cause
long-term mortality. The secondary outcomes were perioperative mortality,
unplanned rehospitalization, reoperation, and composite end points as
defined in the original articles. Result(s): A total of 12 articles
met the inclusion criteria and were included in the final meta-analysis.
The MitraClip procedure did not confer a significant benefit in mortality
and repeated hospitalization compared with medical therapy alone. In
patients with moderate IMR, the adjunct of mitral procedure over coronary
artery bypass graft is not associated with clinical improvements. When
evaluating mitral valve (MV) replacement versus repair, hospital mortality
was greater among patients undergoing replacement (odds ratio [OR], 1.91;
P = .009), but both reoperation and readmission rates were lower (OR,
0.60, P = .05; and OR, 0.45, P < .02, respectively). Comparing restrictive
annuloplasty alone with adjunctive subvalvular repair, subvalvular
procedures resulted in fewer readmissions (OR, 0.50; P = .06) and adverse
composite end points (P = .009). Conclusion(s): MitraClip procedure
is not associated with improved outcomes compared with medical therapy. MV
replacement is associated with increased early mortality but reduced
reoperation rate and readmission rate compared with MV repair using
annuloplasty in moderate-to-severe IMR. Despite no significant benefit in
isolated outcomes comparing annular and adjunct subvalvular procedures,
the adjunct of subvalvular procedures reduces the risk of major
postoperative adverse events. Copyright © 2020 The American
Association for Thoracic Surgery

<53>
Accession Number
2017751607
Title
Use of Midodrine in Heart Failure: Two Case Reports and a Review of the
Literature.
Source
European Journal of Case Reports in Internal Medicine. 9(3) (no
pagination), 2022. Date of Publication: 2022.
Author
Hajjiah A.; Maadarani O.; Bitar Z.; Hanna B.; Elshabasy R.; Abdelfatah M.;
Gohar M.
Institution
(Hajjiah) Clinical Pharmacy Department, Ahmadi Hospital, Kuwait Oil
Company, Al Ahmadi, Kuwait
(Maadarani, Bitar, Hanna, Elshabasy, Abdelfatah, Gohar) Internal Medicine
Department, Ahmadi Hospital, Kuwait Oil Company, Al Ahmadi, Kuwait
Publisher
SMC Media Srl
Abstract
Hypotension in patients with heart failure is much more frequent in daily
clinical practice than the 10-15% reported in clinical trials. In patients
with heart failure with reduced ejection fraction (HFrEF), hypotension
frequently limits the initiation and up-titration of guideline-directed
medical therapy (GDMT). Midodrine is a peripheral alpha-1 agonist and a
vasopressor anti-hypotensive agent approved for the treatment of
orthostatic hypotension. We describe two cases where midodrine was
prescribed in patients with HFrEF and hypotension. Copyright European
Journal of Case Reports in Internal Medicine © EFIM 2022

<54>
[Use Link to view the full text]
Accession Number
2017431911
Title
Revascularization strategies in patients with diabetes and stable ischemic
heart disease: A systematic review and meta-analysis of randomized trials.
Source
Journal of Cardiovascular Medicine. 23(4) (pp 242-246), 2022. Date of
Publication: 01 Apr 2022.
Author
Noguchi M.; Ueyama H.; Fujisaki T.; Takagi H.; Kuno T.
Institution
(Noguchi) Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical
Center, Urayasu, Japan
(Ueyama, Kuno) Department of Medicine, Icahn School of Medicine at Mount
Sinai, Mount Sinai Beth Israel, United States
(Fujisaki) Department of Medicine, Icahn School of Medicine at Mount
Sinai, Mount Sinai Morningside and West, New York, NY, United States
(Takagi) Division of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, 111 East 210th St, Bronx, NY 10467-2401, United
States
Publisher
Lippincott Williams and Wilkins
Abstract
AimsThe optimal treatment strategy comparing invasive revascularization
versus optimal medical therapy (OMT) in patients with diabetes mellitus
(DM) and stable ischemic heart disease (SIHD) still remains unclear. We
aimed to investigate clinical outcomes of invasive revascularization
(percutaneous coronary intervention, coronary artery bypass grafting or
both) versus OMT in patients with DM and SIHD from updated published
randomised-controlled trials (RCTs).MethodsWe conducted a comprehensive
literature search through PubMed and EMBASE to investigate the effect of
revascularization versus OMT for patients with DM and SIHD. The studies
were limited to RCTs or their subgroup data for a meta-analysis. The
outcomes of interest were major adverse cardiovascular events (MACE) in
patients with DM and SIHD.ResultsOur search identified subgroup data with
DM of four RCTs including a total of 5742 patients with SIHD. Our results
showed that invasive revascularization was not associated with a decreased
risk of MACE when compared to OMT [hazard ratio (95% confidence interval):
0.95 (0.85-1.05), P-=-0.31; I2-=-0%].ConclusionInvasive
revascularization was not associated with a decreased risk of MACE when
compared with OMT. Copyright © 2022 Lippincott Williams and
Wilkins. All rights reserved.

<55>
Accession Number
2016949192
Title
Promising results from a residential rehabilitation intervention focused
on fatigue and the secondary psychological and physical consequences of
cardiac arrest: The SCARF feasibility study.
Source
Resuscitation. 173 (pp 12-22), 2022. Date of Publication: April 2022.
Author
Joshi V.L.; Tang L.H.; Kim Y.J.; Wagner M.K.; Nielsen J.F.; Tjoernlund M.;
Zwisler A.-D.
Institution
(Joshi, Zwisler) REHPA, The Danish Knowledge Centre for Rehabilitation and
Palliative Care, Odense University Hospital, Nyborg, Denmark
(Joshi, Zwisler) Department of Clinical Research, University of Southern
Denmark, Odense, Denmark, Studiestraede 6, Copenhagen 1455, Denmark
(Tang) Department of Physiotherapy and Occupational Therapy,
Naestved-Slagelse-Ringsted Hospitals, Denmark
(Tang) The Department of Regional Health Research, University of Southern
Denmark, Denmark
(Kim) 600 Moye Blvd, MS668, HSB3305, Department of Occupational Therapy,
College of Allied Health Sciences, East Carolina University, Greenville,
NC 27834, United States
(Wagner) Department of Cardiology, Copenhagen University Hospital,
Rigshospitalet, Blegdamsvej 9, Copenhagen DK-2100, Denmark
(Nielsen) Hammel Neurorehabilitation Centre and University Research
Clinic, Aarhus, Denmark
(Nielsen) Department of Clinical Medicine, Aarhus University, Midtjylland,
Aarhus, Denmark
(Tjoernlund) Center for Rehabilitation of Brain Injury, Amagerfaelledvej
56 A, Kobenhavn S 2300, Denmark
(Zwisler) Department of Cardiology, Odense University Hospital, J.B.
Winsloews Vej, Odense 5000, Denmark
Publisher
Elsevier Ireland Ltd
Abstract
Aims: This study investigated the feasibility and potential effect of
SCARF (Survivors of Cardiac ARest focused on Fatigue) a multidisciplinary
residential rehabilitation intervention focused on fatigue and the
secondary psychological and physical consequences of cardiac arrest (CA).
 Method(s): This was a prospective one-armed feasibility study. Six
progression criteria were identified related to the feasibility of the
intervention and viability of a future effect study in terms of:
participant recruitment (1), participant retention (2,3,4), and
completeness of outcomes (5,6). Data on participant/clinician satisfaction
with the intervention was also collected along with self-reported
outcomes: fatigue, quality of life, anxiety, depression, function and
disability, and physical activity (at baseline, 12 weeks and 6 months) and
physical capacity (baseline and 12 weeks). Result(s): Four
progression criteria were met including retention (87.5%) and completion
of baseline outcomes (97.5%). Two criteria were not met: recruitment rate
was 2.9 participants per month (estimated rate needed 6.1) and completion
of final outcomes was 65% (estimated proportion needed 75%).
Participant/clinician satisfaction with the intervention was high. Three
months after the SCARF intervention small to moderate effect size changes
of r = 0.18-0.46 were found for self-reported fatigue, quality of life,
anxiety, depression, function and disability and for two of the physical
capacity tests (d = 0.46-0.52). Conclusion(s): SCARF was found to be
a feasible intervention with high participant/clinician satisfaction, high
participant retention and the possible potential to improve self-reported
and physical capacity outcomes. Procedures for study recruitment and
collection of final outcomes should be modified before a fully powered
randomised controlled trial is conducted. Copyright © 2022 The
Author(s)

<56>
Accession Number
2016603907
Title
Treatment Strategies for Proximal Deep Vein Thrombosis: A Network
Meta-analysis of Randomised Controlled Trials.
Source
European Journal of Vascular and Endovascular Surgery. 63(2) (pp 323-334),
2022. Date of Publication: February 2022.
Author
Ashrafi M.; Ahmad S.B.; Antoniou S.A.; Khan T.; Antoniou G.A.
Institution
(Ashrafi, Ahmad, Khan, Antoniou) Department of Vascular and Endovascular
Surgery, Manchester University NHS Foundation Trust, UK, Manchester,
United Kingdom
(Antoniou) Department of Surgery, Mediterranean Hospital of Cyprus,
Limassol, Cyprus
(Antoniou) Division of Cardiovascular Sciences, School of Medical
Sciences, The University of Manchester, UK, Manchester, United Kingdom
Publisher
W.B. Saunders Ltd
Abstract
Objective: To investigate the outcomes of treatment strategies for
proximal and iliofemoral deep vein thrombosis (DVT). Method(s):
Randomised controlled trials (RCTs) investigating outcomes of catheter
directed thrombolysis (CDT), ultrasound assisted CDT (USCDT), percutaneous
aspiration thrombectomy (PAT), and best medical therapy (BMT) for proximal
DVT from 2000 onwards were considered. MEDLINE, EMBASE, and CINAHL were
searched using the Healthcare Databases Advanced Search interface
developed by the National Institute for Health and Care Excellence. The
primary outcome was the rate of post-thrombotic syndrome (PTS), which was
defined using the Villalta scoring system (score of >=5). Secondary
outcomes included vessel patency, recurrence, bleeding, and mortality. The
network of evidence was summarised using network plots, and random effects
network meta-analyses were performed. The certainty of evidence was
assessed using the Certainty In Network Meta-Analysis (CINeMA) approach.
 Result(s): Seven RCTs meeting the inclusion criteria were identified.
There were direct comparisons between medical therapy, CDT, and USCDT
across outcomes, except for patency. There were no direct comparisons
between medical therapy and PAT (except for patency), and USCDT and PAT.
There was no significant difference observed in PTS between the treatment
modalities for proximal and iliofemoral DVT (low certainty). There was a
significant difference in patency rates between medical therapy and USCDT
(odds ratio [OR] 9.46, 95% confidence interval [CI] 3.05 - 29.35; low
certainty) and CDT (OR 2.03, 95% CI 1.46 - 2.80; low certainty) in favour
of USCDT and CDT, respectively, for proximal DVT. USCDT significantly
improved patency rates compared with CDT (OR 4.67, 95% CI 1.58 - 13.81;
very low certainty) for proximal DVT. There was no significant difference
in DVT recurrence, bleeding, or mortality between treatment groups for
proximal and iliofemoral DVT (low to moderate certainty for most
comparisons). Conclusion(s): USCDT may improve patency rates compared
with BMT and the other interventional treatment modalities used for the
management of proximal DVT. However, no treatment modality showed
superiority with regard to a reduction in PTS, and overall, the quality of
available evidence is poor. Copyright © 2021 European Society for
Vascular Surgery

<57>
Accession Number
2015573334
Title
The effect of dexmedetomidine on neuroprotection in pediatric cardiac
surgery patients: study protocol for a prospective randomized controlled
trial.
Source
Trials. 23(1) (no pagination), 2022. Article Number: 271. Date of
Publication: December 2022.
Author
Ji S.-H.; Kang P.; Song I.-S.; Jang Y.-E.; Lee J.-H.; Kim J.-T.; Kim
H.-S.; Kim E.-H.
Institution
(Ji, Kang, Song, Jang, Lee, Kim, Kim, Kim) Department of Anesthesiology
and Pain Medicine, Seoul National University Hospital, Seoul National
University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080,
South Korea
Publisher
BioMed Central Ltd
Abstract
Background: Infants undergoing cardiac surgery under cardiopulmonary
bypass are vulnerable to postoperative neurodevelopmental delays.
Dexmedetomidine has been shown to have protective effects on the heart,
kidneys, and brain in animals and adults undergoing cardiac surgery with
cardiopulmonary bypass. We hypothesized that dexmedetomidine would have a
neuroprotective effect on infants undergoing cardiopulmonary bypass and
planned a prospective randomized controlled trial with postoperative
neurodevelopment measurements. Method(s): This is a single-center,
prospective, double-blinded, randomized controlled trial with 1:1
allocation. A cohort of 160 infants undergoing cardiac surgery with
cardiopulmonary bypass will be enrolled. After induction, dexmedetomidine
will be infused with a loading dose of 1 mug/kg and a maintenance dose of
0.5 mug/kg/h or the same amount of normal saline will be administered.
Upon initiation of cardiopulmonary bypass, an additional dose of
dexmedetomidine (0.01 mug/cardiopulmonary priming volume) will be mixed
with the cardiopulmonary bypass circuit. The primary outcome will be the
proportion of infants who score lower than 85 in any of the cognitive,
language, or motor Bayley scales of infant development-III tests 1 year
after the surgery. Other feasible outcome measures will include
differences in plasma glial fibrillary acidic protein, troponin I,
interleukin-6, urinary neutrophil gelatinase-associated lipocalin, and
perioperative major adverse events. The results of the Bayley scales of
infant development-III test from the study group and the control group
will be compared using a chi-squared test under intention-to-treat
analysis. A generalized estimating equation will be used to analyze
repeated measurements over time. Discussion(s): This study will
enable us to assess whether the use of dexmedetomidine can alter the early
neurodevelopmental outcome in infants undergoing cardiac surgery with
cardiopulmonary bypass and also estimate effects of dexmedetomidine on
other organs. Trial registration: ClinicalTrials.gov NCT04484922.
Registered on 24 July 2020 Copyright © 2022, The Author(s).

<58>
[Use Link to view the full text]
Accession Number
2017549683
Title
Effects of colloid preload on the incidence of hypotension in spinal
anesthesia for cesarean section: a systematic review and meta-analysis.
Source
Chinese Medical Journal. 134(9) (pp 1043-1051), 2021. Date of Publication:
05 May 2021.
Author
Gong R.-S.; Liu X.-W.; Li W.-X.; Zhao J.
Institution
(Gong) Department of Anesthesia, China-Japan Friendship Hospital, Chinese
Academy of Medical Sciences, Peking Union Medical College, Beijing, China
(Liu, Li, Zhao) Department of Anesthesia, China-Japan Friendship Hospital,
Beijing, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background:Hypotension is a common complication caused by spinal
anesthesia (SA), which may have adverse impacts on the condition of the
parturient and fetus. Liquid infusion was found to be relatively effective
for reducing the incidence of hypotension. However, the question of
whether colloid preload can optimize hemodynamic variables in the cesarean
section remains controversial. This study aims to determine the effects of
colloid preload on the incidence of hypotension induced by SA in elective
cesarean section. Method(s):Related keywords were searched on PubMed,
EMBASE, and Cochrane Library from inception dates to May 2020. Studies
included were evaluated for eligibility and quality. The primary outcome
was the intra-operative incidence of hypotension and severe hypotension.
The secondary outcomes included the lowest intra-operative systolic blood
pressure, the maximal intra-operative heart rate, the intra-operative
needs of ephedrine and phenylephrine, the incidence of maternal nausea
and/or vomiting, and neonatal outcomes (umbilical artery pH and Apgar
scores). Apart from the above, RevMan 5.3 was used for the data analysis.
 Result(s):Altogether nine randomized controlled trials were included
in the meta-analysis. There were no significant differences in the
incidence of intra-operative hypotension, severe hypotension, or neonatal
outcomes between the colloid preload group and control group, except for
the umbilical artery pH. Conclusion(s):This meta-analysis suggests
that colloid preload does not significantly reduce the incidence of
hypotension associated with SA in elective cesarean section. Copyright
© 2021 The Chinese Medical Association.

<59>
Accession Number
2013353640
Title
The efficacy and safety of rivaroxaban in coronary artery disease patients
with heart failure and sinus rhythm: a systematic review and
meta-analysis.
Source
European Journal of Clinical Pharmacology. 77(10) (pp 1485-1494), 2021.
Date of Publication: October 2021.
Author
Xie S.; Chen J.; Xiong G.; Li J.; Wan J.; Liu Y.; Xu R.; Zhang W.
Institution
(Xie, Li, Wan, Liu, Xu, Zhang) Department of Pharmacy, the Second
Affiliated Hospital of Nanchang University, Nanchang 330006, China
(Chen) Department of Pharmacy, Guangqian Hospital of Quanzhou, Quanzhou
362321, China
(Xiong) Department of Information, the Second Affiliated Hospital of
Nanchang University, Nanchang 330006, China
(Li, Zhang) Department of Pharmacology, School of Pharmaceutical Science,
Nanchang University, Nanchang, Jiangxi 330006, China
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Purpose: To explore the efficacy and safety of rivaroxaban in patients
with coronary artery disease (CAD), heart failure (HF) and sinus rhythm
(SR). Method(s): Comprehensive literature searches were conducted
using the PubMed, Cochrane Library, Embase, CNKI and Wanfang databases
from inception to February 2021. Randomized controlled trials (RCTs)
focusing on the efficacy and safety of new oral anticoagulant (NOAC)
therapy in CAD and HF patients in SR were eligible. Statistical analyses
were performed using R Programming Language. Result(s): Three RCTs
included 10,658 adult patients treated with antiplatelet drugs with or
without rivaroxaban were ultimately analysed. The average follow-up period
was 20.4-24 months. Rivaroxaban had a favourable point estimate in
myocardial infarction (MI) and stroke (MI rivaroxaban group (3.83%,
203/5306) vs. APT group (4.52%, 214/4731), RR = 0.78, 95% CI 0.65-0.94, P
< 0.01, I2 = 0%), (stroke: rivaroxaban group (1.60%, 85/5306)
vs. APT group (2.52%, 119/4731), RR = 0.64, 95% CI 0.49-0.85, P < 0.01,
I2 = 12%) compared with the placebo. Rivaroxaban was comparable
to the placebo for all-cause death and major bleeding (all-cause death:
rivaroxaban group (12.27%, 688/5606) vs. APT group (14.59%, 737/5052), RR
= 0.73, 95% CI 0.49-1.06, P > 0.05, I2 = 87%), (major bleeding:
rivaroxaban group (1.52%, 85/5586) vs. APT group (1.37%, 69/5043), RR =
1.18, 95% CI 0.86-1.62, P > 0.05, I2 = 0%). Conclusion(s):
In SR patients with CAD and HF, the rates of MI and stroke associated with
rivaroxaban combined with APT were lower than those associated with APT
alone, and the two treatments had similar rates of all-cause death and
major bleeding. Copyright © 2021, The Author(s), under exclusive
licence to Springer-Verlag GmbH Germany, part of Springer Nature.

<60>
Accession Number
2010693263
Title
Complications in children with ventricular assist devices: systematic
review and meta-analyses.
Source
Heart Failure Reviews. 27(3) (pp 903-913), 2022. Date of Publication: May
2022.
Author
George A.N.; Hsia T.-Y.; Schievano S.; Bozkurt S.
Institution
(George, Schievano, Bozkurt) Institute of Cardiovascular Science,
University College London, London, United Kingdom
(Hsia) Pediatric Cardiac Surgery, Arnold Palmer Hospital for Children,
Orlando, FL, United States
Publisher
Springer
Abstract
Heart failure is a significant cause of mortality in children with
cardiovascular diseases. Treatment of heart failure depends on patients'
symptoms, age, and severity of their condition, with heart transplantation
required when other treatments are unsuccessful. However, due to lack of
fitting donor organs, many patients are left untreated, or their
transplant is delayed. In these patients, ventricular assist devices
(VADs) are used to bridge to heart transplant. However, VAD support
presents various complications in patients. The aim of this study was to
compile, review, and analyse the studies reporting risk factors and
aetiologies of complications of VAD support in children. Random effect
risk ratios (RR) with 95% confidence intervals were calculated to analyse
relative risk of thrombosis (RR = 3.53 [1.04, 12.06] I2 = 0% P
= 0.04), neurological problems (RR = 0.95 [0.29, 3.15] I2 = 53%
P = 0.93), infection (RR = 0.31 [0.05, 2.03] I2 = 86% P =
0.22), bleeding (RR = 2.57 [0.76, 8.66] I2 = 0% P = 0.13), and
mortality (RR = 2.20 [1.36, 3.55] I2 = 0% P = 0.001) under
pulsatile-flow and continuous-flow VAD support, relative risk of mortality
(RR = 0.45 [0.15, 1.37] I2 = 36% P = 0.16) under left VAD and
biVAD support, relative risk of thrombosis (RR = 1.72 [0.46, 6.44]
I2 = 0% P = 0.42), infection (RR = 1.77 [0.10, 32.24]
I2 = 46% P = 0.70) and mortality (RR = 0.92 [0.14, 6.28]
I2 = 45% P = 0.93) in children with body surface area < 1.2
m2 and > 1.2 m2 under VAD support, relative risk of
mortality in children supported with VAD and diagnosed with cardiomyopathy
and congenital heart diseases (RR = 1.31 [0.10, 16.61] I2 = 73%
P = 0.84), and cardiomyopathy and myocarditis (RR = 0.91 [0.13, 6.24]
I2 = 58% P = 0.92). Meta-analyses results show that further
research is necessary to reduce complications under VAD
support. Copyright © 2021, The Author(s), under exclusive licence
to Springer Science+Business Media, LLC part of Springer Nature.

<61>
Accession Number
2010407218
Title
Long-term outcomes of transcatheter valve-in-valve replacement for failed
aortic bioprosthesis: A meta-analysis.
Source
Catheterization and Cardiovascular Interventions. 99(4) (pp 1370-1372),
2022. Date of Publication: March 1, 2022.
Author
Abushouk A.I.; Saad A.M.; Isogai T.; Shekhar S.; Krishnaswamy A.; Yun J.;
Kapadia S.R.
Institution
(Abushouk, Saad, Isogai, Shekhar, Krishnaswamy, Yun, Kapadia) Department
of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic
Foundation, Cleveland, OH, United States
Publisher
John Wiley and Sons Inc

<62>
Accession Number
2015666572
Title
A novel nomogram predicting the risk of postoperative pneumonia for
esophageal cancer patients after minimally invasive esophagectomy.
Source
Surgical Endoscopy. (no pagination), 2022. Date of Publication: 2022.
Author
Jin D.; Yuan L.; Li F.; Wang S.; Mao Y.
Institution
(Jin, Yuan, Li, Wang, Mao) Department of Thoracic Surgery, National Cancer
Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing 100021, China
Publisher
Springer
Abstract
Background: Pneumonia is a common complication after minimally invasive
esophagectomy (MIE), which prolongs hospital stay, adding to the cost and
increasing the risk to patients' lives. This study aimed to identify risk
factors and establish a predictive nomogram for postoperative pneumonia
(PP). Method(s): This case control study included 609 patients with
esophageal cancer who underwent MIE between March 2015 and August 2019 in
Cancer Hospital, Chinese Academy of Medical Sciences. We randomly divided
the data into training and validation sets in the ratio of 7:3 and
performed univariate and multivariate logistic regression analyses to
acquire independent risk factors of the training set. We constructed a
nomogram based on the independent risk factors. The concordance index
(C-index), receiver operating characteristic (ROC) curve, calibration
plot, and decision curve analysis (DCA) plots were used to evaluate the
discrimination of the nomogram. Validation set was applied to confirm the
predictive value of the nomogram. Result(s): In the univariate
analysis, age, gender, abdominal procedure method, thoracic operative
time, duration of chest tube placement, anastomotic leakage, and recurrent
laryngeal nerve palsy were found to be correlated with the incidence of
PP. In multivariate analysis, all variables except thoracic operative time
were found to be independent risk factors for PP. A nomogram was
constructed based on these independent risk factors. The C-index of the
training and validation sets was 0.769 and 0.734, respectively, and the
areas under the curve (AUC) of ROC curves of the training and validation
sets were 0.769 and 0.686, respectively. The calibration plots and DCA
plots of the training and validation sets showed the accuracy and
predictive value of the nomogram. Conclusion(s): The nomogram could
accurately identify the risk factors for PP. We could predict the
occurrence of PP based on this nomogram and take corresponding measures to
reduce the incidence of PP. Graphical abstract: [Figure not available: see
fulltext.] Copyright © 2022, The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature.

<63>
Accession Number
2016445164
Title
Cardiopulmonary Outcomes After the Nuss Procedure in Pectus Excavatum.
Source
Journal of the American Heart Association. 11(7) (no pagination), 2022.
Article Number: e022149. Date of Publication: 05 Apr 2022.
Author
Jaroszewski D.E.; Farina J.M.; Gotway M.B.; Stearns J.D.; Peterson M.A.;
Pulivarthi V.S.K.K.; Bostoros P.; Abdelrazek A.S.; Gotimukul A.; Majdalany
D.S.; Wheatley-Guy C.M.; Arsanjani R.
Institution
(Jaroszewski, Farina, Peterson, Pulivarthi, Bostoros, Abdelrazek,
Gotimukul) Department of Cardiovascular and Thoracic Surgery, Mayo Clinic
Arizona, Phoenix, AZ, United States
(Gotway) Department of Radiology, Mayo Clinic Arizona, Phoenix, AZ, United
States
(Stearns) Department of Anesthesiology and Perioperative Medicine, Mayo
Clinic Arizona, Phoenix, AZ, United States
(Majdalany, Wheatley-Guy, Arsanjani) Department of Cardiovascular
Medicine, Mayo Clinic Arizona, Phoenix, AZ, United States
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Pectus excavatum is the most common chest wall deformity.
There is still controversy about cardiopulmonary limitations of this
disease and benefits of surgical repair. This study evaluates the impact
of pectus excavatum on the cardiopulmonary function of adult patients
before and after a modified minimally invasive repair. METHODS AND
RESULTS: In this retrospective cohort study, an electronic database was
used to identify consecutive adult (aged >=18 years) patients who
underwent cardiopulmonary exercise testing before and after primary pectus
excavatum repair at Mayo Clinic Arizona from 2011 to 2020. In total, 392
patients underwent preoperative cardiopulmonary exercise testing; abnormal
oxygen consumption results were present in 68% of patients. Among them,
130 patients (68% men, mean age, 32.4+/-10.0 years) had post-repair
evaluations. Post-repair tests were performed immediately before bar
removal with a mean time between repair and post-repair testing of
3.4+/-0.7 years (range, 2.5-7.0). A significant improvement in
cardiopulmonary outcomes (P<0.001 for all the comparisons) was seen in the
post-repair evaluations, including an increase in maximum, and predicted
rate of oxygen consumption, oxygen pulse, oxygen consumption at anaerobic
threshold, and maximal ventilation. In a subanalysis of 39 patients who
also underwent intraoperative transesophageal echocardiography at repair
and at bar removal, a significant increase in right ventricle stroke
volume was found (P<0.001). CONCLUSION(S): Consistent improvements in
cardiopulmonary function were seen for pectus excavatum adult patients
undergoing surgery. These results strongly support the existence of
adverse cardiopulmonary consequences from this disease as well as the
benefits of surgical repair. Copyright © 2022 The Authors.

<64>
Accession Number
2015663467
Title
Regional Analgesia in Video-Assisted Thoracic Surgery: A Bayesian Network
Meta-Analysis.
Source
Frontiers in Medicine. 9 (no pagination), 2022. Article Number: 842332.
Date of Publication: 06 Apr 2022.
Author
Lin J.; Liao Y.; Gong C.; Yu L.; Gao F.; Yu J.; Chen J.; Chen X.; Zheng
T.; Zheng X.
Institution
(Lin, Liao, Gong, Yu, Gao, Yu, Chen, Chen, Zheng, Zheng) Department of
Anesthesiology, Fujian Provincial Hospital, Shengli Clinical Medical
College of Fujian Medical University, Fuzhou, China
Publisher
Frontiers Media S.A.
Abstract
Background: A variety of regional analgesia methods are used during
video-assisted thoracic surgery (VATS). Our network meta-analysis (NMA)
sought to evaluate the advantages of various methods of localized
postoperative pain management in VATS patients. Method(s): PubMed,
the Cochrane Library, and EMBASE were searched from their date of
inception to May 2021 for randomized controlled trials (RCTs) comparing
two or more types of locoregional analgesia in adults using any
standardized clinical criteria. This was done using Bayesian NMA.
 Result(s): A total of 3,563 studies were initially identified, and 16
RCTs with a total of 1,144 participants were ultimately included. These
studies, which spanned the years 2014 to 2021 and included data from eight
different countries, presented new information. There were a variety of
regional analgesia techniques used, and in terms of analgesic effect,
thoracic epidural anesthesia (TEA) [SMD (standard mean difference) = 1.12,
CrI (Credible interval): (-0.08 to -2.33)], thoracic paravertebral block
(TPVB) (SMD = 0.67, CrI: (-0.25 to 1.60) and erector spinae plane block
(ESPB) (SMD = 0.34, CrI: (-0.5 to 1.17) were better than other regional
analgesia methods. Conclusion(s): Overall, these findings show that
TEA, TPVB and ESPB may be effective forms of regional analgesia in VATS.
This research could be a valuable resource for future efforts regarding
the use of thoracic regional analgesia and enhanced recovery after
surgery. Systematic Review Registration: Identifier [PROSPERO
CRD42021253218]. Copyright © 2022 Lin, Liao, Gong, Yu, Gao, Yu,
Chen, Chen, Zheng and Zheng.

<65>
Accession Number
2006053570
Title
WeChat-based education and rehabilitation program in unprotected left main
coronary artery disease patients after coronary artery bypass grafting: An
effective approach in reducing anxiety, depression, loss to follow-up, and
improving quality of life.
Source
Brazilian Journal of Medical and Biological Research. 54(4) (pp 1-10),
2021. Article Number: e10370. Date of Publication: 2021.
Author
Ma C.; Wang B.; Zhao X.; Fu F.; Zheng L.; Li G.; Guo Q.
Institution
(Ma, Wang, Zhao, Fu, Zheng, Li) Department of Cardiovascular Surgery,
Second Affiliated Hospital, Harbin Medical University, Harbin,
Heilongjiang, China
(Guo) Ministry of Nursing, 4th Affiliated Hospital, Harbin Medical
University, Harbin, Heilongjiang, China
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
This study aimed to investigate the effect of WeChat-based education and
rehabilitation program (WERP) on anxiety, depression, health-related
quality of life (HRQoL), major adverse cardiac/cerebrovascular events
(MACCE)-free survival, and loss to follow-up rate in unprotected left main
coronary artery disease (ULMCAD) patients after coronary artery bypass
grafting (CABG). In this randomized controlled study, 140 ULMCAD patients
who underwent CABG were randomly assigned to WERP group (n=70) or control
care (CC) group (n=70). During the 12-month intervention period, anxiety
and depression (using hospital anxiety and depression scale (HADS)) and
HRQoL (using 12-Item Short-Form Health Survey (SF-12)) were assessed
longitudinally. During the total 36-month follow-up period (12-month
intervention and 24-month non-intervention periods), MACCE and loss to
follow-up were recorded. During the intervention period, HADS-anxiety
score at month 9 (M9) (P=0.047) and month 12 (M12) (P=0.034), anxiety rate
at M12 (P=0.028), and HADS-D score at M12 (P=0.048) were all reduced in
WERP group compared with CC group. As for HRQoL, SF-12 physical component
summary score at M9 (P=0.020) and M12 (P=0.010) and SF-12 mental component
summary score at M9 (P=0.040) and M12 (P=0.028) were all increased in WERP
group compared with CC group. During the total follow-up period, WERP
group displayed a trend of longer MACCE-free survival than that in CC
group but without statistical significance (P=0.195). Additionally, loss
to follow-up rate was attenuated in WERP group compared with CC group
(P=0.033). WERP serves as an effective approach in optimizing mental
health care and promoting life quality in ULMCAD patients after
CABG. Copyright © 2021, Associacao Brasileira de Divulgacao
Cientifica. All rights reserved.

<66>
Accession Number
619949956
Title
Comparison of Arndt-endobronchial blocker plus laryngeal mask airway with
left-sided double-lumen endobronchial tube in one-lung ventilation in
thoracic surgery in the morbidly obese.
Source
Brazilian Journal of Medical and Biological Research. 51(2) (no
pagination), 2018. Article Number: e6825. Date of Publication: 2018.
Author
Zhang Z.J.; Zheng M.L.; Nie Y.; Niu Z.Q.
Institution
(Zhang, Zheng, Nie, Niu) Department of Anesthesiology, The Cangzhou
Central Hospital, Cangzhou, Hebei, China
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
This study aimed to evaluate the feasibility and performance of
Arndt-endobronchial blocker (Arndt) combined with laryngeal mask airway
(LMA) compared with left-sided double-lumen endobronchial tube (L-DLT) in
morbidly obese patients in one-lung ventilation (OLV). In a prospective,
randomized double-blind controlled clinical trial, 80 morbidly obese
patients (ASA I-III, aged 20-70) undergoing general anesthesia for
elective thoracic surgeries were randomly allocated into groups Arndt
(n=40) and L-DLT (n=40). In group Arndt, a LMATM Proseal was placed
followed by an Arndt-endobronchial blocker. In group L-DLT, patients were
intubated with a left-sided double-lumen endotracheal tube. Primary
endpoints were the airway establishment, ease of insertion, oxygenation,
lung collapse and surgical field exposure. Results showed similar ease of
airway establishment and tube/device insertion between the two groups.
Oxygen arterial pressure (PaO<inf>2</inf>) of patients in the Arndt group
was significantly higher than L-DLT (154+/-46 vs 105+/-52 mmHg; P<0.05).
Quality of lung collapse and surgical field exposure in the Arndt group
was significantly better than L-DLT (effective rate 100 vs 90%; P<0.05).
Duration of surgery and anesthesia were significantly shorter in the Arndt
group (2.4+/-1.7 vs 3.1+/-1.8 and 2.8+/-1.9 vs 3.8+/-1.8 h, respectively;
P<0.05). Incidence of hoarseness of voice and incidence and severity of
throat pain at the post-anesthesia care unit and 12, 24, 48, and 72 h
after surgery were significantly lower in the Arndt group (P<0.05).
Findings suggested that Arndt-endobronchial blocker combined with LMA can
serve as a promising alternative for morbidly obese patients in OLV in
thoracic surgery. Copyright © 2018, Associacao Brasileira de
Divulgacao Cientifica. All rights reserved.

<67>
Accession Number
614659366
Title
Comparison of outcomes between off-pump versus on-pump coronary artery
bypass surgery in elderly patients: A meta-analysis.
Source
Brazilian Journal of Medical and Biological Research. 50(3) (no
pagination), 2017. Article Number: e5711. Date of Publication: 2017.
Author
Zhu Z.G.; Xiong W.; Ding J.L.; Chen J.; Li Y.; Zhou J.L.; Xu J.J.
Institution
(Zhu, Chen, Li, Zhou, Xu) Department of Cardiothoracic Surgery, Second
Affiliated Hospital of Nanchang University, Nanchang, China
(Xiong) Guangxi University of Chinese Medicine, Nanning, China
(Ding) Department of Gastroenterology, Second Affiliated Hospital of
Nanchang University, Nanchang, China
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
The aim of this study was to analyze if off-pump coronary artery bypass
surgery (CABG) is associated with better treatment outcomes in elderly
patients (>70 years of age) than on-pump CABG, using meta-analysis.
Medline, PubMed, Cochrane and Google Scholar databases were searched until
September 13, 2016. Sensitivity and quality assessment were performed.
Twenty-two studies, three randomized control trials (RCTs) and 20 non-RCTs
were included with 24,127 patients. The risk of death associated with
on-pump or off-pump CABG in the RCTs were similar (pooled OR=0.945,
95%CI=0.652 to 1.371, P=0.766). However, in the non-RCTs, mortality risk
was lower in patients treated with off-pump CABG than on-pump CABG (pooled
OR=0.631, 95%CI=0.587 to 0.944, P=0.003). No differences were observed
between the two treatment groups in terms of the occurrence of 30-day
post-operative stroke or myocardial infarction (P>=0.147). In the
non-RCTs, off-pump CABG treatment was associated with a shorter length of
hospital stay (pooled standardized difference in means=-0.401,
95%CI=-0.621 to -0.181, P<=0.001). The meta-analysis with pooled data from
non-RCTs, but not RCTs, found that mortality was lower with off-pump
compared with on-pump CABG, and suggested that there may be some benefit
of off-pump CABG compared with on-pump CABG in the risk of mortality and
length of hospital stay. Copyright © 2017, Associacao Brasileira
de Divulgacao Cientifica. All rights reserved.

<68>
Accession Number
610079864
Title
Clinical applications of retrograde autologous priming in cardiopulmonary
bypass in pediatric cardiac surgery.
Source
Brazilian Journal of Medical and Biological Research. 49(5) (no
pagination), 2016. Article Number: e5138. Date of Publication: 26 Apr
2016.
Author
Fu G.W.; Nie Y.F.; Jiao Z.Y.; Zhao W.Z.
Institution
(Fu, Nie, Jiao, Zhao) Department of Cardiovascular Surgery, The First
Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
Retrograde autologous priming (RAP) has been routinely applied in cardiac
pediatric cardiopulmonary bypass (CPB). However, this technique is
performed in pediatric patients weighing more than 20 kg, and research
about its application in pediatric patients weighing less than 20 kg is
still scarce. This study explored the clinical application of RAP in CPB
in pediatric patients undergoing cardiac surgery. Sixty pediatric patients
scheduled for cardiac surgery were randomly divided into control and
experimental groups. The experimental group was treated with CPB using
RAP, while the control group was treated with conventional CPB (priming
with suspended red blood cells, plasma and albumin). The hematocrit (Hct)
and lactate (Lac) levels at different perioperative timepoints, mechanical
ventilation time, hospitalization duration, and intraoperative and
postoperative blood usage were recorded. Results showed that Hct levels at
15 min after CPB beginning (T2) and at CPB end (T3), and number of
intraoperative blood transfusions were significantly lower in the
experimental group (Po0.05). There were no significant differences in CPB
time, aortic blocking time, T2-Lac value or T3-Lac between the two groups
(P40.05). Postoperatively, there were no significant differences in Hct (2
h after surgery), mechanical ventilation time, intensive care unit time,
or postoperative blood transfusion between two groups (P40.05). RAP can
effectively reduce the hemodilution when using less or not using any
banked blood, while meeting the intraoperative perfusion conditions, and
decreasing the perioperative blood transfusion volume in pediatric
patients. Copyright © 2016, Associacao Brasileira de Divulgacao
Cientifica. All Rights Reserved.

<69>
Accession Number
603862284
Title
Effects of conventional vs high-dose rocuronium on the QTc interval during
anesthesia induction and intubation in patients undergoing coronary artery
surgery: A randomized, double-blind, parallel trial.
Source
Brazilian Journal of Medical and Biological Research. 48(4) (pp 370-376),
2015. Date of Publication: 2015.
Author
Ozturk T.; Agdanli D.; Bayturan O.; Cikrikci C.; Keles G.T.
Institution
(Ozturk, Agdanli, Cikrikci, Keles) Department of Anesthesiology and
Reanimation, School of Medicine, Celal Bayar University, Manisa, Turkey
(Bayturan) Department of Cardiology, School of Medicine, Celal Bayar
University, Manisa, Turkey
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
Myocardial ischemia, as well as the induction agents used in anesthesia,
may cause corrected QT interval (QTc) prolongation. The objective of this
randomized, double-blind trial was to determine the effects of high- vs
conventional-dose bolus rocuronium on QTc duration and the incidence of
dysrhythmias following anesthesia induction and intubation. Fifty patients
about to undergo coronary artery surgery were randomly allocated to
receive conventional-dose (0.6 mg/kg, group C, n=25) or high-dose (1.2
mg/kg, group H, n=25) rocuronium after induction with etomidate and
fentanyl. QTc, heart rate, and mean arterial pressure were recorded before
induction (T0), after induction (T1), after rocuronium (just before
laryngoscopy; T2), 2 min after intubation (T3), and 5 min after intubation
(T4). The occurrence of dysrhythmias was recorded. In both groups, QTc was
significantly longer at T3 than at baseline [475 vs 429 ms in group C
(P=0.001), and 459 vs 434 ms in group H (P=0.005)]. The incidence of
dysrhythmias in group C (28%) and in group H (24%) was similar. The QTc
after high-dose rocuronium was not significantly longer than after
conventional-dose rocuronium in patients about to undergo coronary artery
surgery who were induced with etomidate and fentanyl. In both groups,
compared with baseline, QTc was most prolonged at 2 min after intubation,
suggesting that QTc prolongation may be due to the nociceptive stimulus of
intubation. Copyright © 2015, Associacao Brasileira de Divulgacao
Cientifica. All rights reserved.

<70>
Accession Number
2011059434
Title
Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE
Duration of Triple Therapy (COBRA-REDUCE).
Source
Cardiovascular Revascularization Medicine. 34 (pp 17-24), 2022. Date of
Publication: January 2022.
Author
Colleran R.; Joner M.; Cutlip D.; Urban P.; Maeng M.; Jauhar R.; Barakat
M.; Michel J.M.; Mehran R.; Kirtane A.J.; Maillard L.; Kastrati A.; Byrne
R.A.
Institution
(Colleran, Joner, Michel, Kastrati) Deutsches Herzzentrum Munchen,
Technische Universitat Munchen, Munich, Germany
(Joner, Kastrati) German Centre for Cardiovascular Research (DZHK),
partner site Munich Heart Alliance, Munich, Germany
(Cutlip) Cardiology Division, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, United States
(Urban) La Tour Hospital, Geneva, Switzerland
(Urban) CERC (Cardiovascular European Research Center), Massy, France
(Maeng) Aarhus University Hospital, Aarhus, Denmark
(Mehran) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Kirtane) Department of Medicine, Columbia University Irving Medical
Center/New York Presbyterian Hospital, New York, NY, United States
(Kirtane) Cardiovascular Research Foundation, New York, NY, United States
(Maillard) GCS-ES Axium-Rambot, Clinique Axium, Aix en Provence, France
(Byrne) Cardiovascular Research Institute Dublin, Mater Private Hospital,
Dublin, Ireland
(Byrne) School of Pharmacy and Biomolecular Sciences, Royal College of
Surgeons University of Medicine and Health Sciences, Dublin, Ireland
(Jauhar) North Shore University Hospital, Manhasset New York, NY, United
States
(Barakat) Celonova Biosciences Inc., San Antonio, TX, United States
Publisher
Elsevier Inc.
Abstract
Background/purpose: A coronary stent with thromboresistant and pro-healing
properties such as the polymer polyzene F-coated (COBRA PzF) stent might
safely allow for a very short duration of triple therapy in patients
taking oral anticoagulation (OAC) who undergo coronary stenting.
 Method(s): The COBRA-REDUCE trial is a prospective, multinational,
randomized, open-label, assessor-blinded trial. A total of 996 patients at
high bleeding risk because of requirement for OAC (with a vitamin K
antagonist or non-vitamin K antagonist for any indication) will be
randomized at sites in the United States and Europe to treatment with the
COBRA-PzF stent followed by very short duration (14 days) DAPT or a Food
and Drug Administration (FDA)-approved new generation drug-eluting stent
followed by guideline-recommended DAPT duration (3 or 6 months). Two
co-primary endpoints will be tested at 6 months: a bleeding co-primary
endpoint (bleeding academic research consortium [BARC] >=2 bleeding beyond
14 days or after hospital discharge, whichever is later [superiority
hypothesis]) and a thrombo-embolic co-primary endpoint (the composite of
all-cause death, myocardial infarction, definite/probable stent thrombosis
or ischaemic stroke [non-inferiority hypothesis]). The trial is registered
at clinicaltrials.gov (NCT02594501). Conclusion(s): The COBRA-REDUCE
trial will determine whether coronary stenting with the COBRA PzF stent
followed by 14 days of clopidogrel will reduce bleeding without increasing
thrombo-embolic events compared with FDA-approved DES followed by 3-6
months clopidogrel in patients taking OAC and aspirin. Copyright
© 2021 The Authors

<71>
Accession Number
2010819417
Title
Single Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve
Replacement: A Meta-Analysis of Randomized Clinical Trials.
Source
Cardiovascular Revascularization Medicine. 34 (pp 46-53), 2022. Date of
Publication: January 2022.
Author
Ahmad Y.; Howard J.P.; Madhavan M.V.; Leon M.B.; Makkar R.R.
Institution
(Ahmad, Makkar) Smidt Heart Institute, Cedars-Sinai Medical Center, Los
Angeles, CA, United States
(Howard) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Madhavan, Leon) Columbia University Medical Center, New York, NY, United
States
(Leon) Cardiovascular Research Foundation, New York, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Guidelines recommend dual antiplatelet therapy (DAPT) after
transcatheter aortic valve replacement (TAVR) but guidelines predate the
publication of the largest randomized trial. There have been few trials in
the field to date, and with a small number of total patients; pooling
their results may therefore be helpful. Method(s): We systematically
identified all randomized trials comparing SAPT to DAPT after TAVR. The
primary endpoint was the risk of major bleeding. Secondary endpoints
included all bleeding, life-threatening bleeding, stroke, myocardial
infarction, death and cardiac death. Result(s): Four trials,
randomizing 1086 participants, were eligible (541 randomized to SAPT and
545 randomized to DAPT). The weighted mean follow-up was 9.1 months. The
risk of major bleeding was significantly increased after DAPT (relative
risk (RR) 2.36, 95% confidence interval (CI) 1.27 to 4.40, P = 0.007).
There was a similar increased risk for all bleeding (RR 1.65, 95% CI 1.24
to 2.19, P < 0.001), although not for life-threatening bleeding (RR 1.44,
95% CI 0.74 to 2.77, P = 0.282). There were no significant differences in
the risk of stroke, myocardial infarction (MI), death or cardiac death.
There was no heterogeneity observed for any endpoint (I2 =
0.0%). Conclusion(s): DAPT after TAVR is associated with an increased
risk of major bleeding and all bleeding. There is no evidence of a
significant difference between DAPT or SAPT for the risks of stroke, MI,
death or cardiac death. However, the total number of patients randomized
is small and the duration of follow-up is short. Larger scale randomized
trials with longer follow-up are required to assess for any potential
differences in ischemic endpoints or mortality. Copyright © 2021
The Author(s)

<72>
Accession Number
2012311666
Title
Predictors of Mortality in Patients Treated with Veno-Arterial ECMO for
Cardiogenic Shock Complicating Acute Myocardial Infarction: a Systematic
Review and Meta-Analysis.
Source
Journal of Cardiovascular Translational Research. 15(2) (pp 227-238),
2022. Date of Publication: April 2022.
Author
Sohail S.; Fan E.; Foroutan F.; Ross H.J.; Billia F.; Alba A.C.
Institution
(Sohail, Foroutan, Ross, Billia, Alba) Division of Cardiology, Peter Munk
Cardiac Center, University of Toronto, Toronto, ON, Canada
(Sohail, Foroutan, Ross, Billia, Alba) Ted Rogers Centre for Heart
Research, University of Toronto, Toronto, ON, Canada
(Sohail, Fan, Foroutan, Ross, Billia, Alba) Toronto General Hospital,
Toronto, ON, Canada
(Fan) Interdisciplinary Division of Critical Care Medicine, University of
Toronto, Toronto, ON, Canada
Publisher
Springer
Abstract
Background: Mortality for patients on veno-arterial extracorporeal
membrane oxygenation (VA-ECMO) for cardiogenic shock (CS) complicating
acute myocardial infarction (AMI) remains high. This meta-analysis aims to
identify factors that predict higher risk of mortality after VA-ECMO for
AMI. Method(s): We meta-analyzed mortality after VA-ECMO for CS
complicating AMI and the effect of factors from systematically selected
studies published after 2009. Result(s): 72 studies (10,276 patients)
were included with a pooled mortality estimate of 58 %. With high
confidence in estimates, failure to achieve TIMI III flow and left main
culprit were identified as factors associated with higher mortality. With
low-moderate confidence, older age, high BMI, renal dysfunction,
increasing lactate, prothrombin activity < 50%, VA-ECMO implantation after
revascularization, and non-shockable ventricular arrythmias were
identified as factors associated with mortality. Conclusion(s): These
results provide clinicians with a framework for selecting patients for
VA-ECMO for CS complicating AMI. Copyright © 2021, The Author(s),
under exclusive licence to Springer Science+Business Media, LLC, part of
Springer Nature.

<73>
Accession Number
2014343865
Title
Indonesian Study: Triiodothyronine for Infants Less than 5 Months
Undergoing Cardiopulmonary Bypass.
Source
Pediatric Cardiology. 43(4) (pp 726-734), 2022. Date of Publication: April
2022.
Author
Marwali E.M.; Lopolisa A.; Sani A.A.; Rayhan M.; Roebiono P.S.; Fakhri D.;
Haas N.A.; Slee A.; Portman M.A.
Institution
(Marwali, Lopolisa, Sani, Rayhan) Pediatric Cardiac Intensive Care Unit,
National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
(Marwali, Roebiono) Department of Cardiology and Vascular Medicine,
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(Roebiono) Pediatric Cardiology Unit, National Cardiovascular Center
Harapan Kita, Jakarta, Indonesia
(Fakhri) Pediatric Cardiac Surgery Unit, National Cardiovascular Center
Harapan Kita, Department of Cardiothoracic Vascular Surgery, Faculty of
Medicine, Universitas Indonesia, Jakarta, Indonesia
(Haas) Department of Pediatric Cardiology and Pediatric Intensive Care,
Medical Hospital of the University of Munich, Munich, Germany
(Slee) Axio Research, Seattle Children's Hospital and Research Institute,
Seattle, United States
(Portman) Seattle Children's Hospital, University of Washington, Seattle,
WA, United States
(Marwali) National Cardiovascular Center Harapan Kita, Jl. Let. Jend. S.
Parman, Kav 87, West Jakarta, Slipi 11420, Indonesia
Publisher
Springer
Abstract
This study evaluates the efficacy and safety of oral triiodothyronine on
time to extubation for infants less than 5 months undergoing heart surgery
in Indonesia, and primarily relates to patients in emerging programs with
high malnutrition and mortality. In this randomized, double-blind,
placebo-controlled trial, oral triiodothyronine (T3, Tetronine) 1
mug/kg-body weight/dose or placebo (saccharum lactis) was administered via
nasogastric tube every 6 h for 60 h to treatment group. A total of 120
patients were randomized into T3 (61 patients) and placebo (59 patients)
groups. The majority of the patients had moderate to severe malnutrition
(55.83%) with a high post-operative mortality rate of 23.3%. The T3 group
showed significantly higher serum FT3 levels from 1 until 48 h post
cross-clamp removal (p < 0.0001), lower incidence of low cardiac output
syndrome at both 6 h (28 [45.9%] vs. 39 [66.1%] patients, p = 0.03, OR
2.3, 95% CI: 1.10-4.81) and 12 h after cross-clamp removal (25 [41.7%] vs.
36 [63.2%], p = 0.02, OR 2.40, 95% CI: 1.14-5.05). Although not
statistically significant, the treatment group had shorter median (IQR)
intubation time (2.59 [1.25-5.24] vs. 3.77 [1.28-6.64] days, p = 0.16, HR
1.36, 95% CI: 0.88-2.09)] and lower mortality (10 [16.4%] vs. 18 [30.5%],
p = 0.07]. Patients with Aristotle score < 10.0 (low risk) receiving T3
had faster extubation than placebo patients (p = 0.021, HR of 1.90, 95%
CI: 1.10-3.28) and were significantly less likely to require CPR or
experience infection (p = 0.027, OR 8.56, 95% CI:0.99-73.9 and p = 0.022,
OR 4.09 95% CI: 1.16-14.4, respectively). Oral T3 supplementation reduced
overall incidence of low cardiac output syndrome and significantly reduced
the time to extubation in low-risk patients. Therefore, prophylactic oral
T3 administration may be beneficial in these patients. Trial Registration:
ClinicalTrials.gov NCT02222532. Copyright © 2021, The Author(s),
under exclusive licence to Springer Science+Business Media, LLC, part of
Springer Nature.

<74>
Accession Number
2014057689
Title
Proximal junctional kyphosis in pediatric spinal deformity surgery: a
systematic review and critical analysis.
Source
Spine Deformity. 10(2) (pp 257-266), 2022. Date of Publication: March
2022.
Author
Erkilinc M.; Baldwin K.D.; Pasha S.; Mistovich R.J.
Institution
(Erkilinc, Mistovich) Division of Pediatric Orthopaedic Surgery, Rainbow
Babies and Children's Hospital, University Hospitals Cleveland Medical
Center, 11100 Euclid Avenue, Cleveland, OH 44106, United States
(Baldwin, Pasha) Department of Orthopaedic Surgery, Children's Hospital of
Philadelphia, Philadelphia, PA, United States
(Mistovich) Case Western Reserve University School of Medicine, Cleveland,
United States
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Purpose: Proximal junctional kyphosis (PJK) is a commonly encountered
clinical and radiographic phenomenon after pediatric and adolescent spinal
deformity surgery that may lead to post-operative deformity, pain, and
dissatisfaction. Understanding the risk factors of PJK can be useful for
pre-operative informed consent as well as to identify any potential
preventative strategies. Method(s): We performed a systematic review
and critical analysis following the PRISMA statement in July 2019 by
searching the PubMed, Scopus, and Embase databases, including all prior
published studies. We included articles with data on PJK in patients with
operative pediatric and adolescent scoliosis and those that detailed risk
factors and/or preventative strategies for PJK. Levels of evidence were
determined based on consensus. Findings were summarized and grades of
recommendation were assigned by consensus. This study was registered in
the PROSPERO database; 202,457. Result(s): Six hundred and thirty
five studies were identified. Thirty-seven studies met criteria for
inclusion into the analysis. No studies including neuromuscular scoliosis
met inclusion criteria. No findings had Grade A evidence. There were 4
findings found to contribute to PJK with Grade B evidence in EOS: higher
number of distractions, disruption of posterior elements, greater sagittal
plane correction. There was no difference in incidence noted between
etiology of the curvature. Five findings with Grade B evidence were found
to contribute to PJK in AIS populations: higher pre-operative thoracic
kyphosis, higher pre-operative lumbar lordosis, longer fusion constructs,
greater sagittal plane correction, and posterior versus anterior fusion
constructs. Conclusion(s): Greater sagittal plane correction has
Grade B evidence as a risk factor for PJK in both EOS and AIS populations.
In EOS patients, an increased number of distractions and posterior element
disruption are Grade B risk factors. In AIS patients, longer fusion
constructs, higher pre-operative thoracic kyphosis and lumbar lordosis,
and posterior (as opposed to anterior) constructs also contributed to PJK
with Grade B evidence. These findings can guide informed consent and
surgical management, and provide the foundation for future
studies. Copyright © 2021, Scoliosis Research Society.

<75>
[Use Link to view the full text]
Accession Number
2016330533
Title
Risk factors for persistent pain after breast and thoracic surgeries: A
systematic literature review and meta-analysis.
Source
Pain. 163(1) (pp 3-20), 2022. Date of Publication: 01 Jan 2022.
Author
Lim J.; Chen D.; McNicol E.; Sharma L.; Varaday G.; Sharma A.; Wilson E.;
Wright-Yatsko T.; Yaeger L.; Gilron I.; Finnerup N.B.; Haroutounian S.
Institution
(Lim) Saint Louis University, School of Medicine, St. Louis, MO, United
States
(Chen) University of Sydney, School of Medicine, Sydney, Australia
(McNicol) MCPHS University, Boston, MA, United States
(Sharma, Varaday, Sharma, Wilson, Wright-Yatsko, Haroutounian) Department
of Anesthesiology, Washington University in St. Louis, School of Medicine,
St. Louis, MO, United States
(Yaeger) Becker Medical Library, Washington University in St. Louis,
School of Medicine, St. Louis, MO, United States
(Gilron) Department of Anesthesiology and Perioperative Medicine,
Biomedical and Molecular Sciences, Centre for Neuroscience Studies, School
of Policy Studies, Queen's University, Kingston, ON, Canada
(Finnerup) Department of Clinical Medicine, Danish Pain Research Center,
Aarhus University, Aarhus, Denmark
Publisher
Lippincott Williams and Wilkins
Abstract
Persistent postsurgical pain (PPSP) is common after breast and thoracic
surgeries. Understanding which risk factors consistently contribute to
PPSP will allow clinicians to apply preventive strategies, as they emerge,
to high-risk patients. The objective of this work was to systematically
review and meta-analyze the literature on risk factors of PPSP after
breast and thoracic surgeries. A systematic literature search using Ovid
Medline, Cochrane Central Register of Controlled Trials, Cumulative Index
to Nursing and Allied Health Literature, Embase, PsycINFO, and Scopus
databases was conducted. Study screening with inclusion and exclusion
criteria, data extraction, and risk of bias assessment was performed
independently by 2 authors. The data for each surgical group were analyzed
separately and meta-analyzed where possible. The literature search yielded
5584 articles, and data from 126 breast surgery and 143 thoracic surgery
articles were considered for meta-analysis. In breast surgery, younger
age, higher body mass index, anxiety, depression, diabetes, smoking,
preoperative pain, moderate to severe acute postoperative pain,
reoperation, radiotherapy, and axillary lymph node dissection were the
main factors associated with higher risk of PPSP. In thoracic surgery,
younger age, female sex, hypertension, preoperative pain, moderate to
severe acute postoperative pain, surgical approach, major procedure, and
wound complications were associated with PPSP. This systematic review
demonstrated certain consistent risk factors of PPSP after breast and
thoracic surgeries, as well as identified research gaps. Understanding the
factors that increase susceptibility to PPSP can help selectively allocate
resources to optimize perioperative care in high-risk patients and help
develop targeted, risk-stratified interventions for PPSP
prevention. Copyright © 2021 International Association for the
Study of Pain

<76>
Accession Number
2016562522
Title
Rationale and design of a randomized trial evaluating an external support
device for saphenous vein coronary grafts.
Source
American Heart Journal. 246 (pp 12-20), 2022. Date of Publication: April
2022.
Author
Bagiella E.; Puskas J.D.; Moskowitz A.J.; Gelijns A.C.; Alexander J.H.;
Narula J.; Smith P.K.; Hutcheson K.; Chang H.L.; Gammie J.S.; Iribarne A.;
Marks M.E.; Vengrenyuk Y.; Yasumura K.; Raymond S.; Taylor B.S.; Yarden
O.; Orion E.; Dagenais F.; Ailawadi G.; Chu M.W.A.; Gupta L.; Levitan
R.G.; Williams J.B.; Crestanello J.A.; Jessup M.; Rose E.A.; Scavo V.;
Acker M.A.; Gillinov M.; O'Gara P.T.; Voisine P.; Mack M.J.; Goldstein
D.J.
Institution
(Bagiella, Moskowitz, Gelijns, Chang, Marks, Raymond, Gupta, Levitan,
Rose) Department of Population Health Science and Policy, Icahn School of
Medicine at Mount Sinai, New York, NY
(Puskas) Department of Cardiovascular Surgery, Mount Sinai Morningside,
New York, NY
(Alexander, Smith) Department of Surgery, Division of Cardiovascular and
Thoracic Surgery, Duke University Medical Center, Durham, NC
(Narula) Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New
York, NY
(Hutcheson, Mack) Cardiothoracic Surgery, Baylor Scott & White Health,
Plano, TX
(Gammie) Johns Hopkins Heart and Vascular Institute, Johns Hopkins Health
System, Baltimore, MD
(Iribarne) Section of Cardiac Surgery, Dartmouth-Hitchcock Medical Center,
Lebanon, NH
(Vengrenyuk, Yasumura) Division of Cardiology, Mount Sinai Hospital and
Icahn School of Medicine at Mount Sinai, New York, NY
(Taylor) Division of Cardiac Surgery, University of Maryland School of
Medicine, Baltimore, MD
(Yarden, Orion) Vascular Graft Solutions Ltd., Tel Aviv, Israel
(Dagenais, Voisine) Department of Surgery, Institut de Cardiologie et
Pneumologie de Quebec, Quebec City, Quebec, Canada
(Ailawadi) Department of Cardiac Surgery, University of Michigan, Ann
Arbor, MI, United States
(Chu) Division of Cardiac Surgery, Western University, London Health
Sciences Centre, London, Ontario, Canada
(Williams) Cardiovascular Surgery, WakeMed Health and Hospitals, Raleigh,
NC
(Crestanello) Department of Cardiovascular Surgery, Mayo Clinic,
Rochester, MN
(Jessup) American Heart Association, Dallas, TX
(Scavo) Cardiovascular and Thoracic Surgery, Lutheran Medical Group, Fort
Wayne, IN, United States
(Acker) Division of Cardiovascular Surgery, University of Pennsylvania,
Hospital of the University of Pennsylvania, Philadelphia, PA
(Gillinov) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Cleveland, OH
(O'Gara) Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
(Goldstein) Department of Cardiovascular and Thoracic Surgery, Montefiore
Medical Center, Bronx, NY, United States
Publisher
Elsevier Inc.
Abstract
Background: Coronary artery bypass grafting (CABG) is the most common
revascularization approach for the treatment of multi-vessel coronary
artery disease. While the internal mammary artery is nearly universally
used to bypass the left anterior descending coronary artery, autologous
saphenous vein grafts (SVGs) are still the most frequently used conduits
to grafts the remaining coronary artery targets. Long-term failure of
these grafts, however, continues to limit the benefits of surgery.
 Method(s): The Cardiothoracic Surgical Trials Network trial of the
safety and effectiveness of a Venous External Support (VEST) device is a
randomized, multicenter, within-patient trial comparing VEST-supported
versus unsupported saphenous vein grafts in patients undergoing CABG. Key
inclusion criteria are the need for CABG with a planned internal mammary
artery to the left anterior descending and two or more saphenous vein
grafts to other coronary arteries. The primary efficacy endpoint of the
trial is SVG intimal hyperplasia (plaque + media) area assessed by
intravascular ultrasound at 12 months post randomization. Occluded grafts
are accounted for in the analysis of the primary endpoint. Secondary
confirmatory endpoints are lumen diameter uniformity and graft failure
(>50% stenosis) assessed by coronary angiography at 12 months. The safety
endpoints are the occurrence of major adverse cardiac and cerebrovascular
events and hospitalization within 5 years from randomization.
 Conclusion(s): The results of the VEST trial will determine whether
the VEST device can safely limit SVG intimal hyperplasia in patients
undergoing CABG as treatment for coronary atherosclerotic
disease. Copyright © 2021 Elsevier Inc.

<77>
Accession Number
2015339651
Title
Inflammation and Oxidative Stress in the Context of Extracorporeal Cardiac
and Pulmonary Support.
Source
Frontiers in Immunology. 13 (no pagination), 2022. Article Number: 831930.
Date of Publication: 04 Mar 2022.
Author
Hatami S.; Hefler J.; Freed D.H.
Institution
(Hatami, Hefler, Freed) Department of Surgery, University of Alberta,
Edmonton, AB, Canada
(Hatami, Freed) Canadian National Transplant Research Program, Edmonton,
AB, Canada
(Freed) Department of Biomedical Engineering, University of Alberta,
Edmonton, AB, Canada
(Freed) Alberta Transplant Institute, Edmonton, AB, Canada
(Freed) Department of Physiology, University of Alberta, Edmonton, AB,
Canada
Publisher
Frontiers Media S.A.
Abstract
Extracorporeal circulation (ECC) systems, including cardiopulmonary
bypass, and extracorporeal membrane oxygenation have been an irreplaceable
part of the cardiothoracic surgeries, and treatment of critically ill
patients with respiratory and/or cardiac failure for more than half a
century. During the recent decades, the concept of extracorporeal
circulation has been extended to isolated machine perfusion of the donor
organ including thoracic organs (ex-situ organ perfusion, ESOP) as a
method for dynamic, semi-physiologic preservation, and potential
improvement of the donor organs. The extracorporeal life support systems
(ECLS) have been lifesaving and facilitating complex cardiothoracic
surgeries, and the ESOP technology has the potential to increase the
number of the transplantable donor organs, and to improve the outcomes of
transplantation. However, these artificial circulation systems in general
have been associated with activation of the inflammatory and oxidative
stress responses in patients and/or in the exposed tissues and organs. The
activation of these responses can negatively affect patient outcomes in
ECLS, and may as well jeopardize the reliability of the organ viability
assessment, and the outcomes of thoracic organ preservation and
transplantation in ESOP. Both ECLS and ESOP consist of artificial circuit
materials and components, which play a key role in the induction of these
responses. However, while ECLS can lead to systemic inflammatory and
oxidative stress responses negatively affecting various organs/systems of
the body, in ESOP, the absence of the organs that play an important role
in oxidant scavenging/antioxidative replenishment of the body, such as
liver, may make the perfused organ more susceptible to inflammation and
oxidative stress during extracorporeal circulation. In the present
manuscript, we will review the activation of the inflammatory and
oxidative stress responses during ECLP and ESOP, mechanisms involved,
clinical implications, and the interventions for attenuating these
responses in ECC. Copyright © 2022 Hatami, Hefler and Freed.

<78>
Accession Number
2017574401
Title
Effects of Pre-Surgical Education and Physical Therapy Training for
Dyspnea Prevention in Patients Undergoing Valvular Cardiac Surgery.
Source
Pakistan Journal of Medical and Health Sciences. 16(2) (pp 518-520), 2022.
Date of Publication: February 2022.
Author
Ibrar I.; Shabbir S.; Ahmad H.; Zafar M.; Hassan T.; Waheed M.
Institution
(Ibrar) The University of Faisalabad. Consultant physiotherapist at
mahfooz clinic and kidney care center, Pakistan
(Shabbir) Fcps-1 Mass Vaccination Center, Faisalabad, Pakistan
(Ahmad) Fcps-1 COVID Vaccination, Chiniot, Pakistan
(Zafar) Department of anesthesia Mayo hospital, Lahore, Pakistan
(Hassan) Government College University Faisalabad, In Government College
University, Faisalabad, Pakistan
(Waheed) Department of anesthesia Mayo hospital, Lahore, Pakistan
Publisher
Lahore Medical And Dental College
Abstract
Objective: To evaluate the Effects of Pre-operative education and physical
therapy training for dyspnea prevention in patients undergoing valvular
cardiac surgery. Method(s): A Prospective RCT was performed on sample
size of 40 patients of cardiac valvular disease that were obtain from
Faisalabad Institute of cardiology. At the time of admission, all patients
were tested by baseline dyspnea index then the subjects were randomly
assigned into two groups by computerized random generator. Both groups
were having education but treatment group were having additional breathing
exercises and functional tasks for 10 minutes in 1st week regularly and 1
hour in 2nd week regularly. Each group were tested again by BDI after the
treatment on second post-op day. Tracheal extubation and eye-opening time
were also noted as outcome measures of study. Results were compiled on
SPSS.20 for finding post-operative dyspnea. Result(s): Pre-operative
and post-operative findings showed that the patients of treatment group
performed better than control group as the effects of pre-operative
treatment on dyspnea by total baseline dyspnea index is significant
(p<0.05) as well as the treatment group had significant reduction in
eye-opening and tracheal extubation time in comparison of control group
having (p<0.05). Conclusion(s): The results shows that in patients of
valvular cardiac surgery, pre-surgical education and physical therapy
training showed significant reduction in post-surgical dyspnea, tracheal
extubation and eye-opening time. Copyright © 2022 Lahore Medical
And Dental College. All rights reserved.

<79>
Accession Number
2016506550
Title
Sex-Specific Outcomes Following Percutaneous Coronary Intervention Versus
Coronary Artery Bypass Grafting for Left Main Disease: A Systematic Review
and Meta-Analysis.
Source
Heart Lung and Circulation. 31(5) (pp 658-665), 2022. Date of Publication:
May 2022.
Author
Zhou J.Y.; Tie E.N.; Liew D.; Duffy S.J.; Shaw J.; Walton A.; Chan W.;
Stub D.
Institution
(Zhou, Tie, Liew, Duffy, Shaw, Walton, Chan, Stub) Department of
Cardiology, The Alfred Hospital, Melbourne, VIC, Australia
(Liew, Duffy, Stub) School of Public Health and Preventive Medicine,
Monash University, Melbourne, VIC, Australia
(Chan, Stub) Western Health, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Objective: To assess whether outcomes following percutaneous coronary
intervention (PCI) versus coronary artery bypass grafting (CABG) for left
main coronary artery (LMCA) disease differ between men and women.
 Background(s): Current guidelines recommend either PCI or CABG for
patients with unprotected LMCA disease and low-to-intermediate anatomical
complexity. However, it is unclear whether these guidelines apply to
women, who are underrepresented in clinical trials. Method(s): An
electronic search was performed to identify studies reporting sex-specific
outcomes after PCI versus CABG in patients with LMCA disease. Trial level
hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled by
random-effects modelling. Result(s): Eight (8) studies met inclusion
criteria, comprising 13,066 patients (24.3% women). In both sexes, there
was no difference between PCI and CABG with respect to the primary
composite endpoint of death, myocardial infarction or stroke (HR in women:
1.03, 95% CI 0.76-1.40; HR in men: 1.04, 95% CI 0.92-1.17). However, both
sexes were more likely to require repeat revascularisation after PCI.
There was no interaction between sex and treatment effect for the primary
composite endpoint nor for the individual outcomes of death, stroke and
repeat revascularisation. However, in women the risk of myocardial
infarction was higher after PCI compared with CABG (HR 1.84, 95% CI
1.06-3.18), with a trend toward the opposite in men (HR 0.78, 95% CI
0.54-1.13; p-interaction=0.01). Conclusion(s): Percutaneous coronary
intervention and CABG have a comparable risk of the composite outcome of
death, stroke or myocardial infarction in patients undergoing
revascularisation for LMCA disease, with no significant interaction
between sex and treatment effect. Copyright © 2021 Australian and
New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the
Cardiac Society of Australia and New Zealand (CSANZ)

<80>
Accession Number
2014948330
Title
Distal radial approach between theory and clinical practice. Time to go
distal!.
Source
Egyptian Heart Journal. 74(1) (no pagination), 2022. Article Number: 8.
Date of Publication: December 2022.
Author
Sanhoury M.I.; Sobhy M.A.; Saddaka M.A.; Nassar M.A.; Elwany M.N.
Institution
(Sanhoury, Sobhy, Saddaka, Nassar, Elwany) Department of Cardiology and
Angiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Transradial access (TRA), which has a minimal risk of problems
such as radial artery occlusion (RAO), hemorrhage, spasm, and so on, is
now considered the standard procedure for cardiac catheterization. The aim
of the study is to present the distal transradial access (d-TRA) as a
possible promising novel technique in the field of cardiac coronary
interventions comparing it to the standard conventional TRA using primary
and secondary endpoints, exploring its benefits and drawbacks as a new
experience in Alexandria University. One hundred cases with variable
indications for coronary interventions were randomized to two arms using
systematic random sampling method, coronary interventions in the first one
were done via d-TRA (50 patients) and in the second arm via conventional
TRA group (50 patients). Result(s): Technically, there were highly
statistically significant differences between the two arms in favor of TRA
regarding procedural success, number of punctures taken, Access time,
Total procedural time, vasodilator used, and crossover to another access
site; meanwhile safety profile parameters have showed statistically
significant differences in favor of d-TRA regarding post-operative
hematoma, AV fistula, post-operative pain and compression time, and there
were no statistically significant differences regarding RAO although it
occurred more in TRA group. Conclusion(s): In the realm of cardiac
intervention, the distal radial approach is a promising technique. When
compared to TRA, we found it to be a viable and safe method for coronary
angiography and interventions and it could be a real option for the
interventionists in the near future, with a lower risk of radial artery
blockage and no significant differences in wrist hematoma and radial
artery spasm. The success rate of d-TRA is proportional to the steepness
of the operator's learning curve and the quality of the examples
chosen. Copyright © 2022, The Author(s).

<81>
Accession Number
637645878
Title
Incidence of atrial fibrillation in elderly patients with type 2 diabetes
mellitus.
Source
BMJ Open Diabetes Research and Care. 10(2) (no pagination), 2022. Article
Number: e002745. Date of Publication: 31 Mar 2022.
Author
Matsumoto C.; Ogawa H.; Saito Y.; Okada S.; Soejima H.; Sakuma M.; Masuda
I.; Nakayama M.; Doi N.; Jinnouchi H.; Waki M.; Morimoto T.
Institution
(Matsumoto) Department of Cardiology, Center for Health Surveillance and
Preventive Medicine, Tokyo Medical University Hospital, Shinjuku, Japan
(Ogawa) Kumamoto University, Kumamoto, Japan
(Saito) Department of Cardiovascular Medicine, Nara Medical University,
Nara, Kashihara, Japan
(Okada) Department of Diabetes and Endocrinology, Nara Medical University,
Nara, Kashihara, Japan
(Soejima) Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, Kumamoto, Japan
(Soejima) Health Care Center, Kumamoto University, Kumamoto, Japan
(Sakuma, Morimoto) Department of Clinical Epidemiology, Hyogo College of
Medicine, Nishinomiya, Japan
(Masuda) Takeda Hospital Medical Examination Center, Kyoto, Japan
(Nakayama) Nakayama Cardiovascular Clinic, Kumamoto, Japan
(Doi) Department of Cardiovascular Medicine, Nara Prefecture Seiwa Medical
Center, Nara, Japan
(Jinnouchi) Department of Internal Medicine, Jinnouchi Hospital Diabetes
Care Center, Kumamoto, Japan
(Waki) Food Safety Commission of Japan, Tokyo, Japan
Publisher
BMJ Publishing Group
Abstract
Introduction The incidence of atrial fibrillation (AF), a significant risk
factor for cardiovascular disease (CVD), is increasing worldwide. Type 2
diabetes mellitus (T2D) and advanced age are recognized as major risk
factors for AF, but herein, we evaluated the incidence of AF in elderly
patients with T2D and compared the prognosis between these patients
with/without AF. Research design and methods The Japanese Primary
Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD2) study is a
follow-up cohort study of the JPAD trial, a randomized controlled clinical
trial initiated in 2002 in 2535 Japanese patients with T2D, to examine
whether low-dose aspirin prevents CVD. After completion of that trial, we
followed up the patients until 2019 and evaluated the incidence of AF. We
also compared the incidence of cerebral cardiovascular events in elderly
patients with T2D with/without AF. Results During the median follow-up
period of 10.9 years, 132 patients developed AF (incidence rate: 5.14/1000
person-years). The adjusted HRs for cerebral cardiovascular events,
stroke, coronary artery disease, heart failure, and all-cause death in
elderly patients with T2D with versus without AF were 1.65 (95% CI 1.03 to
2.66), 1.54 (95% CI 0.81 to 2.93), 1.96 (95% CI 1.03 to 3.73), 5.17 (95%
CI 2.46 to 10.89), and 1.82 (95% CI 1.24 to 2.67), respectively.
Conclusions Annually, 1 in 200 elderly Japanese patients with T2D are
estimated to develop AF. Because elderly patients with T2D with AF are at
an elevated risk for CVD, careful follow-up of this patient subgroup is
necessary. Trial registration number NCT00110448. Copyright ©

<82>
Accession Number
637616451
Title
Sublingual microcirculatory alterations during the immediate and early
postoperative period: A systematic review and meta-analysis.
Source
Clinical Hemorheology and Microcirculation. 80(3) (pp 253-265), 2022. Date
of Publication: 2022.
Author
Chalkias A.; Papagiannakis N.; Mavrovounis G.; Kolonia K.; Mermiri M.;
Pantazopoulos I.; Laou E.; Arnaoutoglou E.
Institution
(Chalkias, Kolonia, Mermiri, Laou, Arnaoutoglou) Department of
Anesthesiology, Faculty of Medicine, University of Thessaly, University
Hospital of Larisa, C' Wing, 2nd Floor, Mezourlo, Larisa PC41110, Greece
(Chalkias) Outcomes Research Consortium, Cleveland, OH, United States
(Papagiannakis) First Department of Neurology, National and Kapodistrian
University of Athens, Medical School, Athens, Greece
(Mavrovounis, Pantazopoulos) Department of Emergency Medicine, Faculty of
Medicine, University of Thessaly, Larisa, Greece
Publisher
IOS Press BV
Abstract
BACKGROUND: The incidence of postoperative microcirculatory flow
alterations and their effect on outcome have not been studied extensively.
 OBJECTIVE(S): This systematic review and meta-analysis were designed
to investigate the presence of sublingual microcirculatory flow
alterations during the immediate and early postoperative period and their
correlation with complications and survival. METHOD(S): A systematic
search of PubMed, Scopus, Embase, PubMed Central, and Google Scholar was
conducted for relevant articles from January 2000 to March 2021.
Eligibility criteria were randomized controlled and non-randomized trials.
Case reports, case series, review papers, animal studies and non-English
literature were excluded. The primary outcome was the assessment of
sublingual microcirculatory alterations during the immediate and early
postoperative period in adult patients undergoing surgery. Risk of bias
was assessed with the Ottawa-Newcastle scale. Standard meta-analysis
methods (random-effects models) were used to assess the difference in
microcirculation variables. RESULT(S): Thirteen studies were
included. No statistically significant difference was found between
preoperative and postoperative total vessel density (p=0.084; Standardized
Mean Difference (SMD): -0.029; 95%CI: -0.31 to 0.26; I2=22.55%). Perfused
vessel density significantly decreased postoperatively (p=0.035; SMD:
0.344; 95%CI: 0.02 to 0.66; I2=65.66%), while perfused boundary region
significantly increased postoperatively (p=0.031; SMD: -0.415; 95%CI:
-0.79 to -0.03; I2=37.21%). Microvascular flow index significantly
decreased postoperatively (p=0.028; SMD: 0.587; 95%CI: 0.06 to 1.11;
I2=86.09%), while no statistically significant difference was found
between preoperative and postoperative proportion of perfused vessels
(p=0.089; SMD: 0.53; 95%CI: -0.08 to 1.14; I2=70.71%). The results of the
non-cardiac surgery post-hoc analysis were comparable except that no
statistically significant difference in perfused vessel density was found
(p=0.69; SMD: 0.07; 95%CI: -0.26 to 0.39; I2=0%). LIMITATIONS: The
included studies investigate heterogeneous groups of surgical patients.
There were no randomized controlled trials. CONCLUSION(S):
Significant sublingual microcirculatory flow alterations are present
during the immediate and early postoperative period. Further research is
required to estimate the correlation of sublingual microcirculatory flow
impairment with complications and survival. Copyright © 2022 -
IOS Press. All rights reserved.

<83>
Accession Number
2016363642
Title
A Comparative Effectiveness Systematic Review and Meta-analysis of Drugs
for the Prophylaxis of Junctional Ectopic Tachycardia.
Source
Current Cardiology Reviews. 18(1) (pp 101-111), 2022. Article Number:
e030621193817. Date of Publication: January 2022.
Author
Mendel B.; Christianto C.; Setiawan M.; Prakoso R.; Siagian S.N.
Institution
(Mendel, Christianto, Setiawan) Faculty of Medicine, Universitas
Indonesia, Jakarta, Indonesia
(Prakoso, Siagian) Pediatric Cardiology and Congenital Heart Defect
Division, Department of Cardiology and Vascular Medicine, National
Cardiovascular Center Harapan Kita, Jakarta, Indonesia
Publisher
Bentham Science Publishers
Abstract
Background: Junctional Ectopic Tachycardia (JET) is an arrhythmia
originating from the AV junction, which may occur following congenital
heart surgery, especially when the intervention is near the
atrioventricular junction. Objective(s): The aim of this systematic
review and meta-analysis is to compare the effectiveness of amiodarone,
dexmedetomidine, and magnesium in preventing JET following congenital
heart surgery. Method(s): This meta-analysis was conducted according
to the Preferred Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) statement, where 11 electronic databases were searched from the
date of inception to August 2020. The incidence of JET was calculated with
the relative risk of 95% Confidence Interval (CI). Quality assessment of
the included studies was assessed using the Consolidated Standards of
Reporting Trials (CONSORT) 2010 statement. Result(s): Eleven studies
met the predetermined inclusion criteria and were included in this
meta-analysis. Amiodarone, dexmedetomidine, and magnesium significantly
reduced the incidence of postoperative JET [Amiodarone: risk ratio 0.34;
I2= 0%; Z=3.66 (P=0.0002); 95% CI 0.19-0.60. Dexmedetomidine: risk ratio
0.34; I2= 0%; Z=4.77 (P<0.00001); 95% CI 0.21-0.52. Magnesium: risk ratio
0.50; I2= 24%; Z=5.08 (P<0.00001); 95% CI 0.39-0.66]. Conclusion(s):
All three drugs have shown promising results in reducing the incidence of
JET. Our systematic review found that dexmedetomidine is better in
reducing the length of ICU stays as well as mortality. In addition,
dexmedetomidine also has the least pronounced side effects among the
three. However, it should be noted that this conclusion was derived from
studies with small sample sizes. Therefore, dexmedetomidine may be
considered as the drug of choice for preventing JET. Copyright ©
2022 Bentham Science Publishers.

<84>
Accession Number
2016360775
Title
Spine Surgery Assisted by Augmented Reality: Where Have We Been?.
Source
Yonsei Medical Journal. 63(4) (pp 305-316), 2022. Date of Publication: Apr
2022.
Author
Liu Y.; Lee M.-G.; Kim J.-S.
Institution
(Liu, Lee, Kim) Department of Neurosurgery, Seoul St. Mary's Hospital,
College of Medicine, The Catholic University of Korea, Seoul, South Korea
Publisher
Yonsei University College of Medicine
Abstract
This present systematic review examines spine surgery literature
supporting augmented reality (AR) technology and summarizes its current
status in spinal surgery technology. Database search strategies were
retrieved from PubMed, Web of Science, Cochrane Library, Embase, from the
earliest records to April 1, 2021. Our review briefly examines the history
of AR, and enumerates different device application workflows in a variety
of spinal surgeries. We also sort out the pros and cons of current
mainstream AR devices and the latest updates. A total of 45 articles are
included in our review. The most prevalent surgical applications included
are the augmented reality surgical navigation system and head-mounted
display. The most popular application of AR is pedicle screw
instrumentation in spine surgery, and the primary responsible surgical
levels are thoracic and lumbar. AR guidance systems show high potential
value in practical clinical applications for the spine. The overall number
of cases in AR-related studies is still rare compared to traditional
surgical-assisted techniques. These lack long-term clinical efficacy and
robust surgical-related statistical data. Changing healthcare laws as well
as the increasing prevalence of spinal surgery are generating critical
data that determines the value of AR technology. Copyright ©
Yonsei University College of Medicine 2022.

<85>
Accession Number
2017547137
Title
Efficacy and safety of alirocumab and evolocumab: a systematic review and
meta-analysis of randomized controlled trials.
Source
European Heart Journal. 43(7) (pp E17-E25), 2022. Date of Publication:
2022.
Author
Guedeney P.; Giustino G.; Sorrentino S.; Claessen B.E.; Camaj A.; Kalkman
D.N.; Vogel B.; Sartori S.; De Rosa S.; Baber U.; Indolfi C.; Montalescot
G.; Dangas G.D.; Rosenson R.S.; Pocock S.J.; Mehran R.
Institution
(Guedeney, Giustino, Sorrentino, Claessen, Camaj, Kalkman, Vogel, Sartori,
Baber, Indolfi, Dangas, Rosenson, Mehran) Center for Interventional
Cardiovascular Research, The Zena and Michael A. Weiner Cardiovascular
Institute, The Icahn School of Medicine at Mount Sinai, One Gustave L.
Levy Place, Box 1030, New York, NY 10029, United States
(Guedeney, Montalescot) Department of Cardiology, Sorbonne Universite,
ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie (AP-HP),
Hopital Pitie Salpetriere, Paris, France
(Sorrentino, De Rosa) Division of Cardiology, Department of Medical and
Surgical Sciences, Magna Graecia University, Catanzaro, Italy
(Kalkman) Department of Cardiology, Academic Medical Center, University of
Amsterdam, Amsterdam, Netherlands
(Pocock) Department of Medical Statistics, London School of Hygiene and
Tropical Medicine, London, United Kingdom
Publisher
Oxford University Press
Abstract
Aims The effect of low-density lipoprotein cholesterol-lowering therapy
with alirocumab or evolocumab on individual clinical efficacy and safety
endpoints remains unclear. We aimed to evaluate the efficacy and safety of
alirocumab and evolocumab in patients with dyslipidaemia or
atherosclerotic cardiovascular disease. Methods We performed a review of
randomized controlled trials (RCTs) comparing treatment with alirocumab or
evolocu- and results mab vs. placebo or other lipid-lowering therapies up
to March 2018. Primary efficacy endpoints were all-cause death,
cardiovascular death, myocardial infarction (MI), and stroke. We estimated
risk ratios (RR) and 95% confidence intervals (CI) using random effect
models. We included 39 RCTs comprising 66 478 patients of whom 35 896 were
treated with proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors (14 639 with alirocumab and 21 257 with evolocumab) and 30 582
with controls. Mean weighted follow-up time across trials was 2.3 years
with an exposure time of 150 617 patient-years. Overall, the effects of
PCSK9 inhibition on all-cause death and cardiovascular death were not
statistically significant (P = 0.15 and P = 0.34, respectively).
Proprotein convertase subtilisin-kexin type 9 inhibitors were associated
with lower risk of MI (1.49 vs. 1.93 per 100 patient-year; RR 0.80, 95% CI
0.74-0.86; I2 = 0%; P < 0.0001), ischaemic stroke (0.44 vs.
0.58 per 100 patient-year; RR 0.78, 95% CI 0.67-0.89; I2 = 0%;
P = 0.0005), and coronary revascularization (2.16 vs. 2.64 per 100
patient-year; RR 0.83, 95% CI 0.78-0.89; I2 = 0%; P < 0.0001),
compared with the control group. Use of these PCSK9 inhibitors was not
associated with increased risk of neurocognitive adverse events (P =
0.91), liver enzymes elevations (P = 0.34), rhabdomyolysis (P = 0.58), or
new-onset diabetes mellitus (P = 0.97). Conclusion Proprotein convertase
subtilisin-kexin type 9 inhibition with alirocumab or evolocumab was
associated with lower risk of MI, stroke, and coronary revascularization,
with favourable safety profile. Copyright © The Author(s) 2019.
Published on behalf of the European Society of Cardiology. All rights
reserved.

<86>
[Use Link to view the full text]
Accession Number
2017430781
Title
Effect of Evolocumab in Patients with Prior Percutaneous Coronary
Intervention.
Source
Circulation: Cardiovascular Interventions. 15(3) (pp 227-236), 2022. Date
of Publication: 01 Mar 2022.
Author
Furtado R.H.M.; Fagundes A.A.; Oyama K.; Zelniker T.A.; Tang M.; Kuder
J.F.; Murphy S.A.; Hamer A.; Wang H.; Keech A.C.; Giugliano R.P.; Sabatine
M.S.; Bergmark B.A.
Institution
(Furtado) Academic Research Organization, Hospital Israelita Albert
Einstein, Sao Paulo, Brazil
(Furtado) Instituto Do Coracao (InCor), Hospital das Clinicas da Faculdade
de Medicina, Universidade de Sao Paulo, Brazil
(Fagundes, Oyama, Zelniker, Tang, Kuder, Murphy, Giugliano, Sabatine,
Bergmark) Thrombolysis in Myocardial Infarction (TIMI) Study Group,
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United
States
(Oyama) Department of Cardiovascular Medicine, Tohoku University Graduate
School of Medicine, Sendai, Japan
(Oyama) Division of Cardiology, Vienna General Hospital and Medical
University of Vienna, Austria
(Hamer) Cardiol Therapeutics, Oakville, ON, Canada
(Wang) Amgen, Thousand Oaks, CA, United States
(Keech) National Health and Medical Research Council Clinical Trials
Centre, Sydney Medical School, University of Sydney, Australia
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Patients with prior percutaneous coronary intervention (PCI)
are at high residual risk for multiple types of coronary events within and
beyond the stented lesion. This risk might be mitigated by more intensive
LDL-C (low-density lipoprotein cholesterol)-lowering beyond just with
statin therapy. Method(s): FOURIER (Further Cardiovascular Outcomes
Research With PCSK9 Inhibition in Subjects With Elevated Risk) randomized
27 564 patients with stable atherosclerotic disease on statin to the PCSK9
(proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab or
placebo with a median follow-up of 2.2 years. The end points of interest
were major adverse cardiovascular events (MACE; a composite of
cardiovascular death, myocardial infarction, stroke, unstable angina or
coronary revascularization), and major coronary events (a composite of
coronary heart death, myocardial infarction, or coronary
revascularization). We compared the risk of MACE and the magnitude of
relative and absolute risk reductions with evolocumab in patients with and
without prior PCI. Result(s): Seventeen thousand seventy-three
patients had prior PCI. In the placebo arm, those with prior PCI had
higher rates of MACE (13.2% versus 8.3%; hazard ratio
[HR]<inf>adj</inf>1.61 [95% CI, 1.42-1.84]; P<0.0001) and major coronary
events (11.5% versus 6.0%; HR<inf>adj</inf>, 1.72 [95% CI, 1.49-1.99];
P<0.0001). Relative risk reductions with evolocumab were similar in
patients with and without prior PCI (MACE: HR, 0.84 [0.77-0.91] versus HR,
0.88 [0.77-1.01]; P<inf>interaction</inf>0.51; major coronary events: HR,
0.82 [0.75-0.90] versus HR, 0.88 [0.75-1.04];
P<inf>interaction</inf>0.42). Absolute risk reductions for MACE were 2.0%
versus 0.9% (P<inf>interaction</inf>0.14) and for major coronary events
2.0% versus 0.7% (P<inf>interaction</inf>0.045). In those with prior PCI,
the effect of evolocumab on coronary revascularization (HR, 0.76
[0.69-0.85]) was directionally consistent across types of
revascularization procedures: coronary artery bypass grafting (HR, 0.71
[0.54-0.94]); any PCI (HR, 0.77 [0.69-0.86]); PCI for de novo lesions (HR,
0.76 [0.66-0.88]); and PCI for stent failure or graft lesions (HR, 0.76
[0.63-0.91]). Conclusion(s): Evolocumab reduces the risk of MACE in
patients with prior PCI including the risk of coronary revascularization,
with directionally consistent effects across several types of
revascularization procedures, including coronary artery bypass grafting
and PCI for stent or graft failure. Registration: URL:
https://www.clinicaltrials.gov; Unique identifier:
NCT01764633. Copyright © 2022 Lippincott Williams and Wilkins.
All rights reserved.

<87>
Accession Number
2016562090
Title
Evaluating the effect of ultrasound-guided superficial serratus plane
block, deep serratus plane block and thoracic epidural analgesia in cancer
patients undergoing thoracotomy: A randomized controlled trial.
Source
Anaesthesia, Pain and Intensive Care. 25(6) (pp 713-721), 2021. Date of
Publication: 01 Dec 2021.
Author
Abdelrahman A.S.; Al Wasseef M.M.; Hassan M.E.; Abdelghafar E.M.
Institution
(Abdelrahman, Al Wasseef, Hassan, Abdelghafar) National Cancer Institute,
Cairo University, Cairo, Egypt
Publisher
Faculty of Anaesthesia, Pain and Intensive Care, AFMS
Abstract
Background & objective: The serratus anterior plane block (SAPB) is a
recent technique providing effective perioperative analgesia in thoracic
surgeries. This study compared the intra-operative hemodynamics and the
perioperative analgesic efficacy of superficial SAPB, to deep SAPB, and to
thoracic epidural analgesia in thoracotomies. Methodology: One hundred and
eighty lung cancer patients scheduled for thoracotomy were randomly
allocated to three groups; TEA group, which received thoracic epidural
analgesia, SSPB group receiving ultrasound-guided superficial serratus
plane block and DSPB group which received US-guided deep serratus plane
block. Baseline and intra-operative hemodynamics and total consumption of
intraoperative fentanyl and postoperative morphine was noted.
 Result(s): Intra-operative mean arterial pressure (MAP) significantly
decreased in the TEA group compared to baseline values, whereas no
significant changes were found in either SSPB or DSPB groups. Heart rate
(HR) did not show significant changes in any group. The time to
postoperative analgesic demand was significantly longer in the SSPB and
DSPB groups than in the TEA group (p < 0.001). In the first postoperative
hour, TEA group had significantly higher visual analogue scale (VAS)
scores than SSPB or DSPB groups at rest and with cough. The total
consumption of intraoperative fentanyl and postoperative morphine was
comparable among all groups. Conclusion(s): Pre-operative SSPB and
DSPB can provide adequate perioperative analgesia without hemodynamic
instability when compared to TEA in thoracotomies. Copyright ©
2021 Faculty of Anaesthesia, Pain and Intensive Care, AFMS. All rights
reserved.

<88>
Accession Number
2016084886
Title
The Effect of Normal Saline Injection Volumes on the Optic Nerve Sheath
Diameter during Thoracic Epidural Analgesia.
Source
Pain Physician. 24(7) (pp E1007-E1013), 2021. Date of Publication: 2021.
Author
Hong J.; Kim J.S.; Lee Y.H.
Institution
(Hong, Kim, Lee) Department of Anesthesiology and Pain Medicine, Keimyung
University DongSan Hospital, Keimyung University School of Medicine,
Daegu, South Korea
Publisher
American Society of Interventional Pain Physicians
Abstract
Background: Saline or local anesthetic injection into the epidural space
increases intracranial pressure (ICP), at least transiently. Measurement
of the optic nerve sheath diameter (ONSD) using ocular ultrasonography is
one of the noninvasive methods for ICP assessment. Objective(s): The
purpose of this study is to investigate the effects of the different
volume on the ONSD and cerebral oxygen saturation (rSO<inf>2</inf>) during
thoracic epidural saline injection under awake conditions. Study
Design: Prospective randomized, controlled trial. Setting(s): An
interventional pain management practice in South Korea. Method(s):
This study included 71 patients receiving thoracic epidural
catheterization for pain management, following upper abdominal or thoracic
surgery. Following successful epidural space confirmation, patients were
randomly allocated to receive 5 mL (5 mL group), 10 mL (10 mL group), and
20 mL (20 mL group) of epidural normal saline. Transorbital sonography was
performed to measure the ONSD. This was measured at 3 mm posterior to the
optic nerve head. An rSO<inf>2</inf> was measured using cerebral oximeter
sensors. Result(s): All 3 groups showed significant increases of ONSD
from 10 minutes to 40 minutes as compared to baseline (before procedure).
Among the 3 groups, the 20 mL group demonstrated the most significantly
increased ONSD, as compared to the 5 mL and 10 mL groups. At the 20 minute
and 40 minute time points, the ONSD showed a volume-dependent increase (P
= 0.0005, P = 0.014). All 3 groups showed the rSO<inf>2</inf> to be
distributed between 60~70% without any statistical difference.
 Limitation(s): We could not determine the returning point of the
normalized ONSD value. Conclusion(s): Twenty milliliters of normal
saline epidural injection resulted in a significant increase of ONSD, as
compared to the 5 mL and 10 mL groups. Our results also indicate that an
increase of ONSD occurs in accordance with the injected volume of normal
saline. Copyright © 2021, American Society of Interventional Pain
Physicians. All rights reserved.

<89>
Accession Number
2015508266
Title
Aortic Valve Repair Decreases Risks of VRE in AI at 10 Years: A Propensity
Score-Matched Analysis.
Source
Annals of Thoracic Surgery. 113(5) (pp 1469-1475), 2022. Date of
Publication: May 2022.
Author
Jabagi H.; Chan V.; Ruel M.; Mesana T.G.; Boodhwani M.
Institution
(Jabagi, Chan, Ruel, Mesana, Boodhwani) Division of Cardiac Surgery,
University of Ottawa Heart Institute, Ottawa, ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: Aortic valve repair (AVr) has emerged as a feasible and
effective alternative to AV replacement (AVR) in patients with aortic
insufficiency (AI); however, little data exist comparing outcomes. Thus,
the objective of this study was to compare early and long-term
valve-related complications between AVr and AVR in the treatment of AI.
 Method(s): This was a single-center, retrospective study of all
patients (n = 417) undergoing AVr (n = 264) or AVR (n = 153) for primary
AI. Propensity matching using a 1:1 greedy matching algorithm identified
140 patients using 6 covariates (age, sex, left ventricular function,
size, presence of aortopathy, and urgency of operation) for comparison.
The primary outcome was a composite of all valve-related events (VREs),
including endocarditis, myocardial infarction stroke, transient ischemic
attack, thromboembolisms, bleeding, and AV reoperation. VREs were defined
as per published guidelines. Survival and freedom from VREs were reported
using the Kaplan-Meier method. Result(s): Propensity matching
identified 70 well-matched pairs with no major differences in baseline
demographics, comorbidities, or AI severity (P = .57). Perioperative
outcomes showed no significant differences in VREs (AVR 8 vs AVr 7; P =
.78) or mortality (AVR 3 vs AVr 1; P = .62). Event-free survival from the
primary outcome at 10 years was significantly better after AVr than after
AVR (82% vs 68%; P = .024), with no significant differences in 10-year
overall survival between groups (82% vs 72%; P = .29). No significant
differences in AI severity (P = .07) or reoperation rate (P = .44) were
detected between groups. Conclusion(s): This study demonstrated a
lower long-term risk of VREs with repair compared with replacement, with
low mortality and comparable durability. Further prospective randomized
control trials are necessary to formally compare outcomes and determine
superiority. Copyright © 2022 The Society of Thoracic Surgeons

<90>
Accession Number
2015257705
Title
Off-pump versus on-pump coronary artery bypass grafting for octogenarians:
A meta-analysis involving 146 372 patients.
Source
Clinical Cardiology. 45(4) (pp 331-341), 2022. Date of Publication: April
2022.
Author
Sun L.; Zhou M.; Ji Y.; Wang X.
Institution
(Sun, Ji, Wang, Wang) Department of Cardiovascular Surgery, The First
Affiliated Hospital of Nanjing Medical University, Nanjing, China
(Zhou) Department of Endocrine, The First Affiliated Hospital of Nanjing
Medical University, Nanjing, China
Publisher
John Wiley and Sons Inc
Abstract
There is an ongoing debate concerning the optimal surgical option of
myocardial revascularization for octogenarians. The current meta-analysis
aimed to compare clinical outcomes following off-pump coronary artery
bypass grafting (OPCABG) or conventional coronary artery bypass grafting
(CCABG) in octogenarians. PubMed, Cochrane, Web of Science, and EMBASE
databases were searched to identify eligible studies from inception to
March 2021. The analysis was performed using STATA 15.1. A literature
search yielded 18 retrospective studies involving 146 372 patients (OPCABG
= 44 522 vs. CCABG = 101 850). Pooled analysis showed a strong trend
toward reducing mortality risk in the OPCABG group (odds ratio: 0.75, 95%
confidence interval: 0.56-1.00, p =.05). However, it did not reach
statistical significance. The sensitive analysis demonstrated that OPCABG
was less likely to cause death than CCABG. There were comparable data in
myocardial infarction, renal failure, deep sternal wound infection, and
hospital stays between the two groups, although the incidence of stroke,
atrial fibrillation, prolonged ventilation, and reoperation for bleeding
was significantly lower in the OPCAGB group. OPCABG may be an effective
surgical strategy for myocardial revascularization, especially in reducing
the incidence of postoperative stroke, atrial fibrillation, prolonged
ventilation, and reoperation for bleeding. Copyright © 2022 The
Authors. Clinical Cardiology published by Wiley Periodicals LLC.

<91>
Accession Number
2017123210
Title
Randomised open-label trial comparing intravenous iron and an
erythropoiesis-stimulating agent versus oral iron to treat preoperative
anaemia in cardiac surgery (INITIATE trial).
Source
British Journal of Anaesthesia. 128(5) (pp 796-805), 2022. Date of
Publication: May 2022.
Author
Kong R.; Hutchinson N.; Hill A.; Ingoldby F.; Skipper N.; Jones C.;
Bremner S.; Bruce C.; Wright J.; Lewis M.; Newman S.; Chevassut T.;
Hildick-Smith D.
Institution
(Kong, Hutchinson, Hill) Department of Anaesthesia, Royal Sussex County
Hospital, Brighton, United Kingdom
(Ingoldby, Skipper) University Hospitals Sussex NHS Foundation Trust,
Clinical Research Facility, Cardiac Research, Brighton, United Kingdom
(Jones, Bremner, Bruce) Brighton and Sussex Clinical Trials Unit, Brighton
& Sussex Medical School, University of Sussex, Brighton, United Kingdom
(Wright) Brighton and Sussex Medical School, Brighton, United Kingdom
(Lewis) Department of Cardiac Surgery, Royal Sussex County Hospital,
Brighton, United Kingdom
(Newman) School of Health Sciences, University of London, London, United
Kingdom
(Chevassut) Department of Haematology, Royal Sussex County Hospital,
Brighton, United Kingdom
(Hildick-Smith) Department of Cardiology, Royal Sussex County Hospital,
Brighton, United Kingdom
Publisher
Elsevier Ltd
Abstract
Background: Preoperative anaemia is a risk factor for adverse
postoperative outcomes after cardiac surgery. Iron deficiency is a
frequent cause of low preoperative haemoglobin. An effective treatment for
preoperative anaemia associated with iron deficiency has not been
determined. Method(s): We conducted a single-centre, open-label,
pragmatic randomised trial, enrolling 156 elective cardiac surgery
patients who had low preoperative haemoglobin (100-130 g L-1)
with iron deficiency (serum ferritin <100 mug L-1 or
transferrin saturation <30%) to compare intravenous ferric derisomaltose
1000 mg and darbepoetin 200 mug subcutaneously (intervention group) with
oral ferrous sulphate 600 mg daily (control group). The primary outcome
was transfusion of at least one unit of allogeneic red cells during
surgery and within the following 5 days. Secondary outcomes included the
change in haemoglobin concentration between randomisation and surgery, red
cell transfusion volume, postoperative blood loss, pre-specified
postoperative complications, length of hospital stay, and in-hospital
death. Result(s): The odds of red cell transfusion were lower in the
intervention group compared with the control group (adjusted odds
ratio=0.33; 95% confidence interval [CI], 0.15-0.75; P=0.008). Of the
secondary outcomes, the only significant difference was the increase in
haemoglobin between randomisation and surgery, intervention vs control 9.5
g L-1 (95% CI, 6.8-12.2; P<0.001). Conclusion(s): In
patients with a low preoperative haemoglobin and iron deficiency,
preoperative treatment with a single dose of ferric derisomaltose and
darbepoetin decreased the proportion of participants who received a
perioperative blood transfusion as a consequence of a greater increase in
haemoglobin compared with treatment with oral ferrous sulphate. Clinical
trial registration: ISRCTN Number: 41421863; EUDRACT number:
2011-003695-36. Copyright © 2022 British Journal of Anaesthesia

<92>
Accession Number
2016680137
Title
Multicentre analysis of practice patterns regarding benzodiazepine use in
cardiac surgery.
Source
British Journal of Anaesthesia. 128(5) (pp 772-784), 2022. Date of
Publication: May 2022.
Author
Janda A.M.; Spence J.; Dubovoy T.; Belley-Cote E.; Mentz G.; Kheterpal S.;
Mathis M.R.
Institution
(Janda, Dubovoy, Mentz, Kheterpal, Mathis) Department of Anesthesiology,
University of Michigan, Ann Arbor, MI, United States
(Spence) Departments of Anesthesia and Critical Care, McMaster University,
Hamilton, ON, Canada
(Spence, Belley-Cote) Population Health Research Institute, McMaster
University, Hamilton, ON, Canada
(Belley-Cote) Divisions of Cardiology and Critical Care, Department of
Medicine, McMaster University, Hamilton, ON, Canada
Publisher
Elsevier Ltd
Abstract
Background: There is controversy regarding optimal use of benzodiazepines
during cardiac surgery, and it is unknown whether and to what extent there
is variation in practice. We sought to describe benzodiazepine use and
sources of variation during cardiac surgeries across patients, clinicians,
and institutions. Method(s): We conducted an analysis of adult
cardiac surgeries across a multicentre consortium of USA academic and
private hospitals from 2014 to 2019. The primary outcome was
administration of a benzodiazepine from 2 h before anaesthesia start until
anaesthesia end. Institutional-, clinician-, and patient-level variables
were analysed via multilevel mixed-effects models. Result(s): Of 65
508 patients cared for by 825 anaesthesiology attending clinicians
(consultants) at 33 institutions, 58 004 patients (88.5%) received
benzodiazepines with a median midazolam-equivalent dose of 4.0 mg
(inter-quartile range [IQR], 2.0-6.0 mg). Variation in benzodiazepine
dosage administration was 54.7% attributable to institution, 14.7% to
primary attending anaesthesiology clinician, and 30.5% to patient factors.
The adjusted median odds ratio for two similar patients receiving a
benzodiazepine was 2.68 between two randomly selected clinicians and 4.19
between two randomly selected institutions. Factors strongly associated
(adjusted odds ratio, <0.75, or >1.25) with significantly decreased
likelihoods of benzodiazepine administration included older age (>80 vs
<=50 yr; adjusted odds ratio=0.04; 95% CI, 0.04-0.05), university
affiliation (0.08, 0.02-0.35), recent year of surgery (0.42, 0.37-0.49),
and low clinician case volume (0.44, 0.25-0.75). Factors strongly
associated with significantly increased likelihoods of benzodiazepine
administration included cardiopulmonary bypass (2.26, 1.99-2.55), and drug
use history (1.29, 1.02-1.65). Conclusion(s): Two-thirds of the
variation in benzodiazepine administration during cardiac surgery are
associated with institutions and attending anaesthesiology clinicians
(consultants). These data, showing wide variations in administration,
suggest that rigorous research is needed to guide evidence-based and
patient-centred benzodiazepine administration. Copyright © 2021
British Journal of Anaesthesia

<93>
Accession Number
2017717896
Title
Bilateral internal thoracic artery versus single internal thoracic artery
plus radial artery: A double meta-analytic approach.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2022.
Date of Publication: 2022.
Author
Urso S.; Sadaba R.; Gonzalez Martin J.M.; Nogales E.; Tena M.A.; Portela
F.
Institution
(Urso, Tena, Portela) Cardiac Surgery Department, Hospital Universitario
Dr. Negrin, Las Palmas de Gran Canaria, Spain
(Sadaba) Cardiac Surgery Department, Hospital Universitario de Navarra,
Pamplona, Spain
(Gonzalez Martin) Research Unit, Hospital Universitario Dr. Negrin, Las
Palmas de Gran Canaria, Spain
(Nogales) Cardiology Department, Hospital Universitario Insular, Las
Palmas de Gran Canaria, Spain
Publisher
Elsevier Inc.
Abstract
Objectives: We explored the current evidence on the best second conduit in
coronary surgery carrying out a double meta-analysis of propensity score
matched or adjusted studies comparing bilateral internal thoracic artery
(BITA) versus single internal thoracic artery plus radial artery.
 Method(s): PubMed, Embase, and Google Scholar were searched for
propensity score matched or adjusted studies comparing BITA versus single
internal thoracic artery plus radial artery. The end point was long-term
mortality. Two statistical approaches were used: the generic inverse
variance method and the pooled meta-analysis of Kaplan-Meier-derived
individual patient data. Result(s): Twelve matched populations
comparing 6450 patients with BITA versus 9428 patients with single
internal thoracic artery plus radial artery were included in our
meta-analysis. The generic inverse variance method showed a statistically
significant survival benefit of the BITA group (hazard ratio, 0.84; 95%
CI, 0.74-0.95; P = .04). The Kaplan-Meier estimates of survival at 1, 5,
10, and 15 years of the BITA group were 97.0%, 91.3%, 80.0%, and 68.0%,
respectively. The Kaplan-Meier estimates of survival at 1, 5, 10, and 15
years of the single internal thoracic artery plus radial artery group were
97.3%, 91.5%, 79.9%, and 63.9%, respectively. The Kaplan-Meier-derived
individual patient data meta-analysis applied to very long follow-up time
data, showed that BITA provided a survival benefit after 10 years from
surgery (hazard ratio, 0.77; 95% CI, 0.63-0.94; P = .01). No differences
in terms of survival between the 2 groups were detected when the analysis
was focused on the first 10 years of follow-up (hazard ratio, 0.99; 95%
CI, 0.91-1.09; P = .93). Conclusion(s): The present meta-analysis
suggests that double internal thoracic artery may provide, compared with
single internal thoracic artery plus radial artery, a statistically
significant survival advantage after 10 years of follow-up, but not
before. Video Abstract: [Figure presented] Copyright © 2022 The
American Association for Thoracic Surgery

<94>
Accession Number
2013732270
Title
Effect of continuous positive airway pressure associated to exercise on
the breathing pattern and heart rate variability of patients undergoing
coronary artery bypass grafting surgery: A randomized controlled trial.
Source
Brazilian Journal of Medical and Biological Research. 54(11) (no
pagination), 2021. Article Number: e10974. Date of Publication: 2021.
Author
Pantoni C.B.F.; Thommazo-Luporini L.D.; Mendes R.G.; Caruso F.C.R.;
Castello-Simoes V.; Mezzalira D.; Borghi-Silva A.
Institution
(Pantoni) Departamento de Gerontologia, Universidade Federal de Sao
Carlos, Sao Carlos, SP, Brazil
(Pantoni, Thommazo-Luporini, Mendes, Caruso, Castello-Simoes, Mezzalira,
Borghi-Silva) Departamento de Fisioterapia, Universidade Federal de Sao
Carlos, Sao Carlos, SP, Brazil
Publisher
Associacao Brasileira de Divulgacao Cientifica
Abstract
Continuous positive airway pressure (CPAP) has been used to improve gas
exchange and diaphragmatic function, among others benefits. Moreover, it
can be used to increase exercise tolerance and positively influence
ventilatory function and breathing pattern (BP) during exercise. However,
there is no information about the long-term effects of CPAP, as an adjunct
to an inpatient cardiac rehabilitation (CR) program, on BP and heart rate
variability (HRV) of patients after coronary artery bypass grafting
surgery (CABG). Twenty patients were allocated to receive, after
randomization, standard inpatient CR without CPAP (control group-CG) or CR
with CPAP between 10 to 12 cmH<inf>2</inf>O (CPAP group-CPG) associated
with the exercises. Participants were assessed preoperatively and on the
discharge day, in the sitting rest position. Outcome measurements included
BP variables, collected by respiratory inductive plethysmography, and HRV,
collected by polar precision performance. The CPG presented lower values
of percent rib cage inspiratory and expiratory contributions to tidal
volume (%RCi and %RCe) at discharge time, compared to CG. No statistical
differences between groups were observed for HRV variables and both groups
presented lower values of these indices, compared to preoperative ones. In
this context, the patients who received CPAP throughout the whole
rehabilitation program were discharged with a better BP, which could
indicate more synchronized breathing. CPAP did not influence cardiac
autonomic modulation in the long term. Copyright © 2021,
Associacao Brasileira de Divulgacao Cientifica. All rights reserved.

<95>
Accession Number
2017755531
Title
Minimum Core Data Elements for Evaluation of TAVR: A Scientific Statement
by PASSION CV, HVC, and TVT Registry.
Source
Annals of Thoracic Surgery. 113(5) (pp 1730-1742), 2022. Date of
Publication: May 2022.
Author
Simonato M.; Vemulapalli S.; Ben-Yehuda O.; Wu C.; Wood L.; Popma J.;
Feldman T.; Krohn C.; Hardy K.M.; Guibone K.; Christensen B.; Alu M.C.;
Chen S.; Ng V.G.; Chau K.H.; Shahim B.; Vincent F.; MacMahon J.; James S.;
Mack M.; Leon M.B.; Thourani V.H.; Carroll J.; Krucoff M.
Institution
(Simonato) Yale School of Medicine, Connecticut, New Haven
(Vemulapalli, Krucoff) Duke Clinical Research Institute, North Carolina,
Durham
(Ben-Yehuda) University of California-San Diego, San Diego, California,
United States
(Ben-Yehuda, Alu, Shahim, Vincent) Cardiovascular Research Foundation, New
York, New York
(Wu) U.S. Food and Drug Administration, Silver Spring, MD, United States
(Wood, Feldman) Edwards Lifesciences, Irvine, California, United States
(Popma) Medtronic, Minneapolis, MN, United States
(Krohn) The Society of Thoracic Surgeons, Illinois, Chicago
(Hardy) Common Spirit Health, Illinois, Chicago
(Guibone) Beth Israel Deaconess Medical Center, Boston, Massachusetts,
United States
(Christensen) American College of Cardiology, DC, Washington
(Chen, Ng, Chau, Leon) Columbia University Irving School of Medicine, New
York, New York, United States
(MacMahon) Mitre Medical Corporation, Morgan Hill, CA, United States
(James) Department of Medical Sciences and Uppsala Clinical Research
Center, Uppsala, Sweden
(Mack) Baylor Scott and White Health, Texas, Dallas
(Thourani) Piedmont Heart and Vascular Institute, Georgia, Atlanta,
Georgia
(Carroll) University of Colorado School of Medicine, Colorado, Denver
Publisher
Elsevier Inc.
Abstract
Transcatheter aortic valve replacement (TAVR) is the standard of care for
severe, symptomatic aortic stenosis. Real-world TAVR data collection
contributes to benefit/risk assessment and safety evidence for the U.S.
Food and Drug Administration, quality evaluation for the Centers for
Medicare and Medicaid Services and hospitals, as well as clinical research
and real-world implementation through appropriate use criteria. The
essential minimum core dataset for these purposes has not previously been
defined but is necessary to promote efficient, reusable real-world data
collection supporting quality, regulatory, and clinical applications. The
authors performed a systematic review of the published research for
high-impact TAVR studies and U.S. multicenter, multidevice registries. Two
expert task forces, one from the Predictable and Sustainable
Implementation of National Cardiovascular Registries/Heart Valve
Collaboratory and another from The Society of Thoracic Surgeons/American
College of Cardiology TVT (Transcatheter Valve Therapy) Registry convened
separately and then met to reconcile a final list of essential data
elements. From 276 unique data elements considered, unanimous consensus
agreement was achieved on 132 "core" data elements, with the most common
reasons for exclusion from the minimum core dataset being burden or
difficulty in accurate assessment (36.9%), duplicative information
(33.3%), and low likelihood of affecting outcomes (10.7%). After a
systematic review and extensive discussions, a multilateral group of
academicians, industry representatives, and regulators established 132
interoperable, reusable essential core data elements essential to
supporting more efficient, consistent, and informative TAVR device
evidence for regulatory submissions, safety surveillance, best practice,
and hospital quality assessments. Copyright © 2022 The Authors

<96>
Accession Number
2017751345
Title
Ischemic Heart Disease and Risk of Development of Cognitive Disorders: A
literature review.
Source
European Journal of Molecular and Clinical Medicine. 9(3) (pp 2096-2116),
2022. Date of Publication: December 2022.
Author
Prajna T.D.
Institution
(Prajna) Malla Reddy Medical College for Women Hyderabad, Telangana, India
Publisher
EJMCM, International House
Abstract
Aim: A Review of literature on Ischemic Heart Disease and Risk of
Development of Cognitive Disorders Methods: The literature search was
conducted in Medline, Embase, PsycINFO, and CINAHL. The search string
consisted of predictor-related terms (i.e. myocardial infarction, angina
pectoris), outcome-related terms (i.e. dementia, Alzheimer, cognition), as
well as some specific limitations. All publications until 2021 were
included if they fulfilled the following eligibility criteria: 1) MI, AP,
or a CHD variable that is a combination of MI and AP (e.g. ischemic heart
disease (IHD) as predictor variable; 2) Cognition, cognitive impairment or
dementia as outcome; 3) Population-based study; 4) Prospective (>=1 year
follow-up), cross-sectional or case-control study design; 5) >=100
participants; and 6) Aged >=45 years. Reference lists of publications and
secondary literature were hand-searched for possible missing articles.
 Result(s): The search yielded 3500 abstracts, of which 15 were
included in this study. This resulted in 5 cross-sectional studies, 3
case-control studies, 6 prospective cohort studies and 1 study with both
cross-sectional and prospective analyses (designated as crosssectional
regarding study quality). Quality assessment of all 15 included studies
was sufficient (overall mean NOS score = 6.7, SD = 1.30, range = 3-10).
Separate analyses for each study design showed similar results for
prospective (mean NOS score = 6.92, SD = 1.14, range = 5-9) and
cross-sectional studies (mean NOS score = 7.23, SD = 0.98, range = 6-8),
but the quality of case-control studies was somewhat lower (mean NOS score
= 5.9, SD = 1.93, range = 3-7), mainly due to the effects of one
particular study with a score of 3. Conclusion(s): We concluded that
the CHD was associated with an increased risk of cognitive impairment or
dementia in prospective cohort studies. More mechanistic studies are
needed that focus on the underlying biological pathways (e.g. left
ventricular dysfunction, cerebral small vessel disease, hypoperfusion) and
shared risks that link CHD with the occurrence of cognitive impairment or
dementia. Copyright © 2022 Ubiquity Press. All rights reserved.

<97>
Accession Number
2017725917
Title
The Effect of Standardized Guidelines of Intra-Aortic Balloon Pump Care on
Length of Stay in Cardiac Patients.
Source
Pakistan Journal of Medical and Health Sciences. 16(3) (pp 307-309), 2022.
Date of Publication: March 2022.
Author
Ghafoor Y.; Sarwar H.; Afzal M.; Hanif A.; Gilani A.; Ghafoor S.
Institution
(Ghafoor) College of Nursing Govt. Teaching Hospital Shahdara, Lahore,
Pakistan
(Sarwar, Afzal) Lahore School of Nursing, University of Lahore, Pakistan
(Hanif, Gilani) Allied Health Science, University of Lahore, Pakistan
(Ghafoor) School of Nursing, Children Hospital, Lahore, Pakistan
Publisher
Lahore Medical And Dental College
Abstract
Length of stay in the Intensive care units is special as an outcome. The
adverse outcome is defined as the length of stay >= 5 days that is 120
hours and the normal length of stay was defined as < 5 days. Standardized
guideline developed for nurses practice to reduce the length of stay in
cardiac patients durnning the of intra-aortic balloon pump support. This
guidelinewas very helpful for nurse's practices to reduce the length of
stay. heart transplantation is the gold standard management for cardiac
patients with advanced congestive heart failure and myocardial infraction.
Mechanical circulatory support devices have been gradually used as a
'bridge' in order to stand organ function and stabilizehemodynamics while
patients remain on the transplant waiting list or undergo left ventricular
assist device surgery. The intra-aortic balloon pump (IABP) is a
myocardial assist device that was first introduced into clinical practice
in 1968.The procedure of counter pulsation wasfirstlydesignated by Dr
Adrian Kantrowitz in 1953. Aim of study: To assess the effect of
standardized guidelines of intra-aortic balloon pump care on the length of
stay in cardiac patients. Study Design: Randomized control trial
Sample: Randomly, 72 nurses were included in the current study.
 Setting(s): The research was conducted in cardiac intensive care
units of the Punjab Institute of cardiology Lahore. Copyright ©
2022 Lahore Medical And Dental College. All rights reserved.

<98>
Accession Number
2016445073
Title
Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients
With Heart Failure in REDUCE-IT.
Source
Journal of the American Heart Association. 11(7) (no pagination), 2022.
Article Number: e024999. Date of Publication: 05 Apr 2022.
Author
Selvaraj S.; Bhatt D.L.; Steg P.G.; Miller M.; Brinton E.A.; Jacobson
T.A.; Juliano R.A.; Jiao L.; Tardif J.-C.; Ballantyne C.M.
Institution
(Selvaraj) Division of Cardiology, Department of Medicine, Hospital of the
University of Pennsylvania, Philadelphia, PA, United States
(Bhatt) Brigham and Women's Hospital Heart & Vascular Center, Harvard
Medical School, Boston, MA, United States
(Steg) Universite Paris-Cite, AP-HP (Assistance Publique-Hopitaux de
Paris), Hopital Bichat, FACT (French Alliance for Cardiovascular Trials),
INSERM U-1148, Paris, France
(Miller) Department of Medicine, University of Maryland School of
Medicine, Baltimore, MD, United States
(Brinton) Utah Lipid Center, Salt Lake City, UT, United States
(Jacobson) Office of Health Promotion and Disease Prevention, Department
of Medicine, Emory University School of Medicine, Atlanta, GA, United
States
(Juliano, Jiao) Amarin Pharma, Inc (Amarin), Bridgewater, NJ, United
States
(Tardif) Montreal Heart Institute, Universite de Montreal, Montreal, QC,
Canada
(Ballantyne) Department of Medicine, Baylor College of Medicine, Center
for Cardiovascular Disease Prevention, Methodist DeBakey Heart and
Vascular Center, Houston, TX, United States
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Patients with heart failure (HF) are at high risk for
atherosclerotic cardiovascular disease. Studies of atherothrombotic
treatments in this population have been disappointing to date. Icosapent
ethyl reduced the risk of atherosclerotic cardiovascular disease among a
broad array of statin-treated patients at elevated risk for
atherosclerotic cardiovascular disease. Whether the treatment benefits of
icosapent ethyl are consistent among those with HF is unknown. METHODS AND
RESULTS: REDUCE-IT (Reduction of Cardiovascular Events With Icosapent
Ethyl-Intervention Trial) randomized 8179 participants, including 1446
(17.7%) patients with a history of HF (icosapent ethyl, N=703; and
placebo, N=743). The primary end point was a composite of cardiovascular
death, nonfatal myocardial infarction, nonfatal stroke, coronary
revascularization, or unstable angina. We used Cox regression to estimate
the risk of outcomes of participants with and without HF. We estimated the
placebo-controlled change in triglycerides and hs-CRP (high-sensitivity
C-reactive protein) from baseline to 2 years. Among 1446 patients with HF,
median age was 63.0 years, median body mass index was 31.0
kg/m2, and more were men (69.3%). Icosapent ethyl reduced
triglycerides (median reduction, 33.5 mg/dL, or 15.4%; P<0.0001) and
hs-CRP (35.1%; P<0.0001) compared with placebo, similar to patients
without HF (P-interaction>0.90). The treatment effect on the primary end
point in patients with HF history (hazard ratio [HR], 0.87; 95% CI,
0.70-1.08) was consistent with the effects observed in patients without HF
history (HR, 0.73; 95% CI, 0.65-0.81) (P-interaction=0.13).
 CONCLUSION(S): In REDUCE-IT, icosapent ethyl provided similar
improvements in triglyceride levels and hs-CRP as well as similar
cardiovascular risk reduction in patients with and without HF.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier:
NCT01492361. Copyright © 2022 The Authors. Published on behalf of
the American Heart Association, Inc., by Wiley.

<99>
Accession Number
637712460
Title
Dexmedetomidine after Cardiac Surgery for Prevention of Delirium (EXACTUM)
trial protocol: A multicentre randomised, double-blind, placebo-controlled
trial.
Source
BMJ Open. 12(4) (no pagination), 2022. Article Number: e058968. Date of
Publication: 08 Apr 2022.
Author
Gargadennec T.; Oilleau J.-F.; Rozec B.; Nesseler N.; Lasocki S.; Futier
E.; Amour J.; Durand M.; Bougle A.; Kerforne T.; Consigny M.; Eddi D.;
Huet O.
Institution
(Gargadennec, Oilleau, Huet) Departement d'Anesthesie et Reanimation
Chirurgicale, Chu Brest, Brest, France
(Gargadennec, Oilleau, Huet) Universite de Bretagne Occidentale, Brest,
France
(Rozec) Intensive Care Unit, Anesthesia and Critical Care Department,
Hopital Laennec, University Hospital Centre Nantes, Nantes, France
(Rozec) Cnrs, Inserm, L'Institut du Thorax, Universite de Nantes, Nantes,
France
(Nesseler) Anaesthesia and Intensive Care Unit, Centre Hospitalier
Universitaire de Rennes, Rennes, France
(Lasocki) Departement Anesthesie Reanimation, Chu Angers, Angers, France
(Lasocki) Universite Angers Faculte des Sciences, Angers, France
(Futier) Departement de Medecine Perioperatoire, Anesthesie Reanimation,
Hopital Estaing, Chu Clermont-Ferrand, Clermont-Ferrand, France
(Futier) Cnrs, Inserm U-1103, Universite Clermont Auvergne,
Clermont-Ferrand, France
(Amour) Institute of Perfusion, Critical Care Medicine and Anesthesiology
in Cardiothoracic Surgery (IPRA), Jacques Cartier Private Hospital, Massy,
France
(Durand) Pole Anesthesie-Reanimation, Chu Grenoble Alpes, Grenoble, France
(Bougle) Sorbonne Universite, Paris, France
(Bougle) Department of Anesthesiology and Critical Care Medicine,
Institute of Cardiology, Grc 29, Pitie-Salpetriere Hospital, Aphp, Paris,
France
(Kerforne) Faculte de Medecine, Inserm U1082, Ischemie Reperfusion en
Transplantation Modelisation et Innovations Therapeutiques, Universite de
Poitiers, Poitiers, France
(Kerforne) Service d'Anesthesie, Reanimation et Medecine Peri-Operatoire,
Chu Poitiers, Poitiers, France
(Consigny, Eddi) Direction de la Recherche Clinique et de l'Innovation
(DRCI), Chu Brest, Brest, France
Publisher
BMJ Publishing Group
Abstract
Introduction Incidence of delirium after cardiac surgery remains high and
delirium has a significant burden on short-term and long-term outcomes.
Multiple causes can trigger delirium occurence, and it has been
hypothesised that sleep disturbances can be one of them. Preserving the
circadian rhythm with overnight infusion of low-dose dexmedetomidine has
been shown to lower the occurrence of delirium in older patients after
non-cardiac surgery. However, these results remain controversial. The aim
of this study was to demonstrate the usefulness of sleep induction by
overnight infusion of dexmedetomidine to prevent delirium after cardiac
surgery. Methods and analysis Dexmedetomidine after Cardiac Surgery for
Prevention of Delirium is an investigator-initiated, randomised,
placebo-controlled, parallel, multicentre, double-blinded trial. Nine
centres in France will participate in the study. Patients aged 65 years or
older and undergoing cardiac surgery will be enrolled in the study. The
intervention starts on day 0 (the day of surgery) until intensive care
unit (ICU) discharge; the treatment is administered from 20:00 to 08:00 on
the next day. Infusion rate is modified by the treating nurse or the
clinician with an objective of Richmond Agitation and Sedation Scale score
from -1 to +1. The primary outcome is delirium occurrence evaluated with
confusion assessment method for the ICU two times per day during 7 days
following surgery. Secondary outcomes include incidence of agitation
related events, self-evaluated quality of sleep, cognitive evaluation 3
months after surgery and quality of life 3 months after surgery. The
sample size is 348. Ethics and dissemination The study was approved for
all participating centers by the French Central Ethics Committee (Comite
de Protection des Personnes Ile de France VI, registration number
2018-000850-22). The results will be submitted for publication in
peer-reviewed journals. Trial registration number NCT03477344.
 Copyright ©

<100>
Accession Number
637712442
Title
Utility of a smartphone application in assessing palmar circulation prior
to radial artery harvesting for coronary artery bypass grafting: Rationale
and design of the randomised CAPITAL iRADIAL-CABG trial.
Source
BMJ Open. 12(4) (no pagination), 2022. Article Number: e055580. Date of
Publication: 08 Apr 2022.
Author
Goh C.Y.; Parlow S.; Di Santo P.; Simard T.; Jung R.; Ahmed Z.;
Verreault-Julien L.; Kuhar P.; Chan V.; Al-Atassi T.; Toeg H.; Bernick J.;
Wells G.A.; Ruel M.; Hibbert B.
Institution
(Goh, Parlow, Di Santo, Jung, Ahmed, Verreault-Julien, Hibbert) Capital
Research Group, Division of Cardiology, University of Ottawa Heart
Institute, Ottawa, ON, Canada
(Di Santo, Wells) School of Epidemiology and Public Health, University of
Ottawa, Ottawa, ON, Canada
(Simard) Department of Cardiovascular Diseases, Mayo Clinic School of
Medicine, Rochester, MN, United States
(Jung, Hibbert) Department of Cellular and Molecular Medicine, University
of Ottawa, Ottawa, ON, Canada
(Kuhar) Azumio Inc, Redwood City, San Francisco, United States
(Chan, Al-Atassi, Toeg, Ruel) Division of Cardiac Surgery, University of
Ottawa Heart Institute, Ottawa, ON, Canada
(Bernick, Wells) Cardiovascular Research Methods Centre, University of
Ottawa Heart Institute, Ottawa, ON, Canada
Publisher
BMJ Publishing Group
Abstract
Introduction There is emerging evidence supporting the use of the radial
artery (RA) as a preferred secondary conduit for coronary artery bypass
grafting (CABG) as it is associated with higher rates of graft patency at
5 years when compared with saphenous vein grafts (SVG). The modified
Allen's test (MAT) is traditionally regarded as the standard of care in
the assessment of ulnar artery (UA) patency prior to RA harvesting.
Unfortunately, due to high false-positive rates, a substantial number of
pre-CABG patients are found to have an abnormal MAT despite normal UA
patency, resulting in inappropriate exclusion from RA harvesting. The SVG
is generally used in its place when this occurs, resulting in potentially
lower rates of long-term graft patency. Methods and analysis The CAPITAL
iRADIAL-CABG trial is currently enrolling participants 18 years of age or
older undergoing CABG for whom the treating physician is considering the
use of an RA conduit. Eligible patients will be randomised in a 1:1
fashion to MAT or smartphone-based photoplethysmography application
assessment to assess collateral palmar circulation prior to RA harvesting.
The primary outcome of the trial is the use of the RA as a conduit during
CABG. The primary safety outcome is postoperative palmar ischaemia as
determined by clinical assessment or requirement of vascular intervention.
Secondary outcomes include vascular complications, early graft failure,
need for rescue percutaneous coronary intervention during the index
hospitalisation and a composite cardiovascular outcome of myocardial
infarction, stroke and cardiovascular death prior to discharge from
hospital. A total of 236 participants are planned to be recruited. Ethics
and dissemination The study was approved by the Ottawa Heart Science
Network Research Ethics Board (approval number 20180865-01H). The study
results will be disseminated via conference presentations and
peer-reviewed publications. Trial registration number NCT03810729.
 Copyright © Authors 2022

<101>
Accession Number
2017665058
Title
American College of Gastroenterology-Canadian Association of
Gastroenterology Clinical Practice Guideline: Management of Anticoagulants
and Antiplatelets during Acute Gastrointestinal Bleeding and the
Periendoscopic Period.
Source
Journal of the Canadian Association of Gastroenterology. 5(2) (pp
E39-E56), 2022. Date of Publication: 01 Apr 2022.
Author
Abraham N.S.; Barkun A.N.; Sauer B.G.; Douketis J.; Laine L.; Noseworthy
P.A.; Telford J.J.; Leontiadis G.I.
Institution
(Abraham) Division of Gastroenterology and Hepatology, Department of
Medicine, Mayo Clinic, Scottsdale, AZ, United States
(Barkun) Division of Gastroenterology, Department of Medicine, McGill
University, Montreal, QC, Canada
(Sauer) Division of Gastroenterology and Hepatology, University of
Virginia, Charlottesville, VA, United States
(Douketis) Department of Medicine, St. Joseph's Healthcare Hamilton and
McMaster University, Hamilton, ON, Canada
(Laine) Yale School of Medicine, New Haven, CT, United States
(Laine) Virginia Connecticut Healthcare System, West Haven, CT, United
States
(Noseworthy) Department of Cardiovascular Diseases, Electrophysiology,
Mayo Clinic, Rochester, MN, United States
(Telford) Division of Gastroenterology, Department of Medicine, University
of British Columbia, Vancouver, BC, Canada
(Leontiadis) Division of Gastroenterology and Farncombe Family Digestive
Health Research Institute, Department of Medicine, McMaster University,
Hamilton, ON, Canada
Publisher
Oxford University Press
Abstract
We conducted systematic reviews of predefined clinical questions and used
the Grading of Recommendations, Assessment, Development and Evaluations
approach to develop recommendations for the periendoscopic management of
anticoagulant and antiplatelet drugs during acute gastrointestinal (GI)
bleeding and the elective endoscopic setting. The following
recommendations target patients presenting with acute GI bleeding: For
patients on warfarin, we suggest against giving fresh frozen plasma or
vitamin K; if needed, we suggest prothrombin complex concentrate (PCC)
compared with fresh frozen plasma administration; for patients on direct
oral anticoagulants (DOACs), we suggest against PCC administration; if on
dabigatran, we suggest against the administration of idarucizumab, and if
on rivaroxaban or apixaban, we suggest against andexanet alfa
administration; for patients on antiplatelet agents, we suggest against
platelet transfusions; and for patients on cardiac acetylsalicylic acid
(ASA) for secondary prevention, we suggest against holding it, but if the
ASA has been interrupted, we suggest resumption on the day hemostasis is
endoscopically confirmed. The following recommendations target patients in
the elective (planned) endoscopy setting: For patients on warfarin, we
suggest continuation as opposed to temporary interruption (1-7 days), but
if it is held for procedures with high risk of GI bleeding, we suggest
against bridging anticoagulation unless the patient has a mechanical heart
valve; for patients on DOACs, we suggest temporarily interrupting rather
than continuing these; for patients on dual antiplatelet therapy for
secondary prevention, we suggest temporary interruption of the P2Y12
receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy
for secondary prevention, we suggest against its interruption. Evidence
was insufficient in the following settings to permit recommendations. With
acute GI bleeding in patients on warfarin, we could not recommend for or
against PCC administration when compared with placebo. In the elective
periprocedural endoscopy setting, we could not recommend for or against
temporary interruption of the P2Y12 receptor inhibitor for patients on a
single P2Y12 inhibiting agent. We were also unable to make a
recommendation regarding same-day resumption of the drug vs 1-7 days after
the procedure among patients prescribed anticoagulants (warfarin or DOACs)
or P2Y12 receptor inhibitor drugs because of insufficient
evidence. Copyright © 2022 The Authors, 2022. This article is a
co-publication between the Journal of the Canadian Association of
Gastroenterology and The American Journal of Gastroenterology.

<102>
Accession Number
2017665010
Title
Validation and comparison of 28 risk prediction models for coronary artery
disease.
Source
European Journal of Preventive Cardiology. 29(4) (pp 666-674), 2022. Date
of Publication: 01 Mar 2022.
Author
Lenselink C.; Ties D.; Pleijhuis R.; Van Der Harst P.
Institution
(Lenselink, Ties, Van Der Harst) Department of Cardiology, University
Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen
9700, Netherlands
(Pleijhuis) Department of Internal Medicine, University Medical Center
Groningen, Hanzeplein 1, Groningen 9700, Netherlands
Publisher
Oxford University Press
Abstract
Aims: Risk prediction models (RPMs) for coronary artery disease (CAD),
using variables to calculate CAD risk, are potentially valuable tools in
prevention strategies. However, their use in the clinical practice is
limited by a lack of poor model description, external validation, and
head-to-head comparisons. Methods and Results: CAD RPMs were
identified through Tufts PACE CPM Registry and a systematic PubMed search.
Every RPM was externally validated in the three cohorts (the UK Biobank,
LifeLines, and PREVEND studies) for the primary endpoint myocardial
infarction (MI) and secondary endpoint CAD, consisting of MI, percutaneous
coronary intervention, and coronary artery bypass grafting. Model
discrimination (C-index), calibration (intercept and regression slope),
and accuracy (Brier score) were assessed and compared head-to-head between
RPMs. Linear regression analysis was performed to evaluate predictive
factors to estimate calibration ability of an RPM. Eleven articles
containing 28 CAD RPMs were included. No single best-performing RPM could
be identified across all cohorts and outcomes. Most RPMs yielded fair
discrimination ability: mean C-index of RPMs was 0.706 +/- 0.049, 0.778
+/- 0.097, and 0.729 +/- 0.074 (P < 0.01) for prediction of MI in UK
Biobank, LifeLines, and PREVEND, respectively. Endpoint incidence in the
original development cohorts was identified as a significant predictor for
external validation performance. Conclusion(s): Performance of CAD
RPMs was comparable upon validation in three large cohorts, based on which
no specific RPM can be recommended for predicting CAD risk. Copyright
© 2021 The Author(s) 2021. Published by Oxford University Press on
behalf of the European Society of Cardiology.

<103>
Accession Number
2017603659
Title
The use of steroids in treating chylothorax following cardiac surgery in
children: A unique perspective.
Source
Cardiology in the Young. (no pagination), 2022. Date of Publication:
2022.
Author
Saad D.; Makarem A.; Fakhri G.; Al Amin F.; Bitar F.; El Rassi I.; Arabi
M.
Institution
(Saad, Fakhri) Department of Pediatrics and Adolescent Medicine, American
University of Beirut Medical Center, Beirut, Lebanon
(Makarem) Faculty of Medicine, American University of Beirut Medical
Center, Beirut, Lebanon
(Al Amin, Bitar, Arabi) Division of Pediatric Cardiology, Department of
Pediatrics and Adolescent Medicine, American University of Beirut Medical
Center, Beirut, Lebanon
(El Rassi) Department of Cardiothoracic Surgery, American University of
Beirut Medical Center, Beirut, Lebanon
Publisher
Cambridge University Press
Abstract
Background: Chylothorax is the accumulation of chyle fluid in the pleural
space. The incidence of chylothorax is quite common post-cardiac surgeries
in pediatrics especially in Fontan procedures. Although several treatment
lines are known for the management of chylothorax, steroids were scarcely
reported as a treatment option. We present a unique case of a 4-year-old
child who underwent Fontan procedure and suffered a long-term consequence
of chylothorax. The chylothorax only fully resolved after introducing
corticosteroids as part of her management. Method(s): A literature
review about management of chylothorax post-cardiac surgery in children
using Ovid Medline (19462021), PubMed, and google scholar was performed.
 Conclusion(s): Conservative management without additional surgical
intervention is adequate in most patients. Additionally, somatostatin can
be used with variable success rate. However, a few cases mentioned using
steroids in such cases. More research and reporting on the use of steroids
in the treatment of chylothorax post-cardiac surgeries in children is
needed to prove its effectivity. In this article, we describe a case of
chylothorax post-Fontan procedure that supports the use of steroids.
 Copyright © The Author(s), 2022. Published by Cambridge
University Press.

<104>
Accession Number
637817488
Title
Predictive Value of Increased Perioperative Heart Rate for All-Cause
Mortality After Cardiac Surgery: A Systematic Review and Meta-Analysis.
Source
Biological research for nursing. (pp 10998004221085986), 2022. Date of
Publication: 18 Apr 2022.
Author
Xu S.; Lin Y.; Lin L.; Peng Y.; Chen L.
Institution
(Xu, Lin) School of Nursing, 74551Fujian Medical University, Fuzhou, China
(Lin) Department of Nursing, Union Hospital, 117890Fujian Medical
University, Fuzhou, China
(Peng, Chen) Department of Cardiac Surgery, Union Hospital, 117890Fujian
Medical University, Fuzhou, China
Publisher
NLM (Medline)
Abstract
Background: Accumulated studies have revealed that heart rates are
associated with all-cause mortality in cardiac surgery patients, but the
results remain controversial. This meta-analysis aimed to evaluate the
predictive value of increased perioperative heart rate for all-cause
mortality after cardiac surgery. Method(s): We searched PubMed,
Embase, Web of Science, and Cumulative Index of Nursing and Allied Health
Literature (CINAHL) databases for studies from inception to October 11,
2021. Two researchers independently screened the studies. Titles, authors,
publication years, and hazard ratios were extracted. We used a
random-effects model to combine the HRs and 95% confidence intervals.
Several subgroup analyses were conducted. Statistical significance was set
at p < .05. Result(s): Eleven studies were included in the
meta-analysis of 33,849 patients and 3166 (9.4%) deaths. The HR of higher
perioperative heart rates was 2.09 (95% CI 1.53-2.86, p < .001, I2 = 81%).
The HR with a 10-bpm increase in preoperative heart rate was 1.19 (95% CI
1.11-1.26, p < .001, I2 = 51%). Subgroup analysis showed patients with
higher preoperative heart rates had an HR of 1.88 (95% CI 1.51-2.34, p <
.001, I2 = 0%), and patients with a higher postoperative heart rate had an
HR of 2.29 (95% CI 1.28- 4.09, p < .0001, I2 = 91%) compared to patients
with lower postoperative heart rates. Conclusion(s): Increased
perioperative heart rate is associated with all-cause mortality in
patients undergoing cardiac surgery.

<105>
Accession Number
637811941
Title
Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients
with Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.
Source
JAMA Cardiology. (no pagination), 2022. Date of Publication: 2022.
Author
Zhou M.; Ta S.; Hahn R.T.; Hsi D.H.; Leon M.B.; Hu R.; Zhang J.; Zuo L.;
Li J.; Wang J.; Wang B.; Zhu X.; Han Y.; Li X.; Xu B.; Zhang L.; Hou L.;
Han C.; Liu J.; Liu L.
Institution
(Zhou, Ta, Hu, Zhang, Zuo, Li, Wang, Wang, Zhu, Liu, Han, Li, Zhang, Han,
Liu) Xijing Hypertrophic Cardiomyopathy Center, Department of Ultrasound,
Xijing Hospital, Fourth Military Medical University, 127 Changle W Rd,
Shaanxi, Xi'an 710032, China
(Hahn, Leon) Columbia University Medical Center, New York Presbyterian
Hospital, University of Columbia, College of Physicians and Surgeons, New
York, United States
(Hsi) Heart and Vascular Institute, Stamford Hospital, Stamford, CT,
United States
(Hsi) University of Columbia, College of Physicians and Surgeons, New
York, NY, United States
(Zhang) Department of Ultrasound, Xi'An New Changan Maternity Hospital,
Shaanxi, Xi'an, China
(Xu, Liu) Xijing Hypertrophic Cardiomyopathy Center, Department of Cardiac
Surgery, Xijing Hospital, Fourth Military Medical University, 127 Changle
W Rd, Shaanxi, Xi'an 710032, China
(Zhang) Department of Cardiology, Xi'An No. 3 Hospital, Northwest
University, Shaanxi, Xi'an, China
(Hou) Xijing Hypertrophic Cardiomyopathy Center, Department of
Anesthesiology, Xijing Hospital, Fourth Military Medical University,
Shaanxi, Xi'an, China
Publisher
American Medical Association
Abstract
Importance: Patients with hypertrophic obstructive cardiomyopathy (HOCM)
and drug-refractory symptoms and outflow gradients have limited
nonsurgical treatment options. The feasibility of percutaneous
intramyocardial septal radiofrequency ablation (PIMSRA) has been reported
previously; however, procedural and medium-term outcomes are unknown.
 Objective(s): To describe the safety and medium-term outcomes of
PIMSRA in a large patient cohort with drug-refractory HOCM. Design,
Setting, and Participant(s): This was a single-arm, open-label study of
PIMSRA in patients with drug-refractory HOCM. Patients presenting to the
Xijing Hospital in Xi'an, China, between October 2016 to June 2020 with
hypertrophic cardiomyopathy. Of 1314 patients presenting with HOCM, 244
fulfilled inclusion criteria of severe resting/provoked outflow gradients
of 50 mm Hg or higher, and symptoms of New York Heart Association
functional class of II or higher refractory to maximum tolerated
medications. After discussion among the heart team, 40 patients underwent
surgical or alcohol septal reduction therapy and 4 required treatment of
significant coronary artery disease. Intervention(s): PIMSRA
performed in patients. Main Outcomes and Measures: The primary
outcome was 30-day major adverse clinical events: death, emergency
surgery, severe effusion requiring intervention, procedure-related stroke,
bleeding, and stroke. Secondary outcomes included 30-day technical success
and 90-day improvement in outflow obstruction. Result(s): The mean
(SD) age of 200 patients was 46.9 (14.0) years, and 125 (62.5%) were men.
Resting or provoked left ventricular outflow tract gradients were 50 mm Hg
or higher. The median (IQR) follow-up for all patients was 19 (6-50)
months. Thirty-day major adverse clinical events rate was 10.5% (n = 21):
there were 2 in-hospital/30-day deaths (1.0%), 7 patients (3.5%) with
pericardial effusion requiring mini-thoracotomy, 12 patients (6%) with
pericardial effusion requiring pericardiocentesis, and no bleeding or
strokes. Other periprocedural complications included permanent right
bundle branch block in 5 patients (2.5%), resuscitated ventricular
fibrillation in 2 (1.0%), and septal branch aneurysm in 2 (1.0%). There
were no permanent pacemaker implantations. At follow-up, maximum septal
thickness was reduced from a mean (SD) of 24.0 (5.1) mm to 17.3 (4.4) mm
(P <.001), and left ventricular outflow tract gradient was decreased from
a mean (SD) of 79.0 (53.0) mm Hg to 14.0 (24.0) mm Hg (P <.001). Overall,
190 patients (96%) with HOCM were in New York Heart Association functional
class I or II at last follow-up. Conclusions and Relevance: This
study found that PIMSRA in patients with drug-refractory HOCM may be an
effective procedure for relief of left ventricular outflow tract
obstruction and symptoms with acceptable complication rates. These results
are encouraging and support the design of a randomized clinical trial
against well-established septal reduction therapies. Copyright ©
2022 American Medical Association. All rights reserved.

<106>
Accession Number
2014426844
Title
Intracranial atherosclerotic disease and acute ischaemic stroke: A review
of diagnosis and management.
Source
Journal of Medical Imaging and Radiation Oncology. 66(3) (pp 391-403),
2022. Date of Publication: April 2022.
Author
Nguyen L.; Maingard J.; Jhamb A.; Brooks M.; Barras C.; Kok H.K.; Asadi H.
Institution
(Nguyen, Maingard, Asadi) NeuroInterventional Radiology Unit, Monash
Health, Melbourne, VIC, Australia
(Maingard, Asadi) Department of Imaging, Monash Health, Melbourne, VIC,
Australia
(Maingard, Brooks, Asadi) School of Medicine, Deakin University, Geelong,
VIC, Australia
(Jhamb, Brooks, Asadi) Interventional Neuroradiology Service, Austin
Health, Melbourne, VIC, Australia
(Barras) South Australian Health and Medical Research Institute, Adelaide,
SA, Australia
(Barras) The University of Adelaide, Adelaide, SA, Australia
(Kok) Department of Radiology, Northern Health, Melbourne, VIC, Australia
Publisher
John Wiley and Sons Inc
Abstract
Intracranial atherosclerotic disease is highly prevalent and a common
cause of ischaemic stroke globally. With the increasing use of
endovascular treatment for acute stroke management, computed tomography
and magnetic resonance imaging have become an essential part of patient
selection. In this review, we present the typical imaging findings of
intracranial atherosclerosis and an overview of management as relevant to
diagnostic and interventional radiologists. Copyright © 2021 The
Royal Australian and New Zealand College of Radiologists.

<107>
Accession Number
2015448865
Title
Coagulation in pediatric extracorporeal membrane oxygenation: A systematic
review of studies shows lack of standardized reporting.
Source
Research and Practice in Thrombosis and Haemostasis. 6(2) (no pagination),
2022. Article Number: e12687. Date of Publication: February 2022.
Author
Drop J.; Van Den Helm S.; Monagle P.; Wildschut E.; de Hoog M.; Gunput
S.T.G.; Newall F.; Dalton H.J.; MacLaren G.; Ignjatovic V.; van Ommen C.H.
Institution
(Drop, van Ommen) Pediatric Hematology, Erasmus University Medical Center
- Sophia Children's Hospital, Rotterdam, Netherlands
(Drop, Wildschut, de Hoog) Pediatric Intensive Care, Erasmus University
Medical Center - Sophia Children's Hospital, Rotterdam, Netherlands
(Van Den Helm, Monagle, Newall, MacLaren, Ignjatovic) Hematology, Murdoch
Children's Research Institute, Melbourne, VIC, Australia
(Monagle, Newall, MacLaren, Ignjatovic) Department of Pediatrics, The
University of Melbourne, Melbourne, VIC, Australia
(Monagle, Newall) Department of Clinical Hematology, The Royal Children's
Hospital, Melbourne, VIC, Australia
(Monagle) Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW,
Australia
(Gunput) Medical Library, Erasmus MC, University Medical Center,
Rotterdam, Netherlands
(Dalton) Department of Pediatrics, INOVA Heart and Vascular Institute,
Falls Church, VA, United States
(Dalton) Department of Pediatrics, Virginia Commonwealth University,
Richmond, VA, United States
(MacLaren) Department of Paediatric Intensive Care, The Royal Children's
Hospital, Melbourne, VIC, Australia
(MacLaren) Cardiothoracic Intensive Care Unit, National University Health
System, Singapore City, Singapore
Publisher
John Wiley and Sons Inc
Abstract
Objectives: Extracorporeal membrane oxygenation (ECMO) involves complex
coagulation management and frequent hemostatic complications. ECMO
practice between centers is variable. To compare results between
coagulation studies, standardized definitions and clear documentation of
ECMO practice is essential. We assessed how study population, outcome
definitions, and ECMO-, coagulation-, and transfusion-related parameters
were described in pediatric ECMO studies. Data sources: Embase, Medline,
Web of Science, Cochrane Library and Google Scholar. Study selection:
English original studies of pediatric ECMO patients describing hemostatic
tests or outcome. Data extraction: Eligibility was assessed following
PRISMA guidelines. Study population, outcome and ECMO-, coagulation, and
transfusion parameters were summarized. Data synthesis: A total of 107 of
1312 records were included. Study population parameters most frequently
included (gestational) age (79%), gender (60%), and (birth) weight (59%).
Outcomes, including definitions of bleeding (29%), thrombosis (15%), and
survival (43%), were described using various definitions. Description of
pump type, oxygenator and cannulation mode occurred in 49%, 45%, and 36%
of studies, respectively. The main coagulation test (53%), its reference
ranges (49%), and frequency of testing (24%) were the most prevalent
reported coagulation parameters. The transfusion thresholds for platelets,
red blood cells, and fibrinogen were described in 27%, 18%, and 18% of
studies, respectively. Conclusion(s): This systematic review
demonstrates a widespread lack of detail or standardization of several
parameters in coagulation research of pediatric ECMO patients. We suggest
several parameters that might be included in future coagulation studies.
We encourage the ECMO community to adopt and refine this list of
parameters and to use standardized definitions in future
research. Copyright © 2022 The Authors. Research and Practice in
Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of
International Society on Thrombosis and Haemostasis (ISTH).

<108>
Accession Number
2014497934
Title
Evaluation of the analgesic efficacy of bilateral ultrasound-guided
transversus thoracic muscle plane block on post-sternotomy pain: A
randomized controlled trial.
Source
Local and Regional Anesthesia. 14 (pp 145-152), 2021. Date of Publication:
2021.
Author
Shokri H.; Ali I.; Kasem A.A.
Institution
(Shokri, Kasem) Department of Anesthesiology, Ain Shams University, Cairo,
Egypt
(Ali) Department of Cardiothoracic Surgery, Ain Shams University, Cairo,
Egypt
Publisher
Dove Medical Press Ltd
Abstract
Purpose: Transverse thoracic block is a new perioperative analgesic method
for post-sternotomy discomfort. This study discusses the efficacy of an
ultrasound-guided transversus thoracic muscle plane block (TTPB) in
patients undergoing heart surgery, including sternotomy. Patients and
Methods: In this prospective trial, 60 patients were randomly assigned to
two groups: transversus (T) or general anesthesia (GA). Patients in the T
group received TTPB with GA and 15 mL of 0.25% bupivacaine was
administered on either side. Patients in the GA group received TTPB along
with GA, but 15 mL saline was injected on either side instead. The
patients were followed up postoperatively. The percentage of patients
receiving additional opioids, extubation time, intensive care unit (ICU)
length, postoperative morphine dose, and adverse events were documented.
 Result(s): The percentage of patients requiring additional morphine
was significantly lower in the T group (p<0.015). Pain scores were
comparable between the groups at extubation time and 18 h postoperatively.
At 8, 12, and 24 h after surgery, pain scores in the T group were
significantly lower (P<0.001). The total amount of morphine required after
surgery was much lower in the T group (8+/-0.74 mg), and the duration to
initial analgesic necessity was significantly greater in the GA group
(P<0.001). Patients in the GA group had a considerably longer ventilation
time (11.07+/-0.64) (P<0.001). The ICU stay in the T group was
substantially shorter (P<0.001), and postoperative complications were
comparable. Conclusion(s): For patients undergoing heart surgery,
TTPB offers sufficient postoperative pain control, resulting in lower pain
scores, lower postoperative analgesic doses, shorter extubation times, and
shorter ICU stay lengths. Copyright © 2021 Shokri et al.

<109>
Accession Number
2014766137
Title
Stereotactic ablative radiotherapy for operable stage I non-small-cell
lung cancer (revised STARS): long-term results of a single-arm,
prospective trial with prespecified comparison to surgery.
Source
The Lancet Oncology. 22(10) (pp 1448-1457), 2021. Date of Publication:
October 2021.
Author
Chang J.Y.; Mehran R.J.; Feng L.; Verma V.; Liao Z.; Welsh J.W.; Lin S.H.;
O'Reilly M.S.; Jeter M.D.; Balter P.A.; McRae S.E.; Berry D.; Heymach
J.V.; Roth J.A.; Antonoff M.; Hofstetter W.; Rajaram R.; Rice D.; Sepesi
B.; Swisher S.; Vaporciyan A.; Walsh G.; DeGraaf C.; Correa A.; Chen A.;
Gandhi S.; Komaki R.; Lee P.; Nguyen Q.-N.; Ning M.; Gao S.;
Pollard-Larkin J.; Nitsch P.; Sadagopan R.; Wang X.
Institution
(Chang, Verma, Liao, Welsh, Lin, O'Reilly, Jeter) Department of Radiation
Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
United States
(Mehran, Roth) Department of Thoracic and Cardiovascular Surgery, The
University of Texas MD Anderson Cancer Center, Houston, TX, United States
(Feng, Berry) Department of Biostatistics, The University of Texas MD
Anderson Cancer Center, Houston, TX, United States
(Balter) Department of Radiation Physics, The University of Texas MD
Anderson Cancer Center, Houston, TX, United States
(McRae) Department of Interventional Radiology, The University of Texas MD
Anderson Cancer Center, Houston, TX, United States
(Heymach) Department of Thoracic and Head/Neck Medical Oncology, The
University of Texas MD Anderson Cancer Center, Houston, TX, United States
Publisher
Elsevier Ltd
Abstract
Background: A previous pooled analysis of the STARS and ROSEL trials
showed higher survival after stereotactic ablative radiotherapy (SABR)
than with surgery for operable early-stage non-small-cell lung cancer
(NSCLC), but that analysis had notable limitations. This study reports
long-term results of the revised STARS trial, in which the SABR group was
re-accrued with a larger sample size, along with a protocol-specified
propensity-matched comparison with a prospectively registered,
contemporary institutional cohort of patients who underwent video-assisted
thoracoscopic surgical lobectomy with mediastinal lymph node dissection
(VATS L-MLND). Method(s): This single-arm prospective trial was done
at the University of Texas MD Anderson Cancer Center (Houston, TX, USA)
and enrolled patients aged 18 years or older with a Zubrod performance
status of 0-2, newly diagnosed and histologically confirmed NSCLC with
N0M0 disease (squamous cell, adenocarcinoma, large cell, or NSCLC not
otherwise specified), and a tumour diameter of 3 cm or less. This trial
did not include patients from the previous pooled analysis. SABR dosing
was 54 Gy in three fractions (for peripheral lesions) or 50 Gy in four
fractions (for central tumours; simultaneous integrated boost to gross
tumour totalling 60 Gy). The primary endpoint was the 3-year overall
survival. For the propensity-matching analysis, we used a surgical cohort
from the MD Anderson Department of Thoracic and Cardiovascular Surgery's
prospectively registered, institutional review board-approved database of
all patients with clinical stage I NSCLC who underwent VATS L-MLND during
the period of enrolment in this trial. Non-inferiority could be claimed if
the 3-year overall survival rate after SABR was lower than that after VATS
L-MLND by 12% or less and the upper bound of the 95% CI of the hazard
ratio (HR) was less than 1.965. Propensity matching consisted of
determining a propensity score using a multivariable logistic regression
model including several covariates (age, tumour size, histology,
performance status, and the interaction of age and sex); based on the
propensity scores, one patient in the SABR group was randomly matched with
one patient in the VATS L-MLND group using a 5:1 digit greedy match
algorithm. This study is registered with ClinicalTrials.gov, NCT02357992.
 Finding(s): Between Sept 1, 2015, and Jan 31, 2017, 80 patients were
enrolled and included in efficacy and safety analyses. Median follow-up
time was 5.1 years (IQR 3.9-5.8). Overall survival was 91% (95% CI 85-98)
at 3 years and 87% (79-95) at 5 years. SABR was tolerated well, with no
grade 4-5 toxicity and one (1%) case each of grade 3 dyspnoea, grade 2
pneumonitis, and grade 2 lung fibrosis. No serious adverse events were
recorded. Overall survival in the propensity-matched VATS L-MLND cohort
was 91% (95% CI 85-98) at 3 years and 84% (76-93) at 5 years.
Non-inferiority was claimed since the 3-year overall survival after SABR
was not lower than that observed in the VATS L-MLND group. There was no
significant difference in overall survival between the two patient cohorts
(hazard ratio 0.86 [95% CI 0.45-1.65], p=0.65) from a multivariable
analysis. Interpretation(s): Long-term survival after SABR is
non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains
promising for such cases but multidisciplinary management is strongly
recommended. Funding(s): Varian Medical Systems and US National
Cancer Institute (National Institutes of Health). Copyright ©
2021 Elsevier Ltd

<110>
Accession Number
2015115347
Title
Non-vitamin K oral anticoagulants versus vitamin K antagonists in post
transcatheter aortic valve replacement patients with clinical indication
for oral anticoagulation: A meta-analysis.
Source
Clinical Cardiology. 45(4) (pp 401-406), 2022. Date of Publication: April
2022.
Author
Chen Y.-F.; Liu F.; Li X.-W.; Zhang H.-J.; Liu Y.-G.; Lin L.
Institution
(Chen, Li, Zhang, Liu, Lin) Department of Pharmacy, Xiamen Cardiovascular
Hospital of Xiamen University, School of Medicine, Xiamen University,
Xiamen, China
(Liu) Department of Cardiovascular Surgery, Xiamen Cardiovascular Hospital
of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
Publisher
John Wiley and Sons Inc
Abstract
Background: Current guidelines recommend oral anticoagulation (OAC)
following transcatheter aortic valve replacement (TAVR) in patients with
clinical indication, but the optimal antithrombotic regimen remains
uncertain. We aimed to compare the efficacy and safety of non-vitamin K
oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in
patients undergoing TAVR with concomitant indication of OAC. Hypothesis:
Comparing with VKAs therapy, NOACs are similar in reducing the all-cause
mortality and major bleeding in post-TAVR patients requiring OAC
medication. Method(s): We searched the databases of PubMed, Embase,
and Cochrane library databases to identify studies that investigated NOACs
versus VKAs after TAVR in patients with another indication of OAC, which
were published before 28th September 28, 2021. The effectiveness of
outcomes was all-cause mortality and stroke or systemic embolism, while
the main safety outcome was major and/or life-threatening bleeding. The
hazard ratio (HR) with 95% confidence interval (CI) was used as a measure
of treatment effect. Result(s): Our search identified eight studies.
We included 4947 post-TAVR patients with another indication of OAC
allocated to the NOAC (n = 2146) or VKA groups (n = 2801). There were no
significant differences in the all-cause mortality (HR: 0.91, 95% CI:
0.77-1.08, p =.29, I2 = 47%), stroke or systemic embolism (HR:
0.96, 95% CI: 0.68-1.37, p =.84, I2 = 0%), and major and/or
life-threatening bleeding (HR: 1.09, 95% CI: 0.89-1.32, p =.40,
I2 = 30%) in both groups. Conclusion(s): Among post-TAVR
patients who required OAC therapy, NOACs therapy compared to VKAs is
similar in reducing the all-cause mortality, stroke or systemic embolism,
and major and/or life-threatening bleeding events. Copyright ©
2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

<111>
Accession Number
2015089834
Title
Rejection surveillance in pediatric heart transplant recipients: Critical
reflection on the role of frequent and long-term routine surveillance
endomyocardial biopsies and comprehensive review of non-invasive rejection
screening tools.
Source
Pediatric Transplantation. 26(3) (no pagination), 2022. Article Number:
e14214. Date of Publication: May 2022.
Author
Power A.; Baez Hernandez N.; Dipchand A.I.
Institution
(Power, Baez Hernandez) Department of Pediatrics, UT Southwestern Medical
Center and Children's Medical Center, Dallas, TX, United States
(Dipchand) Department of Pediatrics, University of Toronto, Hospital for
Sick Children, Toronto, ON, Canada
Publisher
John Wiley and Sons Inc
Abstract
Background: Despite significant medical advances in the field of pediatric
heart transplantation (HT), acute rejection remains an important cause of
morbidity and mortality. Endomyocardial biopsy (EMB) remains the
gold-standard method for diagnosing rejection but is an invasive,
expensive, and stressful process. Given the potential adverse consequences
of rejection, routine post-transplant rejection surveillance protocols
incorporating EMB are widely employed to detect asymptomatic rejection.
Each center employs their own specific routine rejection surveillance
protocol, with no consensus on the optimal approach and with high
inter-center variability. The utility of high-frequency and long-term
routine surveillance biopsies (RSB) in pediatric HT has been called into
question. Method(s): Sources for this comprehensive review were
primarily identified through searches in biomedical databases including
MEDLINE and Embase. Result(s): The available literature suggests that
the diagnostic yield of RSB is low beyond the first year post-HT and that
a reduction in RSB intensity from high-frequency to low-frequency can be
done safely with no impact on early and mid-term survival. Though there
are emerging non-invasive methods of detecting asymptomatic rejection, the
evidence is not yet strong enough for any test to replace EMB.
 Conclusion(s): Overall, pediatric HT centers in North America should
likely be doing fewer RSB than are currently performed. Risk factors for
rejection should be considered when designing the optimal rejection
surveillance strategy. Noninvasive testing including emerging biomarkers
may have a complementary role to aid in safely reducing the need for
RSB. Copyright © 2022 Wiley Periodicals LLC.

<112>
Accession Number
2014651857
Title
Cardiac allograft vasculopathy: A review.
Source
Pediatric Transplantation. 26(3) (no pagination), 2022. Article Number:
e14218. Date of Publication: May 2022.
Author
Laks J.A.; Dipchand A.I.
Institution
(Laks) Heart Institute, Johns Hopkins All Children's Hospital, St
Petersburg, FL, United States
(Dipchand) Labatt Family Heart Centre, The Hospital for Sick Children,
Toronto, ON, Canada
Publisher
John Wiley and Sons Inc
Abstract
Background: Heart transplantation has become the standard of care for
pediatric patients with end-stage heart disease, and outcomes have
consistently improved over the last few decades. CAV, however, remains a
leading cause of morbidity and mortality in heart transplantation and is
the leading cause of death beyond 3 years post-transplantation. We sought
out to provide an in-depth overview of CAV in the pediatric heart
transplant population. Method(s): Database searches were conducted in
both Medline and Embase on the topic of cardiac vasculopathy in pediatric
heart transplant recipients. The search used five broad concept terms:
heart transplant; pediatric; CAV; diagnosis, prognosis, and risk factors;
and guidelines and reviews. References were captured if there was at least
one term in each of the concepts. The search was limited to articles in
the English language. Result(s): A total of 148 articles were
identified via the literature search with further articles identified via
review of references. Pediatric data regarding the etiology and
development of CAV remain limited although knowledge about the immune and
non-immune factors playing a role are increasing. CAV continues to be
difficult to detect with many invasive and non-invasive methods available,
yet their effectiveness in the detection of CAV remains suboptimal. There
remains no proven medical intervention to treat or reverse established CAV
disease, and CAV is associated with high rates of graft loss once
detected. However, several medications are used in hopes of preventing,
slowing progression, or modifying the outcomes. Conclusion(s): This
review provides a comprehensive overview of CAV, discusses its clinical
presentation, risk factors, diagnostic tools used to identify CAV in the
pediatric population, and highlights the current therapeutic options and
the need for ongoing research. Copyright © 2022 Wiley Periodicals
LLC.

<113>
Accession Number
2015635006
Title
Complete transcatheter versus complete surgical treatment in patients with
aortic valve stenosis and concomitant coronary artery disease: Study-level
meta-analysis with reconstructed time-to-event data.
Source
Journal of Cardiac Surgery. (no pagination), 2022. Date of Publication:
2022.
Author
Sa M.P.; Sun T.; Fatehi Hassanabad A.; Awad A.K.; Van den Eynde J.; Malin
J.H.; Sicouri S.; Torregrossa G.; Ruhparwar A.; Weymann A.; Ramlawi B.
Institution
(Sa, Sun, Torregrossa, Ramlawi) Department of Cardiothoracic Surgery,
Lankenau Heart Institute, Lankenau Medical Center, Main Line Health,
Wynnewood, PA, United States
(Sa, Sicouri, Torregrossa, Ramlawi) Department of Cardiothoracic Surgery
Research, Lankenau Institute for Medical Research, Wynnewood, PA, United
States
(Fatehi Hassanabad) Section of Cardiac Surgery, Department of Cardiac
Sciences, Libin Cardiovascular Institute, Cumming School of Medicine,
University of Calgary, Calgary, AB, Canada
(Awad) Faculty of Medicine, Ain Shams University, Cairo, Egypt
(Van den Eynde) Department of Cardiovascular Sciences, KU Leuven, Leuven,
Belgium
(Van den Eynde) Helen B. Taussig Heart Center, The Johns Hopkins Hospital
and School of Medicine, Baltimore, MD, United States
(Malin) Philadelphia College of Osteopathic Medicine, Bala Cynwyd, PA,
United States
(Ruhparwar, Weymann) Department of Thoracic and Cardiovascular Surgery,
West German Heart and Vascular Center Essen, University Hospital of Essen,
University Duisburg-Essen, Essen, Germany
Publisher
John Wiley and Sons Inc
Abstract
Objectives: To compare outcomes of complete transcatheter (TAVI plus PCI)
versus complete surgical (SAVR plus CABG) approach to treat patients with
aortic stenosis (AS) and concomitant coronary artery disease (CAD).
 Method(s): Study-level meta-analysis with reconstructed time-to-event
data including studies published by November 2021. The primary endpoints
were 30-day mortality, overall survival, and major adverse cardiovascular
and cerebrovascular events (MACCE). The secondary endpoints were 30-day
stroke, myocardial infarction, and permanent pacemaker implantation (PPI);
in-hospital major vascular events and acute kidney injury (AKI).
 Result(s): Eight studies met our eligibility criteria, including a
total of 33,286 patients (3448 for TAVI plus PCI and 29,838 for SAVR plus
CABG). The pooled risk of 30-day mortality was lower for TAVI plus PCI (OR
0.63; 95% CI 0.51-0.80; p <.001). Patients undergoing TAVI plus PCI had
lower risk of in-hospital AKI (OR 0.49; 95% CI 0.28-0.85; p =.01),
however, higher risk of major vascular events (OR 7.33; 95% CI 1.80-29.85;
p =.005) and higher risk of PPI (OR 2.96; 95% CI 1.80-4.85; p <.001). No
statistically significant difference was observed for myocardial
infarction and stroke between the groups. In the follow-up analyses, we
observed a higher risk of mortality (HR 1.64, 95% CI 1.36-1.96, p <.001)
and MACCE with TAVI plus PCI (HR 1.35 (95% CI 1.08-1.69, p =.009).
 CONCLUSION(S): Patients who undergo TAVI plus PCI (in comparison with
SAVR plus CABG) initially experience lower rates of in-hospital death and
AKI; however, they experience significantly lower survival rates and more
MACCE at 5-year follow up. Structural heart surgeons and interventional
cardiologists should consider these aspects when referring patients for
one approach or the other. Copyright © 2022 Wiley Periodicals
LLC.

<114>
Accession Number
636361995
Title
Antifibrinolytic Drugs for the Prevention of Bleeding in Pediatric Cardiac
Surgery on Cardiopulmonary Bypass: A Systematic Review and Meta-analysis.
Source
Anesthesia and analgesia. 134(5) (pp 987-1001), 2022. Date of Publication:
01 May 2022.
Author
Siemens K.; Sangaran D.P.; Hunt B.J.; Murdoch I.A.; Tibby S.M.
Institution
(Siemens, Sangaran, Murdoch, Tibby) From the Pediatric Intensive Care,
Evelina London Children's Hospital, St Thomas' Hospital, London, United
Kingdom
(Hunt) Department of Hematology, St Thomas' Hospital, London, United
Kingdom
Publisher
NLM (Medline)
Abstract
BACKGROUND: Bleeding is one of the commonest complications affecting
children undergoing cardiac surgery on cardiopulmonary bypass.
Antifibrinolytic drugs are part of a multifaceted approach aimed at
reducing bleeding, though sufficiently sized pediatric studies are sparse,
and dosing algorithms are heterogeneous. Our objective was to evaluate the
efficacy and safety of antifibrinolytic agents as well as the
effectiveness of different dosing regimens in pediatric cardiac surgery
using cardiopulmonary bypass. METHOD(S): We performed a systematic
review and meta-analysis evaluating randomized controlled trials published
between 1980 and 2019, identified by searching the databases MEDLINE,
EMBASE, PubMed, and CENTRAL. All studies investigating patients <18 years
of age without underlying hematological disorders were included. The
primary outcome was postoperative bleeding; secondary end points included
blood product transfusion, mortality, and safety (thromboses, anaphylaxis,
renal or neurological dysfunction, and seizures). Different dosing
regimens were compared. Studies were dual appraised, outcomes were
reported descriptively and, if appropriate, quantitatively using the
Review Manager 5 (REVMAN 5) software (The Cochrane Collaboration).
 RESULT(S): Thirty of 209 articles were included, evaluating the
following drugs versus control: aprotinin n = 14, tranexamic acid (TXA) n
= 12, and epsilon-aminocaproic acid (EACA) n = 4. The number of
participants per intervention group ranged from 11 to 100 (median, 25;
interquartile range [IQR], 20.5) with a wide age span (mean, 13 days to
5.8 years) and weight range (mean, 3.1-26.3 kg). Methodological quality
was low to moderate.All agents reduced mean 24-hour blood loss compared to
control: aprotinin by 6.0 mL/kg (95% confidence interval [CI], -9.1 to
-3.0; P = .0001), TXA by 9.0 mL/kg (95% CI, -11.3 to -6.8; P < .00001),
and EACA by 10.5 mL/kg (95% CI, -21.1 to 0.0; P = .05). Heterogeneity was
low for TXA (I2 = 29%; P = .19), moderate for aprotinin (I2 = 41%; P =
.11), and high for EACA (I2 = 95%; P < .00001). All agents also reduced
24-hour blood product transfusion. There was no clear dose-response effect
for TXA nor aprotinin. Studies were underpowered to detect significant
differences in mortality, thromboses, anaphylaxis, and renal or
neurological dysfunction. CONCLUSION(S): The available data
demonstrate efficacy for all 3 antifibrinolytic drugs. Therefore, the
agent with the most favorable safety profile should be used. As sufficient
data are lacking, large comparative trials are warranted to assess the
relative safety and appropriate dosing regimens in
pediatrics. Copyright © 2021 International Anesthesia Research
Society.

<115>
Accession Number
637464280
Title
Bi-level Positive Airway Pressure Versus Nasal CPAP for the Prevention of
Extubation Failure in Infants After Cardiac Surgery.
Source
Respiratory care. 67(4) (pp 448-454), 2022. Date of Publication: 01 Apr
2022.
Author
Zheng Y.-R.; Lin W.-H.; Lin S.-H.; Xu N.; Cao H.; Chen Q.
Institution
(Zheng, Lin, Lin, Xu, Cao, Chen) Department of Cardiac Surgery, Fujian
Branch of Shanghai Children's Medical Center, Fuzhou, China; Fujian
Children's Hospital, Fuzhou, China; Fujian Maternity and Child Health
Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China;
and Fujian Key Laboratory of Women and Children's Critical Diseases
Research, Fujian Maternity and Child Health Hospital, Fuzhou, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Extubation early in the postoperative period is beneficial to
the recovery and rehabilitation of patients. This study compared the
postoperative extubation failure rates among infants who received
postextubation respiratory support by either bi-level positive airway
pressure (BPAP) or nasal CPAP following cardiac surgery. METHOD(S):
This was a single-center randomized controlled trial registered at the
Chinese Clinical Trial Registry (number ChiCTR2000041453) and was
conducted between January 2020 and March 2021. Ventilated infants who
underwent cardiac surgery were randomized to either a BPAP or a nasal CPAP
group for ventilatory support following extubation. The primary outcome
measure was the extubation failure rate within 48 h. RESULT(S): The
analyses included 186 subjects. Treatment failure necessitating
re-intubation was noted in 14 of the 93 infants (15%) in the BPAP group
and in 11 of the 93 infants (12%) in the nasal CPAP group (P = .52).
Moreover, there were no statistically significant differences between the
2 groups regarding the duration of noninvasive ventilation (P = .54),
total enteral feeding time (P = .59), or complications (P = .85). We found
that both the BPAP group and the nasal CPAP group showed significantly
improved oxygenation and relief of respiratory distress after treatment.
However, the PaCO2 level within 24 h was significantly lower in the BPAP
group (P = .001) than in the CPAP group. Additionally, the PaO2 /FIO2 in
the BPAP group was significantly higher than in the nasal CPAP group at 6
h, 12 h, and 24 h after treatment (P < .001). CONCLUSION(S): The
introduction of BPAP for postextubation respiratory support was not
inferior to nasal CPAP in infants after cardiac surgery. Moreover, BPAP
was shown to be superior to nasal CPAP in improving oxygenation and carbon
dioxide clearance. Copyright © 2022 by Daedalus Enterprises.

<116>
Accession Number
637103672
Title
Control of Postoperative Hypotension Using a Closed-Loop System for
Norepinephrine Infusion in Patients After Cardiac Surgery: A Randomized
Trial.
Source
Anesthesia and analgesia. 134(5) (pp 964-973), 2022. Date of Publication:
01 May 2022.
Author
Desebbe O.; Rinehart J.; Van der Linden P.; Cannesson M.; Delannoy B.;
Vigneron M.; Curtil A.; Hautin E.; Vincent J.-L.; Duranteau J.; Joosten A.
Institution
(Desebbe, Delannoy, Hautin) From the Department of Anesthesiology and
Perioperative Care, Lyon, France
(Rinehart) Department of Anesthesiology and Perioperative Care, University
of California, Irvine, CA
(Van der Linden) Department of Anesthesiology, Brugmann Hospital,
Universite Libre de Bruxelles, Brussels, Belgium
(Cannesson) Department of Anesthesiology and Perioperative Medicine, David
Geffen School of Medicine, University of California, Los Angeles, CA,
Mexico
(Vigneron, Curtil) Department of Cardiac Surgery, Lyon, France
(Vincent) Department of Intensive Care, Erasme University Hospital,
Universite Libre de Bruxelles, Brussels, Belgium
(Duranteau, Joosten) Department of Anesthesiology and Intensive Care,
Hopitaux Universitaires Paris-Sud, Bicetre and Paul Brousse Hospitals,
Universite Paris-Sud ,Universite Paris-SaclayAssistance Publique Hopitaux
de Paris, Villejuif, France
(Joosten) Department of Anesthesiology, Erasme University Hospital,
Brussels, Belgium
Publisher
NLM (Medline)
Abstract
BACKGROUND: Vasopressors are a cornerstone for the management of
vasodilatory hypotension. Vasopressor infusions are currently adjusted
manually to achieve a predefined arterial pressure target. We have
developed a closed-loop vasopressor (CLV) controller to help correct
hypotension more efficiently during the perioperative period. We tested
the hypothesis that patients managed using such a system postcardiac
surgery would present less hypotension compared to patients receiving
standard management. METHOD(S): A total of 40 patients admitted to
the intensive care unit (ICU) after cardiac surgery were randomized into 2
groups for a 2-hour study period. In all patients, the objective was to
maintain mean arterial pressure (MAP) between 65 and 75 mm Hg using
norepinephrine. In the CLV group, the norepinephrine infusion was
controlled via the CLV system; in the control group, it was adjusted
manually by the ICU nurse. Fluid administration was standardized in both
groups using an assisted fluid management system linked to an advanced
hemodynamic monitoring system. The primary outcome was the percentage of
time patients were hypotensive, defined as MAP <65 mm Hg, during the study
period. RESULT(S): Over the 2-hour study period, the percentage of
time with hypotension was significantly lower in the CLV group than that
in the control group (1.4% [0.9-2.3] vs 12.5% [9.9-24.3]; location
difference, -9.8% [95% CI, -5.4 to -15.9]; P < .001). The percentage of
time with MAP between 65 and 75 mm Hg was also greater in the CLV group
(95% [89-96] vs 66% [59-77]; location difference, 27.6% [95% CI,
34.3-19.0]; P < .001). The percentage of time with an MAP >75 mm Hg (and
norepinephrine still being infused) was also significantly lower in
patients in the CLV group than that in the control group (3.2% [1.9-5.4]
vs 20.6% [8.9-32.5]; location difference, -17% [95% CI, -10 to -24]; P <
.001).The number of norepinephrine infusion rate modifications over the
study period was greater in the CLV group than that in the control group
(581 [548-597] vs 13 [11-14]; location difference, 568 [578-538]; P <
.001). No adverse event occurred during the study period in both groups.
 CONCLUSION(S): Closed-loop control of norepinephrine infusion
significantly decreases postoperative hypotension compared to manual
control in patients admitted to the ICU after cardiac
surgery. Copyright © 2022 International Anesthesia Research
Society.

<117>
Accession Number
2017687537
Title
Efficacy of Date Palm Pollen in the Male Sexual Dysfunction after Coronary
Artery Bypass Graft: A Randomized, Double-Blind, Clinical Trial.
Source
Evidence-based Complementary and Alternative Medicine. 2022 (no
pagination), 2022. Article Number: 5032681. Date of Publication: 2022.
Author
Hooshang H.; Farahani A.V.; Rezaeizadeh H.; Forouzannia S.K.; Alaeddini
F.; Ashraf H.; Karimi M.
Institution
(Hooshang) Department of Persian Medicine, School of Persian Medicine,
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Farahani) Clinical Cardiac Electrophysiology, Department of Cardiology,
School of Medicine, Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran Heart Center,
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Rezaeizadeh) Traditional Medicine, Department of Persian Medicine, School
of Persian Medicine, Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Forouzannia) Department of General Surgery, School of Medicine, Research
Center for Advanced Technologies in Cardiovascular Medicine,
Cardiovascular Diseases Research Institute, Tehran Heart Center, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Alaeddini) Department of Research, Tehran Heart Center, Tehran University
of Medical Sciences, Tehran, Iran, Islamic Republic of
(Ashraf) Cardiology Sina Hospital, Tehran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Karimi) Traditional Medicine, Department of Persian Medicine, School of
Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran,
Islamic Republic of
Publisher
Hindawi Limited
Abstract
Background. Bypass graft surgery of the coronary artery has a significant
effect on the creation and development of sexual dysfunction among male
patients. The previous studies have demonstrated that date palm pollen
(DPP) increases the count and quality of sperm. Additionally, it has been
shown that DPP has a protective effect against myocardial infarction and
cardiac remodeling. Therefore, this is the first study investigating the
impact of DPP (Phoenix dactylifera L.) on managing male sexual dysfunction
after coronary artery bypass graft. Methods. This randomized,
double-blind, placebo-controlled clinical trial was conducted on 60
patients (DPP group n = 30, control group n = 30) of Iranian men after
coronary artery bypass graft. Two parallel groups were randomly generated
from the study participants. The intervention group was prescribed 3 grams
of the powder of DPP twice a day (9 AM and 9 PM) for two months, while the
control group received the same prescription of the placebo powder.
Results. The DPP consumption significantly increased the International
Index of Erectile Function (IIEF) (from 23.21 to 46.57) and the Hurlbert
Index of Sexual Desire (HISD) (from 59.39 to 64.45) scores over time in
the intervention group. However, there were no significant changes in the
control group. Conclusion. Daily intake of 6 g DPP for two months
exhibited beneficial effects on the symptoms of male sexual dysfunction in
patients who have undergone coronary artery bypass graft (CABG).
 Copyright © 2022 Hamed Hooshang et al.

<118>
[Use Link to view the full text]
Accession Number
2017651760
Title
Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized
Controlled Trials.
Source
Journal of Cardiovascular Pharmacology. 79(4) (pp 549-557), 2022. Date of
Publication: 03 Apr 2022.
Author
Wang Z.; Wang W.; Li H.; Zhang A.; Han Y.; Wang J.; Hou Y.
Institution
(Wang, Wang, Wang, Hou) Department of Cardiology, First Affiliated
Hospital of Shandong First Medical University and Shandong Provincial
Qianfoshan Hospital, Shandong Province, Jinan, China
(Li, Zhang) Cheeloo College of Medicine, Shandong University, Shandong
Province, Jinan, China
(Han) Department of Pharmacy, First Affiliated Hospital of Shandong First
Medical University and Shandong Provincial Qianfoshan Hospital, Shandong
Province, Jinan, China
Publisher
Lippincott Williams and Wilkins
Abstract
This was a meta-analysis of randomized control trials (RCTs) to evaluate
the effect of ivabradine on the risk of atrial fibrillation (AF) and its
effect on the ventricular rate in patients with AF. The PubMed, EMBASE,
Cochrane Controlled Trials Register, and other databases were searched for
RCTs on ivabradine. Thirteen trials with 37,533 patients met the inclusion
criteria. The incidence of AF was significantly higher in the ivabradine
treatment group than in the control group [odds ratio (OR), 1.23; 95%
confidence interval (CI), 1.08-1.41], although it was reduced after
cardiac surgery (OR, 0.70; 95% CI, 0.23-2.12). Regarding left ventricular
ejection fraction (LVEF), ivabradine increased the risk of AF in both LVEF
>40% (OR, 1.42; 95% CI, 1.24-1.63) and LVEF <=40% subgroups (OR, 1.16; 95%
CI, 0.98-1.37). The risk of AF was increased by both small and large
cumulative doses of ivabradine (small cumulative dose: OR, 3.00; 95% CI,
0.48-18.93; large cumulative dose: OR, 1.05; 95% CI, 0.83-1.34).
Furthermore, ivabradine may reduce the ventricular rate in patients with
AF. In conclusion, we found that both large and small cumulative doses of
ivabradine were associated with an increased incidence of AF, and the
effect was more marked in the LVEF >40% subgroup. Nevertheless, ivabradine
therapy is beneficial for the prevention of postoperative AF. Furthermore,
ivabradine may be effective in controlling the ventricular rate in
patients with AF, although more RCTs are needed to support this
conclusion. Copyright © 2022 Lippincott Williams and Wilkins. All
rights reserved.

<119>
[Use Link to view the full text]
Accession Number
2017651747
Title
Colchicine for Patients With Coronary Artery Disease: A Systematic Review
and Meta-analysis.
Source
Journal of Cardiovascular Pharmacology. 79(4) (pp 420-430), 2022. Date of
Publication: 11 Apr 2022.
Author
Shrestha D.B.; Budhathoki P.; Sedhai Y.; Khadka M.; Pokharel S.; Yadav S.;
Patel T.; Elgendy I.; Mir W.A.Y.; Patel N.K.
Institution
(Shrestha, Mir) Department of Internal Medicine, , Mount Sinai Hospital,
Chicago, IL, United States
(Budhathoki) Department of Internal Medicine, Bronxcare Health System,
Bronx, NY, United States
(Sedhai) Department of Internal Medicine, Division of Hospital Medicine,
Virginia Commonwealth University, , School of Medicine, Richmond, VA,
United States
(Khadka, Pokharel, Yadav) Nepalese Army Institute of Health Sciences
(NAIHS), Kathmandu, Nepal
(Patel) P Department of Internal Medicine, Division of Cardiology,
AdventHealth - AdventHealth Medical Group at East Orlando, Orlando, FL,
United States
(Elgendy) Department of Internal Medicine, Weill Cornell Medicine-Qatar,
Doha, Qatar
(Patel) Department of Internal Medicine, Division of Cardiology, VCU
Pauley Heart Center, Virginia Commonwealth University, School of Medicine,
Richmond, VA, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Several randomized controlled trials have studied the role of colchicine,
a potent anti-inflammatory drug, to prevent adverse cardiovascular events
in patients with coronary artery disease (CAD). In this meta-analysis, we
aimed to determine the role of colchicine in patients with CAD in clinical
outcomes and mortality. We searched PubMed, PubMed Central, Scopus, and
Embase for randomized controlled trials/experimental studies evaluating
the role of colchicine in patients with CAD. After assessing the
eligibility for inclusion, risk-of-bias assessment, and data extraction
from the included studies, a narrative synthesis was conducted. Of 17
studies included for the qualitative analysis, 11 studies reported that
inflammatory markers such as C-reactive protein and cytokines were reduced
in the colchicine group, suggesting an anti-inflammatory role of
colchicine in CAD. Quantitative analysis with pooling of data from 9
studies using a fixed-effect model showed 28% lower odds of acute
myocardial infarction [odds ratio (OR) 0.72, 95% CI 0.59-0.86; n =
11,712], 52% lower occurrence of stroke (OR 0.48, 95% CI 0.30-0.76), and
37% reduction in odds of coronary revascularization procedure in the
colchicine group (OR 0.63, 95% CI 0.52-0.76; n= 11,258). However, the odds
of gastrointestinal adverse events were 50% higher in the colchicine group
(OR 1.50, 95% CI 1.01-2.23; n = 12,214). In conclusion, colchicine is
associated with a lower risk of acute myocardial infarction, stroke, and
coronary revascularization. However, there is some increased risk of
gastrointestinal adverse events with the use of colchicine. Copyright
© 2022 Lippincott Williams and Wilkins. All rights reserved.

<120>
Accession Number
2016400095
Title
The Effect of Ultrasound-Guided Low Serratus Anterior Plane Block on
Analgesia and Quality of Recovery After Robot-Assisted Thymectomy via
Subxiphoid Approach: Study Protocol for a Randomized Controlled Trial.
Source
Journal of Pain Research. 15 (pp 939-947), 2022. Date of Publication:
2022.
Author
Fu Y.; Fu H.; Lu Y.; Lv X.
Institution
(Fu, Lu, Lv) Department of Anesthesiology, Shanghai Pulmonary Hospital,
Tongji University School of Medicine, Shanghai, China
(Fu) Department of Anesthesiology, Shanghai Ninth People's Hospital,
Shanghai JiaoTong University School of Medicine, Shanghai, China
Publisher
Dove Medical Press Ltd
Abstract
Purpose: It is pivotal to optimize perioperative analgesia in order to fit
a transition in the surgical approach for removing mediastinal tumors,
from sternotomy to trans-subxiphoid robotic thymectomy (TRT). Serratus
anterior plane block (SAPB) is a safe, effective and easy to perform
analgesic technology, which could provide analgesia in thoracic and upper
abdominal surgery. However, the efficacy of SAPB analgesia in the patients
undergoing TRT is unclear and has never been described in scientific
literature. Therefore, this study aimed to determine the effect of
ultrasonic-guided low SAPB on analgesia and the quality of recovery (QoR)
following the TRT. Study Design and Methods: In this prospective
double-blind, randomized controlled design trial, 40 adults scheduled for
TRT will be randomly allocated to the low SAPB group (Group S) and placebo
control group (Group C). The patient of Group S will be performed SAPB
bilaterally at the level of T8-T9 under ultrasound guidance with 40 mL
0.375% ropivacaine after anesthesia induction. Group C will be
administered normal saline at the same volume and timing. The primary
study outcome is the global Quality of Recovery-40 (QoR-40) score on
postoperative days (POD) 1. The secondary endpoints are numeric rating
scale (NRS) scores and sufentanil consumption at different time points
after surgery, QoR-40 scores on POD 2, 30 and 90, chronic pain at POD 90,
and the incidence of perioperative adverse events. Discussion(s):
This is the first prospective trial to shed light on the efficacy of
ultrasonic-guided low SAPB on postoperative pain and recovery after TRT.
The findings will provide a new strategy of perioperative pain management
for TRT. Copyright © 2022 Fu et al.

<121>
Accession Number
2017779522
Title
Statistical Evaluation of Transformation Methods Accuracy on Derived
Pathological Vectorcardiographic Leads.
Source
IEEE Journal of Translational Engineering in Health and Medicine. (no
pagination), 2022. Date of Publication: 2022.
Author
Vondrak J.; Penhaker M.
Institution
(Vondrak, Penhaker) Faculty of Electrical Engineering and Computer
Science, VSB-Technical University of Ostrava, Ostrava 708 33, Czech
Republic
Publisher
Institute of Electrical and Electronics Engineers Inc.
Abstract
Objective: Vectorcardiography (VCG) as an alternative form of ECG provides
important spatial information about the electrical activity of the heart.
It achieves higher sensitivity in the detection of some pathologies such
as myocardial infarction, ischemia and hypertrophy. However,
vectorcardiography is not commonly measured in clinical practice, and for
this reason mathematical transformations have been developed to obtain
derived VCG leads, which in application in current systems and subsequent
analysis can contribute to early diagnosis and obtaining other useful
information about the electrical activity of the heart. Methods and
procedures: The most frequently used transformation methods are compared,
namely the Kors regression method, the Inverse Dower transformation, QLSV
and the Quasi-orthogonal transformation. These transformation methods were
used on 30 randomly selected records with a diagnosis of myocardial
infarction from the Physikalisch-Technische Bundesanstalt (PTB) database
and their accuracy was evaluated based on the calculation of the mean
square error (MSE). MSE was subjected to statistical evaluation at a
significance level of 0.05. Result(s): Based on statistical testing
using the nonparametric multiselective Kruskall-Wallis test and subsequent
post-hoc analysis using the Dunn method, the Kors regression as a whole
method achieved the most accurate transformation. Conclusion(s): The
results of statistical analysis provide an evaluation of the accuracy of
several transformation methods for deriving orthogonal leads, for possible
application in measuring and evaluation systems, which may contribute to
the correct choice of method for subsequent analysis of electrical
activity of the heart at orthogonal leads to predict various
diseases. Copyright Author

<122>
Accession Number
637797098
Title
Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of
Major Cardiovascular Events: Systematic Review and Meta-Analysis.
Source
Circulation. Cardiovascular quality and outcomes. (pp
101161CIRCOUTCOMES121008552), 2022. Date of Publication: 18 Apr 2022.
Author
Wang N.; Woodward M.; Huffman M.D.; Rodgers A.
Institution
(Wang, Woodward, Huffman, Rodgers) George Institute for Global Health,
University of New South Wales, M.D.H., Sydney, Canada
(Wang) Sydney Medical School, University of Sydney, Australia
(Wang, Rodgers) George Institute for Global Health, School of Public
Health Imperial College, United Kingdom (M.W., London
(Woodward) Department of Epidemiology, Johns Hopkins University,
Baltimore, United States
(Huffman) Feinberg School of Medicine, Departments of Preventive Medicine
and Medicine, Northwestern University, Chicago, Mexico
Publisher
NLM (Medline)
Abstract
BACKGROUND: Mendelian randomization studies use genetic variants as
natural experiments to provide evidence about causal relations between
modifiable risk factors and disease. Recent Mendelian randomization
studies suggest each mmol/L reduction in low-density lipoprotein
cholesterol (LDL-C) sustained over a lifetime can reduce the risk of
cardiovascular disease by more than half. However, these findings have not
been replicated in randomized clinical trials, and the effect of treatment
duration on the magnitude of risk reduction remains uncertain. The aim of
this article was to evaluate the relationship between lipid-lowering drug
exposure time and relative risk reduction of major cardiovascular events
in randomized clinical trials. METHOD(S): We conducted a systematic
review and meta-analysis of randomized clinical trials of statins,
ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors
that report LDL-C levels and effect sizes for each year of follow-up. The
primary end point was major vascular events, defined as the composite of
cardiovascular death, myocardial infarction, stroke, and coronary
revascularization. Hazard ratios during each year of follow-up were
meta-analyzed using random-effects models. RESULT(S): A total of 21
trials with 184012 patients and an average mean follow-up of 4.4 years
were included. Meta-regression showed there was greater relative risk
reduction in major vascular events with increasing duration of treatment
(P<0.001). For example, each mmol/L LDL-C lowered was associated with a
relative risk reduction in major vascular events of 12% (95% CI, 8%-16%)
for year 1, 20% (95% CI, 16%-24%) for year 3, 23% (95% CI, 18%-27%) for
year 5, and 29% (95% CI, 14%-42%) for year 7. CONCLUSION(S): The
benefits of LDL-C lowering do not seem to be fixed but increase steadily
with longer durations of treatment. The results from short-term randomized
trials are compatible with the very strong associations between LDL-C and
cardiovascular events seen in Mendelian randomization studies.

<123>
Accession Number
637795964
Title
Significant valvular dysfunction and outcomes in cardiogenic shock:
insights from the randomized DOREMI trial.
Source
The Canadian journal of cardiology. (no pagination), 2022. Date of
Publication: 14 Apr 2022.
Author
Parlow S.; Weng W.; Di Santo P.; Jung R.G.; Lepage-Ratte M.F.; Motazedian
P.; Prosperi-Porta G.; Abdel-Razek O.; Simard T.; Chan V.; Labinaz M.;
Froeschl M.; Mathew R.; Hibbert B.
Institution
(Parlow, Weng, Motazedian, Prosperi-Porta, Abdel-Razek, Labinaz, Froeschl,
Mathew) CAPITAL Research Group, Division of Cardiology, University of
Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology,
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
(Di Santo) CAPITAL Research Group, Division of Cardiology, University of
Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology,
University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of
Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario,
Canada
(Jung) CAPITAL Research Group, Division of Cardiology, University of
Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular
and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada;
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
(Lepage-Ratte) CAPITAL Research Group, Division of Cardiology, University
of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of
Medicine, University of Ottawa, Ottawa, Ontario, Canada
(Simard) Department of Cardiovascular Diseases, Mayo Clinic School of
Medicine, Rochester, MN, United States
(Chan) Division of Cardiac Surgery, University of Ottawa Heart Institute,
Ottawa, ON, Canada
(Hibbert) CAPITAL Research Group, Division of Cardiology, University of
Ottawa Heart Institute, Ottawa, Ontario, Canada; Division of Cardiology,
University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department
of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario,
Canada
Publisher
NLM (Medline)
Abstract
BACKGROUND: Patients with cardiogenic shock (CS) suffer high rates of
in-hospital mortality, with little evidence guiding management. The impact
of valvular heart disease in patients with CS remains unclear. We
therefore conducted a post-hoc analysis of the randomized DOREMI trial to
determine the impact of valvular disease on outcomes in patients with CS.
 METHOD(S): We defined significant valvular disease as
moderate-to-severe or greater valvular stenosis or regurgitation and
divided participants into a group of those with significant valvular
disease and those without. Our primary outcome was all-cause in-hospital
mortality. Secondary endpoints included resuscitated cardiac arrest,
cardiac transplantation or mechanical circulatory support, non-fatal
myocardial infarction, stroke, initiation of renal replacement therapy, as
well as changes in renal function, perfusion, and hemodynamics over time.
 RESULT(S): 189 (98.4%) participants from the DOREMI trial were
included in our analysis, and 74 (39.2%) had significant valvular
dysfunction. Thirty-six (48.7%) patients with valvular disease died in
hospital, compared to 37 (32.2%) in the comparator group (relative risk
1.5, 95% confidence interval 1.06-2.15; p=0.02). Patients with aortic
stenosis (2.42, 1.56-3.75; p<0.01) and patients with mitral regurgitation
(1.63, 1.1-2.43; p=0.02) also had increased incidence of in-hospital
mortality. There was no significant difference in any secondary outcomes
between groups apart from variances in mean arterial pressure observed in
patients with valvular disease (p<0.01). CONCLUSION(S): Significant
valvular dysfunction is associated with increased in-hospital mortality in
patients with CS. Randomized clinical trial data are needed to further
elucidate the role of transcatheter valvular interventions as a
therapeutic target in this population. Copyright © 2022.
Published by Elsevier Inc.

EPICORE Embase Updates

Saturday, April 30, 2022

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Followers

Blog Archive

About Me